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The aim of this thesis was to investigate some aspects of the
hypothalamic control of hormone release from the anterior pituitary,
and the immunoreactive forms (IR) of neuropeptides released in vivo
into rat hypophysial portal blood with special emphasis on
somatostatin (SS), luteinizing hormone releasing hormone (LHRH) and
thyrotrophin releasing hormone (TRH).
The tetradecapeptide, somatostatin-14 (SS-14), is formed by the
cleavage of a larger precursor molecule to produce a number of IR
forms with intermediate molecular weight. SS-14, the N-terminally
extended form, SS-28, and SS—28(1-12) are released into hypophysial
portal vessel blood and the release of each form was increased (= 5
fold) by electrical stimulation of the median eminence (ME). These
observations together with data on their biological activity,
suggest that SS-28 as well as SS-14, is an hormonally active peptide.
High performance liquid chromatography (HPLC) combined with
radioimmunoassay showed that LHRH-IR in rat hypophysial portal blood
co-eluted as a single peak with synthetic LHRH and with LHRH-IR in
rat and mouse hypothalami. No LHRH could be detected in
hypothalamic extracts from hypogonadal (hpg) mice, in spite of which
the pituitary gland of the hpg mouse contains a small amount of
bioactive as well as immunoreactive LH which can be released by
exogenous LHRH. The priming effect of LHRH can also be elicited in
the hpg mouse, and these data show that previous exposure of
gonadotrophes to LHRH is not required for the synthesis of a small
amount of LH, or the releasing and priming actions of LHRH. Studies
on the secretion of LHRH and LH during suckling in lactating rats,
and after the administration of naloxone or tetrahydrocannabinol
(THC) to female rats at different times during the oestrous cycle
showed that THC reduced LHRH output and blocked the pro-oestrous
surge of LH but naloxone had no effect on plasma LH concentrations
or LHRH release. Peripheral plasma concentrations of LH and portal
plasma concentrations of LHRH were low in lactating animals and were
not reduced by suckling.
Immunoreactive TRH in portal blood was resolved by HPLC into 3 peaks
of about equal magnitude, one of which corresponded to synthetic
TRH. The two other immunoreactive peaks in portal blood did not
correspond in retention time to any known metabolite of TRH and,
since they were not present in the hypothalamus, could not be
attributed to a stored TRH precursor. The injection of anti-TRH
serum blocked the thyrotrophin but not the prolactin responses to
electrical stimulation of the ME or paraventricular nuclei in male
or pro-oestrous female rats, or in response to suckling in the
lactating rat. Thus, TRH is not crucial for prolactin release in
either male or female rats.
The secretion of anterior pituitary hormones was also investigated
in male rats in which the catecholamine (CA)-containing nerve
terminals of the median eminence and neurointermediate lobe were
lesioned by of 6-hydroxydopamine. The results showed that these CA
neurons inhibit the secretion of thyrotrophin and
adrenocorticotrophin, but may not play an important role in the
control of gonadotrophs secretion in the male.
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The role of the hypothalamus in the control of hormone secretion
from the anterior pituitary gland was suggested by early observations
of the effects of electrical stimulation of the hypothalamus and of
pituitary stalk section, and the transplantation of the pituitary
gland to sites distant from the median eminence. Such studies led
to the hypothesis that the release of anterior pituitary hormones
was controlled by inhibitory and facilitatory substances which are
released from nerve terminals in the median eminence and transported
by way of the hypophysial portal vessels to the anterior pituitary
gland (Green and Harris, 1947; Harris, 1955,1972). A crucial step
in the development of this hypothesis was the isolation and
characterization of the peptide hypothalamic releasing (or release
inhibiting) factors (or hormones). The availability of pure
preparations of the synthetic peptides enabled the production of
specific antisera and development of radioimmunoassays (RIA). By
combination of these assays with techniques which enabled the
dissection of discrete brain nuclei (Palkovits, 1973), the presence
of the releasing factors was demonstrated in regions of hypothalamic
and extrahypothalamic brain indicating that these peptides might
also serve a neurotransmitter role in the central nervous system.
The cell bodies of the neurons which project to the median eminence
have been demonstrated by immunohistochemistry and, from studies of
the effect of various lesions and transections, the possible routes
of some of these pathways have been mapped. The development of
techniques for the exposure of the hypophysial portal vessels and
the collection of portal blood from the cut pituitary stalk of
anaesthetized rats, permitted direct studies of the release of
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hypothalamic peptides in vivo. The physiological importance of
known or putative hypothalamic-pituitary regulatory neuropeptides
has also been determined by the administration of specific antisera
to neutralize the endogenous peptides (passive immunization/immuno-
neutralization). Pharmacological and histochemical studies have
broadly identified the role of monoamine and amino acid transmitters
in the regulation of hypothalamic peptide secretion. Recent studies
have focussed attention on the synthesis of the hypothalamic
peptides and shown that the peptides are synthesized as components
of larger precursors which are processed by enzymatic degradation.
These precursor molecules may contain several copies of a single
peptide or a number of structurally unrelated peptides which may
share common functions. Cleavage at different sites within the
precursor molecule may generate different products or, as is the
case with somatostatin, extended forms of the peptide which are
themselves biologically active.
1.1 NEUROHUMORAL CONTROL OF ANTERIOR PITUITARY HORMONE SECRETION
The history of the development of the neurohumoral hypothesis
has been extensively reviewed (Harris, 1955, 1972; Fink, 1976).
Briefly, the first descriptions of the prominent blood vessels which
run along the pituitary stalk and terminate in fine capillary
networks in the anterior pituitary gland and median eminence (ME)
were recorded by Popa and Fielding (1930) and their observations of
these 'hypophysial portal vessels' were subsequently confirmed by
Wislocki and King (1936). For many years the direction of blood
flow through the vessels was a subject of debate (Popa and Fielding,
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1930, 1933; Wislocki, 1937, 1938), but this was finally resolved by
direct observations in anaesthetized amphibians (Houssay, Biasotti
and Sammartino, 1935; Green, 1947) and rats (Green and Harris, 1949)
which showed that blood flowed from the hypothalamus to the
pituitary gland. Several workers have since suggested the presence
of a vascular link between the anterior and posterior (neural lobe)
pituitary gland and also suggest that some blood may pass from the
anterior pituitary gland to the ME, possibly by way of the neural
lobe (Torak, 1964; Ambach, Palkovits and Szentagothai, 1976; Oliver,
Mica! and Porter, 1977; Bergland and Page, 1978, 1979). Direct
observations of pituitary blood flow in the aneasthetized pig have
demonstrated a limited flow of blood from the neural lobe to the
anterior pitutary but failed to demonstrate the passage of blood
from the anterior pituitary gland through the neural lobe to the ME
(Page, 1983).
The physiological importance of the vascular link connecting the
hypothalamus and the pituitary gland was demonstrated in a series of
elegant studies which investigated the effects of pituitary stalk
section and of the grafting of pituitary tissue to sites distant
from the sella turcica. Section of the pituitary stalk was followed
by rapid vascular regeneration across the cut and restoration of
pituitary function (e.g. the majority of animals showed oestrous
cyclicity and became pseudopregnant in response to sterile matings
(Harris, 1950). When the regeneration of the vascular connection
was prevented by insertion of a small plate in the cut, animals
remained in anoestrous and the gonads became atrophied (Harris,
1950). Transplantation studies, in which pituitary gland tissue was
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grafted into hypophysectomized rats, demonstrated the restoration of
normal pituitary function when the graft was placed under the ME and
revascularized by the hypophysial portal vessels but not when the
grafts were placed under the temporal lobe of the brain where they
became vascularized by the cerebral and dural vessels (Harris and
Jacobsohn, 1952). These results were confirmed and extended in
further experiments by Nikitovitch-Winer and Everett (1958, 1959)
who, by a two step operation, showed that there was a loss of
reproductive function when pituitary tissue was grafted under the
kidney capsule whereas normal function was restored by the later
retransplantation of the pituitary beneath the median eminence.
The criteria established by Geoffrey Harris (1972) for the
demonstration of a hypothalamic releasing factor are "a) that the
substance is extractable from hypothalamic or stalk: median eminence
tissue; b) that it is present in hypophysial portal blood in greater
amounts that in systemic blood; and c) that varying concentrations
of the substance in portal blood are related to varying secretion
rates of one of the anterior pituitary hormones under a number of
different experimental and environmental conditions". These
criteria have been fully satisfied for LHRH. Although somatostatin
and TRH are largely undetectable in peripheral blood, both have been
shown to be present in physiologically active concentrations in
hypophysial portal blood. Whilst there is much indirect evidence to
suggest that the secretion rates of somatostatin and TRH vary under
experimental conditions, in contrast to the extensive studies of
LHRH release, there have been few direct studies of the release of
these peptides into portal blood under varying physiological
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conditions.
1.2 THYROTROPHIN RELEASING HORMONE (TRH)
1.2.1 Isolation and characterization of TRH
In the 1960*s intense efforts were directed to the isolation of
TRH from large quantities of porcine or bovine hypothalami. Finally
in 1966 a small quantity of TRH was isolated and shown to contain
only three amino acids (histidine, proline and glutamic acid) which
were present in equimolar quantities (Schally, Bowers, Redding and
Barrett, 1966). Further work in the laboratories of Schally and
Guillemin resulted in the determination of the amino acid sequence
and structure of porcine and bovine TRH respectively, and the
subsequent chemical synthesis of this molecule (Boler, Enzmann,
Folkers et al, 1969; Burgus, Dunn, Desiderio and Guillemin, 1969;
Burgus, Dunn, Ward et al, 1969; Folkers, Enzmann, Boler et al, 1969;
Burgus, Dunn, Desiderio et al, 1970). From these, and other
studies, TRH was shown to be the tripeptide amide -
(pyro)Glu-His-Pro f^.
1.2.2 Hypothalamic distribution of TRH
Radioimmunoassay of the TRH content of microdissected brain
nuclei showed high concentrations of immunoreactive TRH in many
hypothalamic and extrahypothalamic brain areas. Within the
hypothalamus the largest concentration was in the ME but high
concentrations were also found in regions adjacent to the third
ventricle including the periventricular, paraventricular (PVN) and
arcuate nuclei (Brownstein, Palkovits, Saavedra, Bassiri and Utiger,
1974). Losses during tissue processing due to the high solubility
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of TRH prevented detailed immunohistochemistry until it was found
that these technical difficulties were overcome by the application
of a rapid tissue fixation technique using acreolin (Lechan and
Jackson, 1982). High concentrations of TRH were demonstrated along
the length of the ME in the external layer adjacent to the portal
vessels and in the vascular organ of the lamina terminalis (OVLT)
and posterior pituitary gland. In animals pre-treated with
colchicine in order to block axonal transport, the perikarya of the
TRH-containing neurons were demonstrated in several hypothalamic
areas including the suprachiasmatic preoptic nucleus and dorsomedial
nucleus. The highest numbers of TRH-perikarya were contained in the
parvocellular division of the PVN where many cells were seen in the
anterior and medial subdivisions, which had neuronal processes
directed ventromedially towards the third ventricle. Using
retrograde tracers (horseradish peroxidase and true blue) injected
into the external layer of the ME, it has been shown that cell
bodies in the parvocellular division of the PVN project to the ME
(Wiegland and Price, 1980; Lechan, Nestler, Jacobson and Reichlin,
1980) and it is likely that the TRH-containing cell bodies in the
PVN are the origin of the TRH fibres terminating in the ME.
1.2.3 Regulation of thyrotrophin secretion
The role of the hypothalamus in the control of thyrotrophin
secretion was demonstrated by early experiments which relied upon
measuring changes in thyroid function as an index of thyrotrophin
secretion: e.g. the ability of grafted pituitary tissue to maintain
normal thyroidal weight and histology when the graft was placed
under the ME, but not when transplanted under the temporal lobe
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(Harris and Jacobsohn, 1952), and the increased release of I
from the thyroid which followed electrical stimulation of the
anterior hypothalamus (Harris and Woods, 1958). The development of
RIAs for thyrotrophin facilitated more detailed studies and the
hypothesis was formed that thyrotrophin output depends upon a
balance between the stimulatory effects of TRH and the negative
feedback exerted by the thyroid hormones which modulate the
pituitary responsiveness to TRH (Brown-Grant, 1969; Reichlin,
Martin, Mitnick et al, 1972; Morley, 1981).
The basal concentration of thyrotrophin in the plasma was
decreased after passive immunization with anti-TRH sera (Koch,
Goldhaber, Fireman et al, 1971; Szabo, Kovathana, Gordon and
Frohman, 1978; Harris, Christianson, Smith et al, 1978; Fraser and
McNeilly, 1983), but passive immunization only partially reduced the
hypersecretion of thyrotrophin which follows thyroidectomy (Harris
et al, 1978; Szabo et al, 1978). The plasma concentration of
thyrotrophin was reduced by deafferentation of the MBH (Hefco,
Krulich, Aschenbrenner, 1975; Fukuda and Greer, 1977) and lesions of
the PVN (Martin, Boshans, Reichlin, 1970; Aizawa and Greer, 1981).
Conversely, plasma thyrotrophin concentration was elevated by
electrical stimulation of either the ME or PVN (Martin and Reichlin,
1972).
Since early experiments which showed that sectioning the
pituitary stalk of the rat prevented the hypertrophy of the thyroid
in response to cold exposure (Uotila, 1939; Brolin, 1945), a large
number of studies have shown that increased thyrotrophin secretion
followed short or long term cold exposure. The dependence of this
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effect upon TRH release was shown by blockade of the response by
passive immunization with anti-TRH serum (Szabo and Frohman, 1977;
Harris et al, 1978). In conscious rats in which a push-pull cannula
had been implanted into the ME, there was a significant increase in
TRH release into the perfusate when the rats were exposed to cold
(Arancibia, Tapia-Arancibia, Assenmacher and Astier, 1983).
Bilateral electrolytic lesions of the paraventricular nuclei
abolished the thyrotrophin response to cold (Ishikawa, Kakegawa and
Suzuki, 1984).
Many studies have shown that the thyroid hormones decrease basal
and TRH stimulated secretion of thyrotrophin predominantly by a
direct action on the pituitary gland (e.g. Averill, 1969; Bowers,
Schally, Enzmann, Boler and Folkers, 1970; Reichlin, Martin, Boshans
et al, 1970; Bowers, Schally, Reynolds and Hawley, 1967). The major
hormone produced by the thyroid is thyroxine (T^), though some
triiodothyronine (T^) is also produced. Conversion of T^ to the
more potent T^ occurs by monodeiodination in the anterior
pituitary and in other peripheral sites (Larsen, Dick, Markovitz,
Kaplan and Gard, 1979; Connors and Hedge, 1981). In addition, T^
may also be monodeiodinated to produce the less-important reverse
T^ (Baxter, Eberhardt, Apriletti et al, 1979). Approximately only
0.5% T^ and 0.05% T^ are present in plasma as free hormone, the
majority is bound to plasma binding proteins (Brown-Grant, 1969).
T^ is approximately ten times more potent than T^ in the
inhibition of the synthesis and release of thyrotrophin (Larsen and
Frumess, 1977). Both the feedback and the metabolic effects of the
thyroid hormones require the entry of the hormones into the target
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cell (in the case of the pituitary gland, the thyrotrophe) and
binding to a nuclear binding site which has greater affinity for
than (Oppenheimer, 1979). Evidence obtained from in vitro
studies suggests that may induce the synthesis of a protein
which blocks thyrotrophin release (Gard, Bernstein and Larsen,
1981). It has also been shown that may decrease the number of
the binding sites for TRH on the thyrotroph (Connors and Hedge,
1981; Hinkle, Perrone and Schonbrunn, 1981).
There have been few studies of direct effects of the thyroid
hormones on TRH output, but an action of T^ and T^ on the
hypothalamus to regulate TRH secretion cannot be discounted. In the
majority of studies there were no consistent changes in hypothalamic
TRH content after the administration of thyroid hormones, or after
thyroidectomy or hypophysectomy (e.g. Kordon, Marcus, Winokur and
Utiger, 1977). The increased ability of rat hypophysial portal
blood to stimulate the in vitro release of thyrotrophin in response
to electrical stimulation of the anterior hypothalamus was not
prevented by pre-treatment with T^ (Wilbur and Porter, 1970).
Similarly, no consistent differences were reported in the
concentration of immunoreactive TRH in portal blood from normal,
hypothyroid or thyroid hormone-treated rats (Ching and Utiger,
1983). In support of a hypothalamic feedback mechanism, Belchetz,
Gredley, Bird and Himsworth (1978) showed that bilateral injection
of T^ into the dorsomedial nuclei or lateral hypothalamic area of
hypothyroid monkeys resulted in a rapid decrease in serum
thyrotrophin concentration; the low dose of T^ used produced only
a small change in thyrotrophin secretion when injected directly into
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the pituitary gland.
Somatostatin may also participate in the regulation of
thyrotrophin secretion. Somatostatin inhibits both basal and
TRH-stimulated release of thyrotrophin (Vale, Rivier, Brazeau and
Guillemin, 1974; Belanger, Labrie, Borgeat et al, 1974).
Conversely, passive immunization with anti-somatostatin serum
resulted in elevated plasma thyrotrophin concentrations (Arimura and
Schally, 1976; Chihara, Arimura, Chihara and Schally, 1978) and
enhanced the thyrotrophin response to cold exposure (Ferland,
Labrie, Jobin, Arimura and Schally, 1976). Hypothalamic
somatostatin content is decreased in hypothyroid rats and restored
to normal by treatment with (Berelowitz, Maeda, Harris and
Frohman, 1980). Berelowitz et al (1980) also demonstrated that
stimulated the in vitro release of somatostatin from hypothalami
from normal rats and showed that somatostatin secretion from
hypothalami from hypothyroid rats was reduced.
1.3 SOMATOSTATIN
1.3.1 Isolation and characterization of somatostatin
Extracts of ovine hypothalami were shown to contain a substance
which inhibited the release of growth hormone (GH) from the rat
anterior pituitary gland (Krulich, Dhariwal and McCann, 1968).
Subsequently a tetradecapeptide (H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-
Lys-Thr-Phe-Thr-Ser-Cys-OH), which was later termed, somatostatin,
was isolated from sheep and pig hypothalami and shown to inhibit the
release of immunoreactive GH in vivo and in vitro (Brazeau, Vale,
Burgus et al, 1973; Schally, Dupont, Arimura et al, 1976).
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Somatostatin was also shown to inhibit the secretion of insulin
(Alberti, Christensen, Iversen et al, 1973; Mortimer, Carr, Lind et
al, 1974), glucagon (Mortimer et al, 1974), gastrin (Bloom,
Mortimer, Thorner et al, 1974) and somatostatin (Vale et al, 1974;
Belanger et al, 1974).
1.3.2 Pistribution
Somatostatin has been shown by immunohistochemistry to be widely
distributed throughout the CNS (Johansson, Hokfelt and Elde, 1984)
and, in addition, its presence has been demonstrated in peripheral
nerves and secretory cells of the gastro-intestinal tract and in the
D cells of the pancreatic islets (Arimura, Sato, Dupont, Nishi and
Schally, 1975; Hokfelt, Johansson, Efendic, Luft and Arimura, 1975;
Hokfelt, Efendic, Hellerstrom, Johansson, Luft and Arimura, 1975).
The highest concentrations of immunoreactive somatostatin in the CNS
are found in the ME, where a high concentration of somatostatin-
containing fibres form a dense plexus surrounding the hypophysial
portal vessels in the external layer (Johansson et al, 1984);
smaller concentrations of somatostatin are present in the pre-optic
area, medial basal hypothalamus (MBH) and amygdala. Within the
hypothalamus, somatostatin-containing cell bodies are found in high
numbers in the anterior hypothalamic periventricular nucleus
(extending caudally into the parvocellular portion of the PVN);
fewer numbers of immunoreactive cells are also present in the
arcuate, suprachiasmatic nucleus and ventromedial nucleus (Johansson
et al, 1984; Kawano, Daikoku and Saito, 1982). The ME content of
somatostatin is depleted by complete or anterolateral
deafferentation of the MBH suggesting that the innervation of the
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median eminence arises from cell bodies outside of the MBH
(Brownstein, Arimura, Fernandez-Durango et al, 1977; Epelbaum,
Willoughby, Brazeau and Martin, 1977; Kawano et al, 1982). Krisch
(1978) suggested that fibres from the cell bodies in the
hypothalamic periventricular nucleus follow a short direct route,
along the wall of the third ventricle, to the median eminence. A
similar direct pathway was proposed for the projections of the
lesser number of somatostatin-containing cell bodies in the preoptic
periventricular nucleus (Jew, Leranth, Arimura and Palkovits,
1984). However, from studies of the ME content of somatostatin
after various transections, it has been suggested that the
somatostatin fibres may leave the hypothalamic periventricular
nucleus and project to the ME by way of a loop, through the lateral
hypothalamus, which joins the medial forebrain bundle, and enters
the MBH mainly in the lateral retrochiasmatic area near the ventral
surface (Epelbaum, Tapia-Arancibia, Herman, Kordon and Palkovits,
1981; Makara, Palkovits, Antoni and Kiss, 1983). Some innervation
of the ME from fibres originating in the amygdala has also been
reported (Crowley and Terry, 1980; Terry and Crowley, 1986).
1.3.3 Regulation of growth hormone secretion
The secretion of GH from the anterior pituitary is regulated by
an interaction between the inhibitory and facilitatory influences of
somatostatin and a growth hormone releasing factor (GHRH)
respectively. The precise details of the interactions between these
two peptides is not firmly established. Although many earlier
studies had indicated the presence of a hypothalamic factor
responsible for the stimulation of GH release (e.g. Deuben and
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Meites, 1964; Krulich et al, 1968), it is only recently that
peptides (hp GRF-44 and hp GRF-40) with high GH-releasing activity
have been isolated and characterized from human pancreatic tumour
cells (Guillemin, Brazeau, Bohlen et al, 1982; Rivier, Spiess,
Thorner and Vale, 1982). In the rat, the GHRH isolated and
characterized from the hypothalamus was found to be a 43 amino acid
peptide which showed 67%-70% homology with the sequence of the human
GHRH peptides. (Spiess, Rivier and Vale, 1983).
Growth hormone is secreted from the anterior pituitary gland in
a pulsatile manner characterized by high amplitude pulses of short
duration which occur at approximately 3 to 4 h intervals (Tannenbaum
and Martin, 1976). Passive immunization with anti-somatostatin
serum resulted in increased basal GH secretion, but did not alter
the pulsatile secretion of GH (Ferland et al, 1976; Terry and
Martin, 1981) whereas administration of a monoclonal antibody raised
against a purified preparation of GHRH resulted in abolition of GH
pulses both in normal and in anti-somatostatin treated rats
(Wehrenberg, Brazeau, Lubin, Bohlen and Guillemin, 1982).
Tannenbaum and Ling (1984) proposed that superimposed upon a tonic
release of somatostatin and GHRH were additional rhythmic surges of
each peptide, about 180° out of phase with each other, and with a
periodicity of 3-4 h. Direct evidence for episodic secretion of
these peptides was provided by studies of their secretion into
hypophysial portal blood in rats anaesthetized with an anaesthetic
combination (Ketamine and Xylazine) which does not block pulsatile
GH release (Plotsky and Vale, 1985). It was also suggested that
somatostatin may directly, or indirectly, inhibit GHRH secretion,
-13-
such that surges of GHRH only occur in the presence of diminished
somatostatin secretion (Plotsky and Vale, 1985).
The hypothalamic content of somatostatin is reduced following
hypophysectomy - an effect which was reversed or prevented by GH
administration (Baker and Yen, 1976; Hoffman and Baker, 1977;
Fernandez-Durango, Arimura, Fishback and Schally, 1978; Terry and
Crowley, 1980). Daily administration of GH to normal rats increased
both the hypothalamic content and the release of somatostatin, and
conversely, somatostatin content and release were reduced in animals
in which plasma concentrations of GH were reduced by either
hypophysectomy or by administration of anti-GH serum (Berelowitz,
Firestone and Frohman, 1981). Intracerebroventricular injection of
GH resulted (after a latent period of 30-45 minutes) in increased
secretion of somatostatin into hypophysial portal blood (Chihara,
Minamitani, Kaji, Arimura and Fujita, 1981). The negative feedback
regulation of GH secretion implied by these studies, may be mediated
either by the direct effect of changes in plasma growth hormone
concentration or indirectly by way of the altered synthesis of the
hepatic peptide, somatomedin C. GH regulates the production of the
somatomedin C (the mediator of the effects of GH on muscular and
skeletal growth) and somatomedin C both stimulates the release of
somatostatin from the hypothalamus in vitro and directly inhibits
the pituitary release of GH (Berelowitz, Szabo, Frohman et al, 1981).
1.4 LUTEINIZING HORMONE RELEASING HORMONE (LHRH)
1.4.1 Isolation and characterization of LHRH
Data from several laboratories indicated the presence in the
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hypothalamus of a substance capable of releasing LH and FSH from the
anterior pituitary gland (e.g. McCann, Taleisnik and Friedman, 1960;
Campbell, Feuer and Harris, 1964; Schally and Bowers, 1964).
Finally, Schally and his co-workers succeeded in isolating LHRH from
porcine hypothalami (Matsuo, Baba, Nair, Arimura and Schally, 1971)
and showed it to be a decapeptide with the sequence -
(pyro) Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly
a finding confirmed by Guillemin for ovine LHRH (Burgus, Butcher,
Amos et al, 1972). Since it stimulates the release and synthesis of
both LH and FSH, LHRH has long been regarded as the sole
hypothalamic releasing factor for both hormones, however, recent
data indicates that the possibility of a separate FSH-RH still
cannot be discounted. For example, the pro-oestrous surge of FSH
was incompletely blocked by the administration of a LHRH-antagonist
(Condon, Heber, Stewart, Sawyer and Whitmoyer, 1984). Condon et al
(1984) also suggested that the surge in the plasma concentration of
FSH which occurs early on the morning of oestrus (at about the time
at which ovulation occurs) is completely independent of the
hypothalamic release of LHRH, though in this context it should be
noted that an increase in the concentration of LHRH in hypophysial
portal plasma does occur at this time (Sarkar, Chiappa, Fink and
Sherwood, 1976). Lesion of the paraventricular nuclei-dorsal
anterior hypothalamus resulted in diminished secretion of FSH, but
did not reduce either the plasma concentration of LH or the median
eminence content of LHRH (Lumpkin and McCann, 1984). Passive
immunization with anti-LHRH serum, or the administration of
LHRH-antagonists, blocks the pulsatile secretion of LH seen in
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gonadectomized animals, but whilst these treatments reduced the
plasma concentration of FSH, neither the frequency nor amplitude of
the FSH pulses was affected (de Paolo, 1985; Culler and Negro-Vilar,
1986) suggesting that although LHRH regulates the baseline secretion
of FSH, generation of pulsatile FSH secretion is controlled by an
LHRH independent mechanism. There is also biochemical evidence
which indicates the presence of a bio-active FSH-RH which was
partially separated from the LHRH decapeptide by gel filtration of
rat hypothalamic extracts (Mizunuma, Samson, Lumpkin et al, 1983).
1.4.2 LHRH pathways
Immunohistochemical studies have shown that within the
hypothalamus the highest density of LHRH-containing nerve terminals
are located in the lateral palisade zone of the ME, though in
addition a dense plexus of LHRH terminals are also found in the OVLT
(King and Gerall, 1976; Fuxe Hokfelt, Andersson et al, 1978).
Studies in which the afferent connections to the MBH were severed,
indicate that most of the LHRH in the ME is derived from cell bodies
outside of this area (Weiner, Pattou, Kerdelhue and Kordon, 1975;
Brownstein, Arimura, Schally, Palkovits and Kizer, 1976).
LHRH-containing cell bodies have been demonstrated in both the
anterior and mediobasal hypothalamus of many species, but in the
mouse and rat the presence of LHRH-immunoreactive cell bodies in the
MBH is controversial (Krey and Silverman, 1983). However, the
presence of LHRH cell bodies in the preoptic-suprachiasmatic area of
the rat is well established (e.g. Barry, Dubois and Poulain, 1973;
Setalo, Vigh, Schally, Arimura and Flerko, 1976; Kawano and Daikoku,
1981; Rethelyi, Vigh, Setalo et al, 1981; Witkin, Paden and
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Silverman, 1982). The cell bodies are not arranged in compact
nuclei but are diffusely aggregated across several nuclear groups
which extend from the septal nuclei and diagnonal band of Broca,
through the preoptic region and into the anterior hypothalamic area.
There was a marked reduction in the content of LHRH in the ME
after bilateral knife cut lesions were placed in the lateral
hypothalamus between the pre-optic area and the ME, whereas midline
cuts were ineffective (Jew et al, 1984) suggesting that most of the
fibres to the ME follow a lateral hypothalamic route through the
medial forebrain bundle. Immunohistochemical studies have shown
that the fibres from the cell bodies in the preoptic area to the ME
form two major divisions (preoptico infundibular tracts) which
converge in the basal hypothalamus close to the ME: a mediobasal
path which descends through the hypothalamus along the wall of the
third ventricle, and a lateral path which projects to the ME by way
of the medial forebrain bundle (e.g. Kawano and Kaikoku, 1981;
Rethelyi et al, 1981). More detailed studies indicate that within
these major divisions are a number of diffuse fibre pathways which
may differentially innervate different portions of the ME (Rethelyi
et al, 1981; Hoffman and Gibbs, 1982). Some of the fibres may
course through the OVLT (where some fibres may terminate) before
continuing to the ME by way of either the ventral surface of the
optic chiasm or the floor of the third ventricle (Hoffman and Gibbs,
1982); this observation may explain the decrease in ME content of
LHRH seen following lesions of the OVLT (Samson and McCann, 1979).
The failure to lesion the LHRH tract which passes beneath the optic
chiasm (Rethelyi et al, 1971; Hoffman and Gibbs, 1982) may also
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explain the finding of some LHRH remaining in the MBH after 'total'
hypothalamic deafferentation (e.g. Weiner, Pattou, Kerdelhue and
Kordon, 1975).
1.4.3 Regulation of gonadotrophin secretion
The capacity of hypophysial portal blood to release LH was shown
initially by bioassay (Fink, Nallar and Worthington, 1967; Fink and
Harris, 1970). After the development of a specific RIA for LHRH
(Nett, Akbar, Niswender, Hedlund and White, 1973), Fink and Jamieson
(1976) were able to demonstrate greater concentrations of
immunoreactive LHRH in hypophysial portal than in peripheral blood;
results which were confirmed by Eskay, Mical and Porter (1977). The
release of LHRH was increased significantly by the application of an
electrical stumulus applied to the medial preoptic area (Fink and
Jamieson, 1976) using stimulation parameters which were optimal for
the release of LH (Jamieson and Fink, 1976). The effectiveness of
the stimulation was greater when the stimulus was applied to the ME
(Chiappa, Fink and Sherwood, 1977). The responsiveness of the
preoptic area to stimulation varied during the oestrous cycle such
that responsiveness increased between di-oestrus and pro-oestrus and
reached a peak at around 13.00 h of pro-oestrus (Sherwood, Chiappa
and Fink, 1976) and could be enhanced by administration of
oestradiol benzoate or testosterone (Sherwood et al, 1976).
In male rats and for the greater part of the oestrous cycle in
the female, the plasma concentrations of LH and FSH are kept low by
the negative feedback effects of the gonadal steroids (McCann, 1962;
Goodman, 1978; Fink, 1979a,b). In the majority of female rats
maintained under controlled lighting conditions (14 h light and 10 h
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dark), ovulation occurs once every four days in response to a
spontaneous LH surge. This LH surge is, in turn, triggered by a
daily neural signal (Everett and Sawyer, 1950) which is only
expressed in response to the prolonged elevation in the plasma
concentration of oestradiol-17e (Knobil, 1974; Legan and Karsch,
1975). The plasma concentration of oestradiol-17e, secreted from
the ovary, begins to increase slowly on the afternoon of dioestrus,
and, after a more rapid increase during the morning of pro-oestrus,
reaches a peak early in the afternoon of pro-oestrus (Ferin,
Tempone, Zimmering and Van der Wiele, 1969; Aiyer and Fink, 1974;
Fink, 1977). This increase in plasma oestradiol concentration
results in a massive increase in the pituitary responsiveness to
LHRH (Aiyer, Fink and Greig, 1974; Aiyer and Fink, 1974) and
triggers the surge of LHRH (Sarkar, Chiappa, Fink and Sherwood,
1976; Sherwood, Chiappa, Sarkar and Fink, 1980; Ching, 1982). The
responsiveness of the anterior pituitary gland to LHRH is further
enhanced by the increased secretion of ovarian progesterone during
the LH surge (Aiyer and Fink, 1974; Feder, Brown-Grant and Corker,
1971; Fink and Henderson, 1977a; Turgeon and Waring, 1981) and the
"priming effect" of LHRH (Aiyer, Chiappa and Fink, 1974). The
priming effect may serve to co-ordinate maximum output of LHRH with
peak responsiveness to LHRH, thereby ensuring the massive ovulatory
surge (Fink, Stanley and Watts, 1983) which occurs between 17.00 and
19.00 h. A second, and smaller in magnitude, surge of LHRH occurs
at the time of maximum sexual activity and ovulation at around
02.00 h on the morning of oestrus (Sarkar et al, 1976) and may be
related to the prolonged surge of FSH. The plasma concentration of
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FSH begins to rise at the same time as LH, but maximum FSH secretion
is not achieved until early in the morning of oestrus (Daane and
Parlow, 1971; Fink and Aiyer, 1974). The pro-oestrous gonadotrophs
surge appears to be terminated mainly by the fall in LHRH
concentration in hypophysial portal blood (Blake, 1976) which may be
due to an inhibitory action of progesterone (Freeman, Dupke and
Croteau, 1976; Drouva, Laplante and Kordon, 1983).
Studies of the effects of LHRH on the synthesis and release of
gonadotrophins have been facilitated by the discovery of a mutant
(hpg) mouse which is deficient in hypothalamic LHRH and as a
consequence has a marked reduction in pituitary gonadotrophins and
hypogonadism (Cattanach, Iddon, Charlton, Chiappa and Fink, 1977).
Administration of LHRH to hpg mice (most effectively by multiple
daily injection) resulted in an increased pituitary content of
gonadotrophins and gonadal development, and demonstrated that in
these mice LHRH is a more potent stimulator of FSH than of LH
synthesis (Charlton, Halpin, Iddon et al, 1983). Charlton et al
(1983) also showed that in the hpg female mouse the major site of
oestrogen feedback was the anterior pituitary gland, whereas in the
male, testosterone exerted its inhibitory effects at the
hypothalamus or some other brain site.
1.5 NEURAL CONTROL OF PROLACTIN SECRETION
The secretion of prolactin is regulated by complex interactions
between a number of inhibitory and facilitatory factors which are
released by the hypothalamus (Leong, Frawley and Nei11, 1983). In
mammals the predominant influence of the hypothalamus on prolactin
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secretion is inhibitory as was indicated initially by the presence
of functional lactotrophes in pituitary glands transplanted under
the kidney capsule (Nikitovitch-Winer and Everett, 1958, 1959).
Increased plasma concentrations of prolactin were measured after
deafferentation of the MBH (Blake, Scaramuzzi, Norman, Hilliard and
Sawyer, 1973) or after pituitary stalk section (Kanematsu and
Sawyer, 1973; Diefenbach, Carmel, Frantz, Ferin, 1976) and the
presence of a prolactin inhibitory factor (PIF) was demonstrated in
hypothalamic extracts (e.g. Talwalker, Ratner and Meites, 1963;
Kragt and Meites, 1967). In general, indoleamines appear to
stimulate, and catecholamines inhibit, prolactin secretion (Meites,
Lu, Wuttke et al, 1972; Weiner and Ganong, 1978) and a large number
of studies have suggested that DA is the major PIF (Ben-Jonathan,
1980; Leong et al, 1983). Dopamine and DA-agonists are effective
inhibitors of prolactin release both in vivo and in vitro (Vale,
Rivier and Brown, 1977) and DA receptors have been identified in the
anterior pituitary gland (e.g. Calabro and MacLeod, 1978; Cronin and
Weiner, 1979; Heiman and Ben-Jonathan, 1982). DA is present in
hypophysial portal blood (Ben-Jonathan, Oliver, Weiner, Mical and
Porter, 1977; Plotsky, Gibbs and Neill, 1978; Ben-Jonathan, Nei11,
Arbogast, Peters and Hoefer, 1980) in concentrations which are
sufficient to inhibit prolactin secretion (Gibbs and Neill, 1978).
However, DA does not appear to be the sole PIF (Leong et al, 1983)
and in low concentrations DA may even facilitate prolactin release
(Denef, Manet and Dewals, 1980). Several other factors also have
been shown to have PIF activity, including Y-aminobutyric acid
(Schally, Redding, Arimura, Dupont and Linthicum, 1977; Enjalbert,
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Ruberg, Arancibia et al, 1979a). The cyclic dipeptide metabolite of
TRH, diketopiperazine, has also been claimed to inhibit prolactin
release in vitro (Enjalbert, Ruberg, Arancibia et al, 1979b; Prasad,
Wilbur, Akerstrom and Banerji, 1980) but had no effect when injected
in vivo (Emerson, Alex, Braverman and Saffan, 1981). Recently the
56 amino acid peptide found at the C-terminus of the LHRH precursor
and called GnRH associated peptide (GAP), was also reported to
inhibit prolactin release (Nikolics, Mason, Szonyi, Ramachandran and
Seeburg, 1985).
The plasma concentration of prolactin is increased by a number
of different stimuli including suckling (Grosvenor, Mena and
Whitworth, 1979a), stress (Valverde, Chieffo and Reichlin, 1973;
Shin, 1979), and mating (Gunnet and Freeman, 1983). A surge of PRL
also occurs on the afternoon of pro-oestrus (Amenomori, Chen and
Meites, 1970) which, like LH, is dependent upon an increase in the
plasma concentration of oestrogen (Neill, Freeman and Tillson, 1971;
Freeman, Reichert and Neill, 1972). In a number of these situations
the abrupt withdrawal of PIF inhibition is insufficient to account
for the rapid increase in the rate of secretion of prolactin (e.g.
Valverde et al, 1973; Plotsky and Neill, 1982b). The presence of
prolactin releasing factors (PRF) has been demonstrated in
hypothalamic extracts (Dular, La Bella, Vivian and Eddie, 1974;
Rivier and Vale, 1974). Many peptides have been shown to release
prolactin and suggested as physiologically active PRF's, including
TRH (Tashjian, Barowsky, Jensen, 1971), vasoactive intestinal
peptide (Kato, Iwasaki, Iwasaki et al, 1978; Shaar, Clemens and
Dininger, 1979; Enjalbert, Arancibia, Ruberg et al, 1980), peptide
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histidine isoleucine (Kaji, Chihara, Kita et al, 1985a), and
oxytocin (Lumpkin, Sampson and McCann, 1983).
1.6 CATECHOL- AND INDOLEAMINERGIC INNERVATION OF THE HYPOTHALAMUS
There is considerable evidence for the involvement of central
aminergic neurons in the regulation of hormone secretion from the
anterior and posterior pituitary gland (e.g. Fink and Geffen, 1978;
Weiner and Ganong, 1978, Moos and Richard, 1982; Mason, 1983). A
detailed description of the aminergic innervation of all the
hypothalamic nuclei is beyond the scope of this chapter, but a brief
account follows of the major aminergic pathways to the hypothalamus
and the distribution of catechol- and indoleamine-containing nerve
terminals in the ME and pituitary gland. Changes in amine turnover
in the ME and pituitary gland have been shown to accompany
alterations in the concentration of hormones in peripheral blood.
Aminergic nerve fibres terminating in the ME may regulate anterior
pituitary hormone secretion either by way of direct axo-axonic
contact with the terminals of peptide secreting axons or by direct
action on the cells of the anterior pituitary gland following the
release of amines into hypophysial portal blood. Aminergic neurons
also participate in the control of hormone secretion from the
intermediate lobe of the pituitary gland by way of direct synaptic
contacts with the secretory cells, for example the inhibition of
melanocyte-stimulatory hormone secretion by dopamine (Tilders, Van




The DA pathways in the brain have been the subject of numerous
reviews (e.g. Moore and Bloom, 1978; Palkovits, 1981; Bjorklund and
Lindvall, 1984). Most of the DA terminals in the hypothalamus
originate from intrahypothalamic cell bodies; however, one
extrahypothalamic pathway (the mesocortical system) may have
projections to the ME from its cell bodies in the ventral tegmentum
and substantia nigra (Kizer, Palkovitz and Brownstein, 1976). There
are two intrahypothalamic DA pathways - the incerto-hypothalamic
system and the tuberoinfundibular system. The incerto-hypothalamic
fibre system (Lindvall, Bjorklund, Moore and Stenevi, 1974;
Bjorklund, Lindvall and Nobin, 1975) can be topographically
subdivided into two - in the caudal part, cell bodies are found in
the caudal thalamus, posterior hypothalamic area and medial zona
incerta and in the rostral part, cell bodies in the periventricular
nucleus (Bjorklund et al, 1975). The fibres from this system are
short and locally projecting (Bjorklund et al, 1975). The cell
bodies of the tuberoinfundibular system are located in the arcuate
nucleus and the anterior portion of the periventricular nucleus
(Dahlstrom and Fuxe, 1964; Hokfelt and Fuxe, 1972; Bjorklund, Falck,
Nobin and Stenevi, 1973a). The axons from these cell bodies project
to the neural and intermediate lobes of the pituitary gland (Smith
and Fink, 1972) and to the median eminence (Bjorklund, Falck,
Hromek, Owman and West, 1970; Smith and Fink, 1972; Jonsson, Fuxe
and Hokfelt, 1972; Bjorklund et al, 1973a,b; Ajika and Hokfelt,
1975).
Dopamine accounts for about 70% of the total catecholamine
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content of the ME (Cuello, Horn, Mackay and Iversen, 1973). Within
the ME the greatest concentration of DA terminals is present in the
lateral portions of the external layer (Bjorklund et al, 1970;
Lofstrom, Jonsson and Fuxe, 1976a). In the pituitary gland, the
largest content of DA is in the neural lobe, with smaller
concentrations in the anterior lobe (Saavedra, Palkovits, Kizer,
Brownstein and Zivin, 1975). Pituitary stalk section shows that the
DA content of both the neural and intermediate lobes originates from
the tuberohypophysial DA system (Saavedra, 1985).
1.6.2 Noradrenaline pathways
In contrast to DA, no NA containing cell bodies have been
identified within the hypothalamus; deafferentation of the medial
hypothalamus results in a major reduction of NA content (Brownstein,
Palkovitz, Tappaz, Saavedra and Kizer, 1976). There are two
principal NA neuron systems in the brain, which are comprised of
those neurons which have their cell bodies in the locus coeruleus
and those with cell bodies in the lateral tegmentum (Swanson and
Hartman, 1975; Moore and Card, 1984). Although the majority of the
NA input to the nuclei of the hypothalamus (including the ME)
originates from the cell bodies in the lateral tegmentum (Moore and
Card, 1984), several nuclei (the supra-optic, dorsomedial,
paraventricular and periventricular nuclei) also receive fibres from
the locus coeruleus (Segal, Pickel and Bloom, 1974; Jones and Moore,
1977; Moore and Card, 1984).
The NA containing terminals in the ME are mainly located in the
internal layer (Bjorklund et al, 1970; Lofstrom et al, 1976). In
addition, NA has been detected biochemically in both the neural and
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intermediate lobe of the pituitary (Saavedra et al, 1975). Whilst
all of the NA present in the intermediate lobe is probably of
central origin, approximately 40% of £ may be derived from fibres
of the sympathetic nervous system which originate in the superior
cervical ganglia (Saavedra, 1985).
1.6.3 5-Hydroxytryptamine pathways
It was difficult to demonstrate 5-HT-containing terminals in the
hypothalamus using fluorescence histochemistry due to the relative
insensitivity of the technique for this amine. However, with
biochemical (Saavedra, Palkovits, Brownstein and Axelrod, 1974),
autoradiographic (Chan-Palay, 1977; Parent, Descarries and Beaudet,
1981) and immunohistochemical (Steinbusch, 1981; Steinbusch and
Nieuwenhuys, 1981) techniques it was possible to show the widespread
distribution of 5-HT and 5-HT-containing nerve terminals throughout
the hypothalamus with high concentrations present in the
suprachiasmatic and ventromedial nuclei. The 5-HT neurons which
terminate in the hypothalamus, and pituitary, originate from the
dorsal and medial raphe nuclei which are located in the midbrain
(Dahlstrom and Fuxe, 1964; Fuxe, 1965). The hypothalamic content of
5-HT is reduced to approximately one third by lesion of the dorsal
raphe nuclei (Palkovits, Saavedra, Jacobovitz et al, 1977) or by
deafferentation of the MBH (Brownstein, Palkovits, Tappaz, Saavedra
and Kizer, 1976). The presence of intrahypothalamic 5-HT-containing
cell bodies has been reported (e.g. Chan-Palay, 1977; Beaudet and
Descarries, 1979; Parent et al, 1981). However, there are doubts as
to the specificity of the techniques used in these studies (Fuxe et^
al, 1978; Steinbusch and Nieuwenhuys, 1981) and no 5-HT cell bodies
*the NA in the neural lobe
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were found in the hypothalamus in the immunohistochemical studies of
Steinbusch and Nieuwenhuys (1981).
3
Autoradiography using H-5-HT (Calas, Alonso, Arnauld and
Vincent, 1974) and immunohistochemistry (Steinbusch and Nieuwenhuys,
1981) reveal an accumulation of 5-HT in the vicinity of the
hypophysial portal vessels in the external layer of the ME.
Biochemical studies also have shown a high content of 5-HT in the
neural lobe and smaller quantities in the anterior pituitary gland
(Saavedra, Palkovits, Kizer, Brownstein and Zivin, 1975) and
immunohistochemistry (Steinbusch and Nieuwenhuys, 1981) showed
5-HT-containing fibres in the neural lobe, but not in the
intermediate lobe or anterior pituitary. Since in the latter study
a high concentration of the 5-HT staining fibres were in the region
of the neural lobe adjacent to the intermediate lobe, it was
suggested that these fibres may be involved in the regulation of
peptide release from the intermediate lobe. Although the
immunoreactive 5-HT fibres of the neural lobe disappear after
pituitary stalk section, as measured biochemically, approximately
half the 5-HT remains (Friedman, Kreiger, Mezey et al, 1983) and
this is probably accounted for by the 5-HT content of non-neuronal
structures such as mast cells and platelets (Palkovits, Mezey,
Chiueh et al, 1986).
1.7 BIOSYNTHESIS OF NEUROPEPTIDES
Most biologically active peptides are synthesized as a component
of a larger molecular weight precursor which is formed by ribosomal
synthesis using a messenger RNA (mRNA) template. For some
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neuropeptides both the amino acid sequence of the precursor molecule
and the nucleotide sequence of the encoding mRNA are now known. The
primary product of the translation of mRNA is a polypeptide
(pre-pro-peptide), the N-terminal of which consists of a hydrophobic
signal peptide (about 15-30 amino acids in length) which is believed
to promote the passage of the pro-peptide, through the membrane of
the rough endoplasmic reticulum (RER) into the cisternae. The
signal peptide is cleaved from the remainder of the molecule by the
action of a metallo-endopeptidase which is associated with the inner
membrane of the RER (e.g. Jackson and Blobel, 1977; Zwizinski and
Wickner, 1980). The pro-peptide is translocated from the cisternae
of the RER into the Golgi apparatus where it is packaged into
secretory granules. Further processing occurs in the secretory
granules, though for some peptides some proteolytic cleavage may
occur first in the Golgi apparatus.
Within the pro-peptide molecule, subsequent proteolytic cleavage
usually occurs at sites which are denoted by pairs of basic amino
acids - generally Lys-Arg, but also Arg-Arg and Lys-Lys. Exceptions
to this occur with the cleavage at a single Arg residue in
pro-vasopressin to generate neurophysin II and a C-terminal
glycopeptide (Land, Schutz, Schmale and Richter, 1982) and the
cleavage of somatostatin-28 from pro-somatostatin. Peptides may be
modified in one or more ways either before or after cleavage by
glycosylation, phosphorylation, acetylation of the N-terminus,
amidation of the C-terminus, formation of disulphide bonds between
cysteine residues, and by the cyclization of glutamic acid to form
pyroglutamate. Sites for the amidation of a C-terminal are
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signalled by a glycine residue at the N-terminal side of a basic
amino acid pair - the enzyme necessary for this conversion has been
demonstrated (Bradbury, Finnie and Smythe, 1982).
Precursors may contain more than one active peptide within their
sequence and may be differentially processed in different tissues.
An example of this is pro-opiomelanocorticotrophin which is
processed in the anterior pituitary gland and intermediate lobe to
yield 0-1ipotrophin (e-LPH), adrenocorticotrophin (ACTH) and an
N-terminal fragment; in the intermediate lobe further processing of
ACTH generates o-melanotrophin (a-MSH) and corticotrophin-1ike
intermediate lobe peptide (CLIP) whereas s-LPH is cleaved to produce
y-LPH and 0-endorphin (Roberts, Phillips, Rosa and Herbert, 1978).
Precursors may also contain more than one copy of an active peptide,
e.g. six copies of methionine-enkephalin and one copy of the
leucine-enkephalin are contained within the sequence of pro-
enkephalin A (Gubler, Seeburg, Hoffmann, Gage and Udenfriend, 1982).
1.8 AIMS OF THIS THESIS
The objectives of this thesis were to examine the immunoreactive
forms of the hypothalamic peptides, LHRH, TRH and somatostatin,
which are released into hypophysial portal vessel blood and to study
some aspects of the hypothalamic control of anterior pituitary
hormone secretion. The technique of passive immunization, with an
anti-TRH serum, was used to examine the role of TRH in mediating the
prolactin response to suckling in lactating rats and the increased
secretion of thyrotrophin and prolactin in response to electrical
stimulation of the median eminence or paraventricular nuclei in male
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rats. The priming effect of LHRH was investigated in normal and in
hypogonadal mice to determine whether previous exposure of the
anterior pituitary gland to normal levels of LHRH, and a normal
pituitary content of LH, were necessary for the priming and the
releasing actions of LHRH. The bioreactivity of the small amount of
immunoreactive LH present in the anterior pituitary gland of
hypogonadal mice was also studied using an in vitro bioassay.
Direct measurements of LHRH release into rat hypophysial portal
blood were made to examine (i) the mechanism underlying the
suppression of LH release during lactation, (ii) the mechanism by
which A^-tetrahydrocannabinol blocks the pro-oestrous surge of LH,
and (iii) the role of endogenous opioid peptides in the regulation
of LHRH release in pro-oestrous or oestrous rats. In a final series
of experiments, 6-hydroxydopamine was used to lesion the terminals
of the catecholaminergic neurons in the median eminence and neuro-
intermedial lobe of the pituitary gland to examine the role of these






The animals used for the majority of the experiments were adult
male or female Wistar rats (180-300 g body weight) supplied by the
Edinburgh University Centre for Laboratory Animals. For some of the
experiments described in Chapters 6 and 9, female (180-300 g) or
lactating female (300-500 g) Wistar Cobs (caesarian originated
barrier sustained) rats were purchased from Charles River U.K. Ltd.
(Margate, Kent). At least 10 days were allowed for acclimatization
to the animal house before animals were used in experiments. Normal
and hypogonadal (hpg) male and female mice were bred in the
Department of Pharmacology from stocks obtained from the Department
of Human Anatomy, University of Oxford.
All animals were maintained under controlled lighting (lights
on 05.00 h - lights off 19.00 h) and temperature (22°C) and allowed
free access to food (for rats, Diet 41B, Oxoid, Basingstoke; for
mice, Oxoid breeding diet) and tap water. Chlortetracycline hydro¬
chloride (40 mg/1) was added to the drinking water of rats with
electrode implants, and the diet of these animals was supplemented
with bread and milk.
The oestrous cycles of female rats were determined by daily
inspection of vaginal smears and only animals which showed regular
4-day oestrous cycles were used. Each day of the cycle was termed
either metoestrus, dioestrus, pro-oestrus or oestrus depending on
the predominant cell type present in the smear. The characteristic
smears for each day were:
metoestrus - predominantly leucocytes together with some
epithelial and cornified cells
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dioestrus - leucocytes
pro-oestrus - clumps of nucleated epithelial cells
oestrus - cornified epithelial cells.
2.2 SURGICAL AND EXPERIMENTAL PROCEDURES
2.2.1 Anaesthetics
The following anaesthetics were used:
(A) 2,2,2-tribromoethanol (Aldrich Chemical Company, Gillingham,
Kent) in amylene hydrate (tert. amy! alcohol; BDH, Poole, Dorset)
1 g/ml (formerly available as 'Avertin'); 2 ml diluted with 8 ml of
absolute alcohol and 90 ml 0.9% saline solution. The dose used was
1.0 ml/100 g body weight administered by intraperitoneal (i.p.)
injection.
(B) Urethane (ethyl carbamate; Sigma, Poole, Dorset), administered
i.p. as a 10% solution (w/v) in 0.9% saline solution at a dose of
1.0 to 1.2 g/kg body weight.
(C) Saffan (Glaxovet Ltd., Uxbridge; formerly supplied as 'Althesin')
- 9 mg/ml alphaxalone (3a-hydroxy-5a-pregnane-ll,20-dione) and 3
mg/ml alphadolone acetate (21-acetoxy-3a-hydroxy-5a pregnane-11,20-
dione) solubilized in saline by 20%w/v polyoxyethylated castor oil.
(D) Anaesthetic ether - purchased from Macfarlane Smith Ltd.,
Edinburgh.
(E) Sodium pentobarbitone - purchased as Sagatal (May & Baker Ltd.,
Dagenham) and consisted of 60 mg/ml sodium pentobarbitone in
alcohol:propylene glycol vehicle (10:20 v/v). The dose used was
40-50 mg/kg body weight injected i.p.
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2.2.2 Collection of Peripheral Blood
Anaesthetized animals were placed and secured in a supine
position and a small incision (approximately 1.0-2.0 cm long) was
made longitudinally over one or both external jugular veins (EJV).
The tissue overlying the vein was gently retracted to expose the
vein. A 25 gauge hypodermic needle was introduced into the vein
through the pectoral is major muscle and the appropriate volume of
blood (generally 0.5 ml) was withdrawn into a syringe which had been
heparinized by rinsing with a small volume of heparinized saline
(1000 IU/ml). Immediately after collection, blood samples were
expelled into plastic tubes (LP2, Luckhams Ltd., Burgess Hill,
Sussex) which had been cooled on ice. The samples were centrifuged
at 4°C and the plasma aspirated with a glass pipette and stored in
plastic tubes (PT0944, Luckhams Ltd.) at -40°C.
2.2.3 The Collection of Hypophysial Stalk Blood
Hypophysial portal vessel blood was collected using the method
described by Worthington (1966) and modified by Fink and Jamieson
(1976). The method was based on the transpharyngeal approach used
by Green and Harris (1949) to expose and visualize the hypophysial
portal vessels.
The animal was anaesthetized with either urethane or Saffan and
placed in a supine position on a rat operating board. A midline
incision was made from the lower lip, extending apporoximately 5 cm
caudally. The subcutaneous tissues and salivary glands were
separated in the midline to expose the muscles overlying the
trachea. A 1 cm longitudinal incision was made in these muscles and
the trachea exposed and freed from the surrounding tissue to enable
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the passage of a small silk suture (3/0) underneath. A small
transverse incision was made in the trachea and one end of a short
(1.5 cm) length of polythene tubing (2.08 mm o.d., 1.57 mm i.d.)
inserted through the incision and tied in position with the suture.
The floor of the mouth was then injected with a 2% w/v solution of
lignocaine (Xylocaine; Astra Pharmaceuticals, Watford, Herts). A
long suture was placed through the tip of the tongue and gentle
traction applied to it. A tight ligature was placed around each
mandibular ramus in order to prevent bleeding from branches of the
lingual arteries. Long sutures were placed through each of the
flaps of the divided lower lip and were used for lateral retraction
of the two sides of the jaw. The lower jaw was then divided in the
midline, starting between the incisor teeth and continuing
caudually, dividing the musculature of the floor of the mouth and
oral mucosa along the left and right side of the mandible thus
resulting in mobilization of the tongue. The extent of these
incisions was limited so as to avoid damage to the lingual
arteries. A suture was placed around the base of the tongue to
prevent bleeding, and with the aid of a suture through its tip, the
tongue was retracted and secured in position over the chest, thereby
resulting in visualization of the soft palate and the epiglottis.
To ensure haemostasis small pieces of oxidised cellulose gauze
(Surgicel; Johnson & Johnson, Slough) were placed on the cut edges
of muscle and bone where the mandible and floor of the mouth had
been cut. From this stage onwards, the preparation was continued
with the aid of a Zeiss binocular operating microscope. A small
volume (0.1-0.2 ml) of lignocaine was injected into the soft palate
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which was then incised with an iris electrocautery (Weiss and Son,
London). The incision extended longitudinally along the midline from
about 1 mm anterior to the epiglottis, to the posterior edge of the
hard palate, and laterally to the pterygoid processes of the
sphenoid. The mucosa overlying the basosphenoid was removed with a
small pledget of cotton wool. A midline hole was drilled in the
basosphenoid bone from the sphenoid-basosphenoid suture extending
rostrally to the basophenoid-presphenoid suture. During drilling
the hole was packed with bone wax (Ethicon Ltd., Edinburgh) in order
to prevent bleeding from the spongy bone layer. The hole was
drilled deep enough to expose the inner table of bone which, when
fully exposed along the full length of the trough, was carefully
'polished' around its edge with a fine drill. When sufficiently
thin to yield to touch, the inner table of bone was gently removed
with watchmaker's forceps thus exposing the dura mater overlying the
portal vessels. Bleeding was controlled by applying gentle pressure
with a piece of cotton wool for a few minutes. A fragment of a
stainless steel razor blade held in a pin vice was used to make a
"V"-shaped cut in the dura and arachnoid mater. The cuts were
started over the pituitary gland and were extended rostrally
lateral to the portal vessels; the apex formed by the cuts lay just
rostral to the median eminence. Cerebrospinal fluid which entered
the operating field after the dura and arachnoid mater had been cut,
was absorbed with small pieces of cotton wool. The portal vessels
were fully exposed by reflecting the flap of dura mater and
arachnoid mater formed by the cuts. After ensuring haemostasis, the
animal was injected intravenously with 2500 IU of heparin (heparin
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sodium [mucous] 5000 IU/ml; Weddel Pharmaceuticals, London) by way
of the external jugular vein. Using fine iridectomy scissors
(Weiss and Son, London) the pituitary stalk was cut as close as
possible to the pituitary gland so as to include as many of the
portal vessels as possible. The blood issuing from the cut stalk
collected in the trough in the basosphenoid bone and was carefully
removed using a Pasteur pipette. To prevent the inclusion of any
fragments of pituitary stalk tissue the blood which collected during
the first 5 min after stalk section was discarded. Thereafter the
collection was continued for 15 min periods into either small
ice-cold plastic tubes (LP2; Luckhams Ltd.) or into ice-cold
ethanol. At the end of the collection period the volume of blood
was recorded as was, when appropriate, the volume of plasma obtained
after centrifugation. Unextracted plasma, and alcohol extracts of
plasma or blood were stored at -40°C until required for assay or
high performance liquid chromatography.
2.2.4 Electrode Preparation, Implantation and Stimulation Parameters
Unipolar and bipolar electrodes were constructed (Jamieson and
Fink, 1976; Chiappa, Fink and Sherwood, 1977) from 10-13 mm lengths
of platinum wire (0.125 mm in diameter) which were insulated to
within 0.3 mm of the tip with close-fitting glass capillary tubing.
A short length of insulated copper wire was soldered onto the upper
end of the electrode. The electrode assembly was mounted in a
Teflon jig and fixed in place with self-curing dental acrylic cement
(Simplex rapid; Howmedica, London). For bipolar electrodes, which
were used for stimulation of the paraventricular nuclei (PVN) the
electrode tips were separated by 1.0 mm.
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For implantation of PVN stimulating electrodes, male rats
(200-220 g body weight) were anaesthetized with tribromoethanol-
amylene hydrate and positioned with the head immobilized in a
stereotaxic frame in which the incisor bar was 5 mm higher than the
ear bars. A midline incision was made in the scalp to expose the
frontal and parietal bones, a hole (4x4 mm) drilled in the frontal
bones immediately anterior to the bregma, and the dura mata
revealed; care was taken to avoid damage to the superior sagittal
sinus. Bleeding during any point of the operative procedure was
controlled with gentle pressure with cotton wool soaked in 0.9%
saline solution. Three small stainless steel screws (approximately
1.5 ran in diameter) were driven into small drill holes made around
the outside margin of the exposed area. The dura mata was carefully
ruptured and the electrode implanted (co-ordinates; 6.4 mm anterior,
-1.6 mm vertical and 0.5 mm on either side of the midline; de Groot,
1959) with the aid of a triplanar micromanipulator (Prior U.K.).
The electrode assembly was secured to the skull using dental cement
which was carefully applied round the electrode and screws. Once
the cement had set firmly, the animal was removed from the
stereotaxic frame and the scalp sutured. Animals were used 3-10
days after implantation.
For median eminence (ME) stimulation the median eminence was
exposed using the transpharyngeal approach (2.2.3) at the time of
the experiment and a unipolar electrode placed onto the ME under
visual control and with the aid of a triplanar micromanipulator.
Care was taken to avoid damage to the hypophysial portal vessels. A
metal clip attached to the muscles of the jaw served as an
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indifferent electrode.
The electrical stimulus (Fink and Jamieson, 1976) for both ME
and PVN preparations was produced by a Neurolog constant current
stimulator (Digitimer, Welwyn Garden City, Herts), and consisted of
accurately balanced trains (30 s on, 30 s off) of biphasic
rectangular pulses with a frequency of 50 Hz, pulse amplitude of 500
pA and pulse duration of 1 ms. The stimulus was monitored with a
calibrated oscilloscope (Model 14D-15; Scopex, Letchworth, Herts)
and for most experiments was applied for one or two 15 min periods.
At the end of the experiment, the heads were removed from
animals with PVN electrode implants, trimmed and fixed in 4%
phosphate buffered formalin. Subsequently the electrodes were
carefully removed after disolving the dental cement with chloroform,
and the brains dehydrated in alcohol and embedded in paraffin wax.
Serial 10 pm sections were cut, stained with haematoxylin and eosin
and examined for correct placement of the electrode tips.
2.2.5 Preparation and Implantation of Oestradiol-Containing Capsules
Silastic capsules containing oestradiol-170 were prepared
according to the method of Karsch, Dierschke, Weick, Yamaji,
Hotchkiss and Knobil (1973) and as used by Henderson, Baker and Fink
(1977). 'Silastic' medical grade tubing (2.6 mm internal diameter,
4.9 mm outer diameter; catalogue number 601-321, Dow Corning
Corporation, Michigan, U.S.A.) was cut into 3 mm lengths. One end
of the capsule was sealed with 'Silastic' elastomer which was made
by mixing catalyst and elastomer (approximately 1:1000 v/v;
catalogue number 382, Dow Corning Corporation). The 4-5 mm length
of the inside of the capsule was then packed with crystalline
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oestradiol-17e (Sigma, Poole) and the open end then sealed with
elastomer. Capsules were implanted subcutaneously into the middle
of the back of animals through a small skin incision made on the
back of the neck. The capsules were incubated in donor animals
(long-term ovariectomized rats) for at least 24 hours before their
removal and immediate re-implantation into experimental animals. By
pre-incubation of the capsules in donor rats, the initial high
spikes of plasma oestradiol-17g, observed in animals during the
first 24 h after implantation of non-incubated capsules, were
avoided (Karsch et al, 1973).
2.2.6 Preparation of Hypothalamic and Pituitary Homogenates
Animals were decapitated and the brains quickly dissected onto
an ice-cold glass microscope slide. A block of hypothalamic tissue,
which extended from the anterior edge of the optic chiasma to the
caudal edge of the mammillary body and laterally to the hypothalamic
sulci and 2 mm deep, was removed using a fine pair of scissors. For
assay of hypothalamic peptides the block of tissue was weighed using
a torsion balance, transferred to 1 ml of ice-cold 0.1 N HC1 and
homogenized in an all glass, hand held, homogenizer (Jencons,
U.K.). For determination of catecholamines, only the SME (median
eminence together with the remains of the pituitary stalk) was
dissected. The SME was removed by gently holding the stalk in
watchmaker's forceps and, using iridectomy scissors, undercutting
an area of the ME about 2 mm wide, from the stalk-ME junction and as
deep as the floor of the third ventricle. The pituitary was removed
from its dural capsule and the neurointermediate lobe (NIL)
dissected from the anterior pituitary. SME and NIL samples were
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stored in 2 ml screw top ampules (Sterilin, Teddington, catalogue
number 506) in liquid nitrogen. The anterior pituitary was weighed
and homogenized in 1 ml of 0.9% (w/v) saline solution. Hypothalamic
and anterior pituitary homogenates were stored at -40°C until
required for assay.
2.3 FLUORESCENCE HISTOCHEMISTRY
Several methods have been developed to enable the visualization
of catechol- and indoleamine-containing nerve terminals and cell
bodies in the central and peripheral nervous system by the
production of fluorescent derivatives which are formed as a result
of condensation reactions between the amines and formaldehyde or
glyoxylic acid (e.g. Falck, Hillarp, Thieme and Torp, 1962; Lindvall
and Bjorklund, 1974; Corrodi and Jonsson, 1976). By perfusion of
the brain with a mixture of formaldehyde and gluteraldehyde (the
'FAGLU1 technique) the brain is rapidly fixed and the fluophores,
which are formed at room temperature remain stable even when the
tissue is maintained in aqueous solution (Furness, Heath and Costa,
1978). The FAGLU method provides a relatively simple and reliable
technique for the examination of catecholamine distribution in
serial sections of rat brain, and was used in the experiments
described in Chapter 9 to investigate the extent of the
6-hydroxydopamine-induced lesions of the mediobasal hypothalamus.
2.3.1 Apparatus and Solutions for Perfusion
The perfusion apparatus, which was only slightly modified from
that described by Furness et al. (1978), consisted of two 1 litre
aspirator bottles which were connected to an 18 gauge hypodermic
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needle by way of a three way tap, and also connected to a
sphygmomanometer bulb and mercury manometer to maintain and monitor
the perfusion pressure respectively. All connections were made
using short lengths of wide bore, thick-walled tubing. The one
bottle contained a 1% (w/v) solution of sodium nitrite and the other
contained the fixative solution (4% formaldehyde ['Analar' grade,
BDH Chemicals Ltd., Poole] - 0.5% gluteraldehyde ['Electron
Microscope1 grade, TAAB Laboratories, Reading] in 0.1 M sodium
phosphate buffer, pH 7.0).
2.3.2 Perfusion of Animals and Preparation of Brain Sections
Animals were anaesthetized with sodium pentobarbitone and
injected with heparin (4000 IU/kg body weight i.p.), and immobilized
on an operating board. The thorax was opened to expose the heart
and 4 mg gallamine triethiodide (Flaxedil, May and Baker, Dagenham)
injected into the heart. The tip of the 18 gauge needle was
inserted into the left ventricle and held in position with a clamp
across the ventricle. A second clamp was placed upon the abdominal
aorta. The vena cava was cut and the blood flushed out by perfusing
the animal with the sodium nitrite solution for 1-2 min. The
perfusion was then continued with fixative for a further 10 min at a
perfusion pressure of 120 mm Hg. When the perfusion was completed
(after about 200 ml of fixative had been used) the fixed brain was
quickly removed and transferred to approximately 50 ml of ice-cold
fixative and stored in the dark at 4°C for 3-5 days until
sectioned. The brain was trimmed to a 5 mm thick block which
contained the hypothalamus and was mounted onto a glass slide with
Loctite quick setting adhesive (B10-904, Loctite Corporation,
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Newington). The block was held in position until set by applying
gentle pressure with a glass plate for about 5 min, after which 30
pm thick sections were cut at room temperature using a 'Vibrotome'
(Model G, Oxford Laboratories, California) (Furness, Costa and
Blessing, 1977). Throughout the sectioning procedure the blocks
were kept moist with ice-cold fixative. Sections were removed from
the blade of the vibrotome using a fine brush, transferred to a dish
of fixative and floated onto glass microscope slides. The sections
were dried for 30 min over phosphorous pentoxide in a dessicator in
the dark and mounted in 'Fluoromount' (Gurr, Essex). Fluorescence
was examined using a Leitz Orthoflux f 1 uorescencemicroscope with
epi-illumination provided by a 200 W high pressure mercury lamp
(Wotan, Germany) and photographed on Tri-X, 400 ASA film (Kodak).
2.4 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)
2.4.1 HPLC separation of peptides
Reversed-phase HPLC, used in combination with sensitive
radioimmunoassays, provides a powerful technique for qualitative and
quantitative studies of biologically important peptides (e.g. 0'Hare
and Nice, 1979; Cody, Wilkes and Hruby, 1984; Herman, Lang, Unger,
Bayer and Ganten, 1984), and was used in the following studies to
examine the immunoreactive forms of TRH (Chapter 4) and LHRH
(Chapter 6) which are present in the hypothalamus and released into
hypophysial portal vessel blood.
2.4.1.1 Sample Preparation
Freeze- or vacuum-dried tissue or blood extracts were
redissolved in 1.4 ml 0.1% trifluoroacetic acid (TFA; Rathburn
*using BG 12/3 mm primary filter
and Leitz K510 or K530 secondary
filters.
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Chemicals Ltd., Walkerburn, Scotland) and centrifuged briefly (two
minutes at full speed in a MSE Micro Centaur centrifuge) to remove
particulate material. One mi 11i1itre of the supernatant was applied
to the HPLC column and the remaining solution evaporated to dryness,
re-constituted in assay buffer, and assayed for total immunoreactive
LHRH or TRH content. In a few samples, a small amount of fine
particulate material remained in suspension and this was removed
before sample injection by filtration through 0.2 urn regenerated
cellulose filters (BAS Inc., West Lafayette, Ind.).
2.4.1.2 Chromatography
The chromatographic separation of peptides in tissue and blood
extracts was achieved using an Altex HPLC system as described
below. The mobile phase was pumped through the system at a constant
flow rate of 1 ml/min by two Altex 110A pumps. Samples were applied
onto the column either manually by way of an Altex 210 injection
valve fitted with a 1 ml injection loop or automatically using an
Altex model 500 autosampler. The analytical column consisted of a
4.6 x 250 mm column packed with 5 urn Ultrasphere ODS (Altex,
Berkely, CA); this main column was protected by a 2.1 x 50 mm
pre-column packed with Co Pell ODS (Whatmans). Separation was
achieved with the aid of a linear gradient produced with the aid of
an Altex 421 controller. The gradient changed from 100% solvent A
to 100% solvent B over 50 minutes, where
Solvent A was 0.1% (v/v) aqueous TFA (HPLC grade water; Fisons,
Loughborough)




The eluant from the column was passed through an Altex
spectrophotometer flow cell in an Hitachi model 100-10
spectrophotometer and the absorbance at 210 nm recorded on a Gil son
N2 chart recorder. As a result of the large number of absorbing
compounds present in portal blood, the spectrophotometer trace
provided little information about the peptides in portal blood
extracts, but was useful for monitoring column performance and
examining the retention times of peptide analogues during screening
runs before radioimmunoassay. Finally, the outflow from the column
was passed to an LKB 2111 multirac fraction collector and fractions
were collected every 0.3 min (maximum of 180 fractions). All the
connections between the various components of the HPLC system were
made with the shortest possible lengths of narrow bore stainless
steel tubing. The collected fractions were stored at -40°C until
vacuum dried over phosphorous pentoxide, reconstituted in assay
buffer and assayed for LHRH or TRH-like immunoreactivity.
2.4.2 HPLC with Electrochemical Detection (LCED)
HPLC with electrochemical detection was used for the
simultaneous determination of noradrenaline (NA), dopamine (DA),
dihydroxyphenylacetic acid (D0PAC), 5-hydroxytryptamine (5-HT) and
5-hydroxyindole acetic acid (5-HIAA) in extracts of the SME and NIL
of 6-OHDA lesioned rats (Chapter 9). Full details of the principles
of continuous flow voltametry and theory of the electrochemical
reactions involved in electrochemical detection have been described
by Adams (1969), Weber and Purdy (1978) and Mefford (1981).
Briefly, the method depends upon the ability of the amines under
study to undergo oxidation when subjected to a fixed potential.
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Application of the oxidative potential results in the loss of two
electrons from each catechol- or indoleamine molecule to the
detector electrode. The concentration of the amine in solution can
be determined since the molar concentration is proportional to the
current generated by this oxidative mechanism.
2.4.2.1 Sample Preparation
Samples for LCED (SME and NIL dissected as described in 2.2.6)
were homogenized, using glass hand-held homogenizers, in 80 pi of
A
0.2 M perchloric acid in 10 M cysteine solution to which had
been added 400 pg/20 pi of n-acetyl dopamine (n-AcDA; Sigma, U.K.)
as internal standard (IS). The homogenates were centrifuged at
2000 £ for 5 minutes, the supernatant was removed immediately before
injection and filtered through 0.2 pm regenerated cellulose filters
(BAS Inc., West Lafayette, Ind.) using BAS MF 1 centrifugal
microfiIters .
2.4.2.2 Chromatography and Detection
Separation of the catechol- and indoleamines in the samples was
achieved on a 250 x 4.6 mm analytical column of Ultrasphere 0DS
(5 pm) (Altex, Berkley, CA) protected with a 50 x 4.6 nm Ultrasphere
0DS precolumn. 20 pi of either standards or filtered tissue
homogenate were applied to the column by way of a Rheodyne 7125
injection valve fitted with a 20 pi sample loop. An Altex 110A pump
was used to deliver the mobile phase to the system at a constant
rate of 1 ml/min. The mobile phase (Mayer and Shoup, 1983, as
modified by Watts, 1982) consisted of 0.1 M sodium acetate - 0.1 M
sodium citrate buffer, methanol (HPLC grade; Rathburn Chemicals
Ltd., Walkerburn, Scotland) and tetrahydrofuran (Spectrophotometric
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grade and inhibitor free; Aldrich Chemical Company, Gillingham)
(95:5:2, v/v) adjusted to pH 5.0 by the addition of 6.5 g sodium
hydroxide, and with the addition of 100 mg/1 of sodium
octanesulphonic acid (Fisons, Loughborough) as ion-pair reagent.
Before the inclusion of tetrahydofuran, the buffer was filtered by
passage through 0.22 pm Millipore^ filters and degassed under
vacuum. Eluant from the analytical column was passed through a
LC-17 glassy carbon transducer cell connected to a LC-4A
amperometric detector. The working potential of the electrode was
maintained at + 0.70 V with respect to an Ag/AgCl reference
electrode and the generated current amplifed and displayed on a
Tarkan 600 chart recorder set at a range of 1 V.
Fresh standard solutions of NA, DA, D0PAC, 5-HT, 5-HIAA and
n-AcDA (Sigma, U.K.) were prepared daily in 0.2 M perchloric acid in
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10 M cysteine solution from 100 pg/ml stock solutions (stock
solutions were stored in the dark at 4°C for a maximum of 2
months). Standards were routinely injected at concentrations of 50,
100, 200 and 2000 pg/20 pi injection and the standard curves were
linear over a range of 20-2000 pg/injection. The lower limit of
sensitivity of the assay was taken as three times the amplitude of
baseline noise and was between 15 and 25 pg/injection. Typical LCED
traces produced by two of the standard mixtures, and a portion of a
typical standard curve are show in Figures 2-1 and 2-2, respectively.
2.4.2.3 Identification of Compounds and Calculation of Results
Routinely, peaks in traces from sample extracts were identified
on the basis of similar retention time to the known compounds in the


















FIGURE 2-1: Standard chromatograms for (A) 2 ng/20 pi and (B) 100 pg/20 pi
of noradrenaline (NA), dopamine (DA), 3,4 dihydroxyphenyl-
acetic acid (DOPAC), 5-hydroxyindole acetic acid (5-HIAA) and
5-hydroxytryptamine (5-HT) with 1 ng/20 pi of n-acetyl dopamine
(IS - internal standard).
Concentration (pg^ 20|il)
FIGURE 2-2: Standard curves for noradrenaline (▼), 3,4 dihydroxyphenyl-
acetic acid (V), dopamine (•), 5-hydroxytryptamine (□) and
5-hydroxyindole acetic acid (O), calculated by peak height
ratio relative to the internal standard. All standard
curves were linear up to 2 ng/20 ul injection.
extracts of NIL and SME samples were chromatographed on the LCED
system and analysed using two different oxidation potentials (+0.60
and + 0.45 V). Since the compounds being measured differ in their
abilities to oxidise at different applied potentials, by comparing
the response ratios of the unknown compounds and standards at two
potentials, the identity of the compounds in the sample can be
confirmed (Blank, 1976; Mefford, 1981; Mayer and Shoup, 1983).
Table 2-A shows that the response ratios in the tissue extracts were
similar to those produced by the standard compounds and indicate
that each of the peaks analysed in the tissue extracts is due to the
presence of a single compound with similar electrochemical
properties to the standard compounds.
The heights of all the identified peaks above the baseline of
the chart record were measured and standard curves were constructed
for each of the amines by linear regression of peak height ratio
(PHR) against concentration where
p„n = Peak height of standards
Peak height of the internal standard
As the same quantity of IS was added to both samples and standards,
once the PHR was measured for the unknown sample, it was possible to
calculate the amine concentration in the sample directly from the
standard curve whilst simultaneously correcting for variations in
injection volume and the recovery through the extraction procedure.
2.5 RADIOIMMUNOASSAYS AND PROTEIN BINDING ASSAYS
The techniques and general principles of protein binding assays
and radioimmunoassays (RIA) have been the subject of numerous
reviews (Midgley, Niswender and Rebar, 1969; Kirkham and Hunter,
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1971; Odell and Daughaday, 1971; Yalow and Berson, 1971; Ekins,
1974; Jaffe and Behrman, 1979; Yalow, 1980) and only a brief
description of the general methods for RIA will be outlined here.
Individual details of the methods of preparation and purification of
radiolabelled hormones and the composition of the buffers used in
the assays are given in the Appendices. The principle of RIA is the
competition between radio-labelled and unlabelled antigen for
binding sites on a finite number of specific antibody molecules.
The binding of the added labelled antigen is inversely proportional
to the concentration of the unlabelled antigen in the sample, which
can hence be determined.
1 PR 1 PR
Hormones were labelled with I (Na I, 100 mCi/ml;
Amersham International U.K.) using a modification of the
chloramine-T method (Greenwood, Hunter and Glover, 1963). With the
exception of the TRH and corticosterone assays, for which bound and
free hormone were separated by alcohol precipitation of the
antibody-hormone complex or dextran-coated charcoal separation
respectively, double antibody radioimmunoassay techniques (Utiger,
Parker and Daughaday, 1962) were used throughout. In all assays the
bound hormone was retained for counting, either by liquid
scintillation counting or using a Berthold Mag 310 Gamma counter
(Scotlab Instrument Sales, Bellshill, Scotland).
Assay results were calculated either by the inbuilt machine
programme of the Berthold counter, or manually by linear regression
from standard curves constructed with logit B/Bo as ordinate and log
concentration as abscissa, where B/Bo represents the ratio of bound
to total bound and,
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logit B/Bo = loge B/Bo
(1 - B/Bo)
Upper and lower limits of detection of the assay were taken as the
concentrations at which 10 and 90%, respectively, of the labelled
antigen was bound to the primary antibody. The reproducibi1ity and
reliability of the assays were determined by the inclusion of two
known quality control pools in each assay, thereby enabling
calculation of inter- and intra-assay coefficients of variation (CV)
(Rodbard, 1971). The pools consisted of plasma from ovariectomized
rats (LH and FSH, low and high pools), male rat plasma to which had
been added either acid extracts of rat hypothalamic tissue (LHRH
high pool) or synthetic LHRH (LHRH low pool), or plasma from
unstressed or ether-stressed male rats (prolactin and TSH, low and
high pools); for the TRH radioimmunoassay, the pools consisted of
solutions of the synthetic tripeptide in assay buffer. Additional
quality control data were obtained by monitoring total counts, blanks
and total bound (both as percentages of total counts) and the
calculated equivalent concentration of hormone corresponding to 20%,
50% and 80% of total bound.
Samples for all assays were aliquoted into disposable plastic
test-tubes (LP3, Luckhams Ltd.) using automatic pipettes (Pipetman,
Gilson) and reagents dispensed using a Micromedic automatic
pipetting system.
2.5.1 Radioimmunoassay of Thyrotrophin Releasing Hormone
The TRH content of hypophysial portal blood extracts or HPLC
fractions was determined using an anti-TRH serum (number 420) raised
and characterized by Dr. Hamish Fraser (MRC Reproductive Biology
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Unit, Edinburgh) (Fraser and McNeilly, 1982). The antiserum was
raised in sheep immunized using a TRH-bovine serum albumin (BSA)
conjugate. The cross-reaction of this antiserum with TRH, analogues
of TRH and with some other hypothalamic peptides are summarized in
Table 2-B.
Synthetic TRH (Peninsula Laboratories, San Carlos, California)
was used for standards (range 2-800 pg/assay tube) and for
125
iodination. [ I]—TRH was prepared and purified (Joseph-Bravo,
Charli, Palacios and Kordon, 1979). Samples and standards, diluted
with phosphate-buffered saline (PBS) pH 7.4 with 0.25% BSA, were
pre-incubated with antiserum for 24 h at 4°C, after which
radiolabeled TRH was added (5000 cpm/tube). The final antiserum
concentration was 1:120,000 in an assay volume of 400 pi. After a
1 25
further 36 h incubation at 4°C, antibody-bound and free I-TRH
were separated by the addition of 1.4 ml ice-cold ethanol. Typical
standard curves, which also demonstrate the parallel displacement of
radiolabelled TRH by hypothalamic, or hypophysial portal blood
extracts, are shown in Figures 2-3 and 2-4. The lower limit of
detection of the assay ranged from 2-4 pg/tube, and the inter- and
intra-assay coefficients of variation were 3.8% and 2.6% (for
quality control of 9 pg/tube), and 5.2% and 10.8% (for quality
control of 174 pg/tube), respectively. Other quality control data
is shown in Figure 2-5.
2.5.2 Radioimmunoassay of Luteinizing Hormone Releasing Hormone
(LHRH)
LHRH was measured in hypophysial portal blood and fractions
recovered from the HPLC of hypothalamic or portal blood, using the
-50-
Table 2-B Cross-reaction of TRH, analogues of TRH and other
hypothalamic peptides with ovine anti-TRH serum number 420
Peptide Relative cross-reactivity
pGlu - His - ProNH2 100
pGlu - Phe - ProNH2 100
pGlu - Lys - ProNH2 12.5
pGlu - Met - ProNH2 1.4
pGlu - His - ProOH < 0.005
pGlu - Leu - ProOH < 0.005
pGlu - Ala - ProOH < 0.005
pGlu - His - Pro-propylamide 0.03
H.His - ProNH2 0.004
pGlu - His - TrpNH2 0.05
Glu(BOC) - His - ProNH2 0.96




Corticotrophin releasing hormone < 0.005
Substance P < 0.005
B-Endorphin < 0.005
From data in Fraser and McNeilly (1982) and H.M. Fraser
(personal communication).
TRH(pg/TUBE)






































































FIGURE 2-5: Quality control data for thyrotropin releasing hormone (TRH)
radioimmunoassays.
double antibody radioimmunoassay developed by Nett, Akbar,
Niswender, Hedlund and White (1973) as used and described by Fink
and Jamieson (1976) and Chiappa and Fink (1977). The primary
antibody was either the R-42 anti-LHRH antiserum (provided by Dr.
G.D. Niswender, NIADDK) which was raised in a rabbit against a
conjugate of the free acid form of LHRH conjugated to BSA, or
antiserum HC-6 which was raised in rabbits by G. Fink against a
LHRH-haemocyanin conjugate. The R-42 antiserum recognizes the whole
LHRH molecule and does not cross-react with a series of fragments of
LHRH although it does recognise the free-acid (Nett et al., 1973;
Fink and Jamieson, 1976). The cross-reactions of the HC-6 antiserum
are summarized in Table 2-C. Synthetic LHRH (ICI Pharmaceuticals,
Macclesfield, U.K.) was used for standards and for iodinations.
Samples for assay were diluted with PBS/0.1% Gelatine buffer and
incubated for 24 h at 4°C with antiserum (added at a working
dilution of 1/90,000 [HC-6] or 1/80,000 [R-42]; all antisera were
diluted with PBS/0.5 M disodium EDTA/0.5% normal rabbit serum, pH =
1
7.0) and I labelled LHRH (5000 cpm/tube) before the separation
of bound and free hormone by incubation for a further 24 h with the
second antibody (ARGG, anti-rabbit gamma globulin raised in donkeys,
Scottish Antibody Production Unit, Carluke) added at a working
dilution of 1:20 in PBS. A typical standard curve for an assay in
which the HC-6 antiserum was used is illustrated in Figure 2-6.
Only a small number of LHRH assays were performed and, therefore,
full quality control data cannot be given, but the assays conformed
to the quality control parameters previously established.
Table 2-C Cross-reaction of LHRH, analogues of LHRH, and other
hypothalamic peptides with the HC-6 anti-LHRH serum
Peptide Relative cross-reactivity (%)
LHRH 100%
LHRH fragments: 1-9 < 0.05
1-8 < 0.05
1-6 < 0.05







[D-pG1y1,D-Ph e2,D-Trp3'6 j-LHRH 3.5
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FIGURE2-6:Standardcurvefromrepresentativessaylu inizinghormo el si(LHRH)obtained usingtheHC-6anti-LHRHserumpr maryantibody.E chointrep e ntstm aof3r li ates.
2.5.3 Radioimmunoassay of Thyrotrophin (TSH)
Plasma or pituitary concentrations of thyrotrophin were
determined by double antibody RIA using materials supplied by
NIADDK. The samples obtained in the experiments described in
Chapter 9 were assayed as used and described by Pickering (1978) and
Pickering and Fink (1979b) using NIADDK-rat TSH RP-1 as reference
material. Samples and standards were incubated with antibody for 24
h at 4°C before addition of ^1 labelled thyrotrophin (10,000
cpm/tube). After a further 48 h incubation, ARGG was added to
separate antiserum-bound and free hormone. The majority of assays
were performed using a modification of this assay as described below.
Samples and standards were diluted with PBS/1% BSA and
incubated at 4°C for 6 days with rabbit anti-rat TSH-S-2 added at a
125
working dilution of 1/2500 and I labelled thyrotrophin
(rTSH-I-6). Bound and free hormone were separated by incubation for
24 h with ARGG at 4°C. The standard for these assays was
NIADDK-rTSH-RP-2 which is 176 times more potent than the RP-1
reference preparation. Inter- and intra-assay CV were 4.8 and 6.5%,
respectively. Figures 2-7 and 2-8 show a typical standard curve and
summarize the quality control data for the assays included in this
thesis.
2.5.4 Radioimmunoassay of Prolactin
Plasma and pituitary concentrations of prolactin (PRL) were
determined by double antibody RIA using materials supplied by the
NIADDK as used by Pickering and Fink (1979b) and Pickering (1978).
The standard curve (range 0.5-64 ng/ml) was prepared from
rat-PRL-RP-1 and rat-PRL-I-5 was used for iodination. Standards and
-52-
TSH(ng/ml)














































FIGURE 2-8: Quality control data for the thyrotrophin (TSH) radio¬
immunoassays .
samples for the assay were suitably diluted in assay buffer (PBS/1%
BSA) and incubated with the antiserum (anti-rat-PRL-S5, added at a
working dilution of 1:5000) for 24 h at 4*0 before the addition of
125
I-PRL (approximately 10000 cpm/tube). After further incubation
for 48 h at 4°C, the antiserum-bound hormone was separated from the
free hormone using ARGG (SAPU) at a working dilution of 1:20. A
typical standard curve is shown in Figure 2-9 and quality control
data in Figure 2-10. Inter- and intra-assay C.V. were 5.3% and 1.4%
respectively. For plasma samples assayed in duplicate in 2-20 ul
aliquots,. the lower limits of detection were 15-50 ng/ml.
2.5.5 Radioimmunoassay for Luteinizing Hormone
LH was measured in rat and mouse plasma and pituitary samples
using the ovine-ovine RIA developed by Niswender, Midgley, Monroe
and Reichert (1968). The protocol used was that described by Aiyer
(1974) and Aiyer and Fink (1974). Ovine-LH (LER-1056-C2) provided
by Dr. L.E. Reichert, Jr. (NIADDK) was used for iodination and ovine
LH (NIH-LH-S18) used to prepare the standards (range 0.25-16
ng/ml). The anti-ovine LH antiserum (GDN-15) was provided by Dr.
G.D. Niswender (NIADDK).
Samples and standards were diluted in PBS/1% BSA and
pre-incubated with antiserum (added at a working dilution of 1:6000)
for 24 h at 4°C before the addition of ^I-LH (10,000 cpm/tube).
The second antibody (ARGG, SAPU 1:20) was added after a further 48 h
incubation period at 4°C. A typical standard curve is reproduced in
Figure 2-11, and quality control data in Figure 2-12. The inter-
and intra-assay coefficients of variation were 7 and 9%
respectively. For a 50 yl plasma sample the lower limit of
-53-
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FIGURE 2-10: Quality control data for the prolactin radioimmunoassays,
-3J
i1 0-255712486 LH(ng/ml)




























































FIGURE 2-12: Quality control data for the luteinizing hormone (LH)
radioimmunoassays.
sensitivity of the assay was generally 0.8 ng LH/ml.
2.5.6 Radioimmunoassay of FSH
The concentration of FSH in rat plasma and pituitary samples
was determined by RIA using materials provided by the NIADDK
according to the method of Danne and Parlow (1971) as used by
Chiappa (1976) and Sarkar (1979). NIADDK-rat-FSH-I 1 was used for
iodination and rat-FSH-RP-1 for the preparation of the standard
curves. Standards and samples were diluted with PBS/1% BSA and
incubated at 4°C with antiserum (NIADDK-anti-rat-FSH-S6, used at a
1 oc
working dilution of 1:2500) and I FSH (12000 cpm/tube). After
6 days incubation, antibody bound and free hormone were separated
using ARGG. A representative standard curve is shown in Figure
2-13. All samples were incubated in a single assay for which the
intra-assay coefficient of variation was 7.1%.
2.5.7 Measurement of Plasma Corticosterone
Plasma corticosterone was estimated using the competitive
protein binding assay (Chiappa and Fink, 1977; Chiappa, 1976) which
was based on the method described by Corker, Naftolin and Richards
(1971).
Progesterone, which would otherwise have interfered in the
assay, was removed from the plasma samples by extraction with
petroleum ether. The aqueous phase from this extraction contained
corticosterone which was then extracted with diethyl ether. The
aqueous phase from the second extraction was discarded and the ether
removed by evaporation under a stream of nitrogen. The samples were
redissolved in TRIS buffer (pH 8.0) for assay. The efficiency of
the extraction was monitored by the recovery of 1000 cpm of
-54-
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FIGURE2-13:Standardcurveofthefolliclstimulatingh rmon( SH)adioi munoassay.E hpoiepresents themeanof3replicates.
3
H-corticosterone added to each plasma sample at the start of the
extraction procedure. The final concentration of corticosterone
measured in the assay was corrected for losses during extraction.
The assay was performed in clean glass test tubes (75 x 10 mm;
Gallenkamp). Extracted samples and standards (Corticosterone,
Sigma, U.K.) together with corticosterone binding globulin (human
3
female plasma, diluted 1:500) and H-corticosterone (la, 2a
3
[n]- H corticosterone, Amersham International, UK; approximately
10,000 cpm/tube) were incubated for 45 min at 45°C followed by 10
min at 4°C. Bound and free hormone were separated by addition of
dextran-coated charcoal (Norit-A activated charcoal and dextran
T—70; Sigma, UK). A typical standard curve is shown in Figure 2-14.
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FIGURE2-14:Standardcurveoftheorticosteronecompetitivbi di gas ay.E chp intepr sen shanf duplicateeterminations.
CHAPTER 3
The Immunoreactive Forms of Somatostatin Released Into
Hypophysial Portal Vessel Blood
3.1 INTRODUCTION
The tetradecapeptide somatostatin-14 (SS-14) is produced by
cleavage of a larger precursor molecule from which a number of
immunoreactive (IR) forms of intermediate molecular weight are also
formed. The sequence of Pre-Pro-SS has been determined by the
cell-free translation of messenger RNA (mRNA) from rat medullary
thyroid carcinoma (Goodman, Aron and Roos, 1983) and shown to be a
peptide containing 116 amino acids (molecular weight, 12,737
daltons) with the SS-14 sequence at the C-terminus (amino acid
residues 102-116). Removal of the signal peptide (residues 1-14)
yields Pro SS (92 amino acid residues, 10,388 daltons; Goodman ert
al., 1983) and further cleavage of this may generate at least 7
other peptides (Benoit, Ling, Alford and Guillemin, 1982b; Benoit,
Bohlen, Esch and Ling, 1984) as summarized in Figure 3-1. The
N-terminally extended form of SS-14, comprised of 28 amino acids
(SS—28; Fig. 3-2), had first been identified in the intestine
(Pradayrol, Jornvall, Mutt and Ribet, 1980) and was later
characterized in the hypothalamus (Esch, Bohlen, Ling et al, 1980;
Schally, Huang, Chang, Arimura et al, 1980; Spiess, Villarreal and
Vale, 1981). Since a pair of basic amino acid residues is
interposed between the SS-14 sequence and the extension, SS-28 was
thought to be a precursor of SS-14. However, SS-28 proved to be
more potent than SS-14 in inhibiting the secretion of growth hormone
(Brazeau, Ling, Esch et al, 1981), prolactin and insulin (Meyers,
Murphy, Redding, Coy and Schally, 1980; Tannenbaum, Ling and
Brazeau, 1982) and this suggests that SS-28 may be a regulatory
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SS—28(1—12) (Fig. 3-2), the N-terminal fragment of SS-28, has also
been characterized in the hypothalamus and pancreas of the rat
(Benoit, Bohlen, Ling et al, 1982a) and shown by radioimmunoassay to
be present in extrahypothalamic areas of the nervous system and in
the gastrointestinal tract (Benoit et al. 1982b; Benoit, Ling,
Bakhit et al, 1982c).
Earlier studies (e.g. Chihara, Arimura and Schally, 1979)
showed that SS-14 was released into hypophysial portal blood,
confirming a likely role for SS-14 in the neural control of the
secretion of growth hormone and other anterior pituitary hormones
such as thyrotrophin and prolactin. Similarly, before SS-28 and
SS-28(1-12) can be accepted as hypothalamic-pituitary releasing
hormones it must be shown that they are released from the
hypothalamus in physiologically active quantities. SS-28 can be
released in vitro from synaptosomal preparations of the median
2+
eminence by depolarizing stimuli or by Ca ionophores (Kewley,
Millar, Berman and Schally, 1981), and calcium dependent release of
SS-28(1-12) from rat hypothalamic slices has also been demonstrated
in vitro (Bakhit, Benoit and Bloom, 1983a). Hypophysial portal
plasma has been shown by gel filtration to contain several peaks of
immunoreactive SS (Gillioz, Giraud, Conte-Devolx et al, 1979;
Chihara et al, 1979). One of the peaks corresponded to SS-14, but
the additional immunoreactive peaks were not identified in these
studies. The following experiments were carried out to determine
whether SS-28 and SS-28(1-12) like immunoreactivity (IR) were present
in hypophysial portal vessel blood in order to assess whether these
peptides may serve as physiological neurohormones.
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3.2 MATERIALS AND METHODS
Male Wistar rats (200-350 g body weight) were supplied and
maintained under controlled conditions as described in Chapter 2
(2.1). Animals were anaesthetized with urethane, and hypophysial
portal vessel blood was collected for four consecutive periods of 15
min each (2.2.3). During the second and fourth period of collection
an electrical stimulus was applied to the median eminence by way of
a unipolar glass insulated electrode (2.2.4). The portal blood was
collected into ice cold tubes containing a solution (10 pi for each
100 pi of blood) of 10-2 M Bacitracin (Sigma, U.K.), 1000 KIU
Trasylol (Bayer, U.K.) and 0.1 M EDTA (B.D.H., Poole). At the end
of collection the blood samples were centrifuged at 4°C and the
plasma was extracted twice with 2 ml ethanol-1.0 N-HC1 (95/5: v/v).
The samples were stored at -40°C, dried under vacuum, and
subsequently reconstituted in the appropriate buffer for
chromatography or RIA. The significance of differences between mean
SS concentrations was determined by the Mann Whitney U test (Siege!,
1956).
3.2.1 HPLC of Somatostatin-14 and 28
Dried extracts of hypophysial portal blood were sent to Dr.
R.P. Millar at the University of Capetown where they were
reconstituted in 500 pi of 0.05 M ammonium acetate buffer (pH 5.5)
of which 50 pi were used for the assay of total somatostatin and the
remaining 450 pi chromatographed using a Walters HPLC system. The
sample was applied on to a cation exchange column (40 x 250 mm
Partisil PXC 10/25 SCX; Whatman) and eluted with a stepwise gradient
of increasing concentrations of ammonium acetate buffer in 10%
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methanol, as shown below:
1-15 minutes 0.05 M ammonium acetate in 10% ethanol, pH 5.5
16-30 minutes 0.2 M ammonium acetate in 10% ethanol, pH 4.6
31-60 minutes 0.5 M ammonium acetate in 10% ethanol, pH 4.1;
the flow rate was 1.6 ml/min throughout. The fractions eluting from
the column were freeze dried and the somatostatin content determined
by RIA using an antiserum (number 774) which recognizes the
mid-region of the molecule and hence cross-reacts with both SS-28
and SS-14 (Kewley, Millar, Berman and Schally, 1981).
3.2.2 Determination of SS—28(1—12) by radioimmunoassay
The extracts of corresponding samples of either hypophysial
portal or peripheral plasma (derived from samples of peripheral
blood withdrawn from the external jugular vein either before, or
immediately after, the onset of the first period of median eminence
stimulation) from 5 animals were pooled, dried under vacuum and sent
to Dr. R. Benoit in San Diego for assay. The dried samples were
reconstituted in 0.05 M ammonium acetate pH 5.5; this solution was
centrifuged at 12000 x g for 10 min and the pH of the supernatant
adjusted to pH 7.0 with NaOH solution. After a further
centrifugation, SS—28(1—12) was determined by radioimmunoassay
(Benoit et al. 1982c) using antiserum S 320 which recognizes the
C-terminus of SS—28(1—12) but shows no cross-recativity with SS-14
and negligible cross-reactivity with SS-28 (< 0.01%).
3.3 RESULTS
Figure 3-3 shows that electrical stimulation of the median
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Time (min.)FIGURE 3-3: The mean (±SEM) concentrations of immunoreactive somatostatin
per millilitre of plasma and the total amount released into
hypophysial portal plasma collected from 6 animals during 4
consecutive periods of 15 min. An electrical stimulus was
applied to the median eminence during the second and fourth
periods of collection (STIM).
released per unit time and the concentration of SS per millilitre of
hypophysial portal plasma (P < 0.001 for the first and P < 0.05 for
the second stimuli. Cessation of the hypothalamic stimulation
resulted in a prompt drop in SS output to a level similar to that
before the onset of stimulation; application of the second stimulus
resulted in a further increase in SS output which was lower than in
response to the first, but not significantly so. With the
antiserum 774 and the HPLC conditions used in these experiments,
the SS—IR in hypophysial portal blood was resolved into two
components which eluted in precisely the same positions as SS-14 and
SS-28 respectively (Figs. 3-4 and 3-5). There was no significant
difference in the relative secretion of the two peptides into portal
blood collected during electrical stimulation of the median eminence
compared with that secreted after the stimulus had been switched off
(Fig. 3-4). Using the same extraction and assay procedures, the
concentration of SS detected in extracts of peripheral blood,
sampled from either the inferior vena cava or aorta, was 35 pg/ml.
Figure 3-6 shows that SS—28(1—12)—IR was present in extracts of
hypophysial portal blood and that ME stimulation produced a 4-5 fold
increase (P < 0.005) both in the concentration and the total amount
of SS-28(1-12) released per unit time. The response to the second
stimulus was significantly (P < 0.005) less than that to the first
stimulus. In peripheral plasma the concentrations of SS-28(1-12)
were below the limit of detection (< 150 pg/ml) in all but two of
the samples in which the concentrations of SS—28(1—12) were 192 and
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FIGURE 3-4: Representative profiles of somatostatin immunoreactivity in
HPLC fractions of extracts of portal plasma collected during
(upper trace) and after (lower trace) the application of the
electrical stimulus to the median eminence. Heavy bars denote
the increasing concentrations of ammonium acetate buffer
(molarity shown) used to elute the immunoreactive somatostatin
from the HPLC column. The total amounts of immunoreactive
SS-14 and SS-28 detected were respectively 90 and 92 pg during
the stimulus and 35 and 52 pg after the stimulus.
Arrows indicate the elution positions of synthetic SS-14 and SS-28.
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FIGURE 3-5: Profiles of somatostatin immunoreactivity in HPLC fractions
of extracts of portal plasma collected before (A and B) and
during (C and D) the application of the electrical stimulus

































































0-15 15-30 30-45 45-60
Time (min)
Mean (±SEM) concentration of SS-28C1 -12)-like IR in
hypophysial portal vessel plasma and the total amount
released during successive 15 min periods of blood
collection. Each mean value is based on estimations of
five separate pooled extracts: each pool was comprised
of samples collected from 5 animals. An electrical
stimulus was applied to the median eminence during the
second and fourth collection periods, denoted by SUM.
3.3 DISCUSSION
The concentration of SS in portal blood and the amount of SS
secreted per unit time in the period of collection before
stimulation of the median eminence (Fig. 3-3) were of the same order
as those found by Chihara et al. (1979b) and Gillioz et al. (1979).
The 6 to 7-fold increase in both the plasma concentration and the
secretion rate of SS produced by stimulation of the median eminence
was similar to that reported for preoptic stimulation (Chihara,
Arimura, Kubli-Garfias and Schally, 1979a). Median eminence
stimulation produced a similar increase also in the concentration
and secretion rate of luteinizing hormone releasing hormone (LHRH)
(Sherwood, Chiappa and Fink, 1976). Cessation of hypothalamic
stimulation resulted in a prompt drop in total SS output to levels
recorded before application of the stimulus, and the application of
second stimulus resulted in another increase in SS output that was
not significantly different from the response to the first
stimulus.
The amount of somatostatin in portal blood was only sufficient
to analyse by a single HPLC chromatographic system which provides
the best resolution of somatostatin molecular forms. However, the
two peaks of SS-IR in hypophysial portal blood extracts eluted in an
identical manner to that released from median eminence
synaptosomes. The immunoreactive material released from
synaptosomes has been characterized in a series of different
chromatographic systems (Kewley et al., 1981); on Sephadex G-25 the
SS contained in, and secreted from, median eminence synaptosomes
eluted as two major immunoreactive peaks, a 3K species co-eluting
•61-
with SS-28 and a 1.6K species co-eluting with SS-14. The 3K species
on HPLC was shown to elute identically with SS-28 in both a reverse
phase and in the same cation exchange system used for separating the
extract of hypophysial portal plasma (Fig. 3-4). Similarly, the
SS-14 (1.6K) species behaved in an identical manner to synthetic
SS-14 in this HPLC system.
In the rat hypothalamus and amygdala, SS-14 and SS-28 represent
approximately 60% and 10% respectively of the total SS content
(Pierotti and Harmar, 1985). Similarly, SS-14 is reported as the
major immunoreactive form of SS released from the hypothalamus in
vitro in response to either a reduction in glucose concentration
(Lengyel, Kruseman, Grossman, Rees and Besser, 1984) or depolarizing
stimuli (Pierotti, Harmar, Tannahill and Arbuthnott, 1985). By
contrast, SS-14 and SS-28 are present in the median eminence in
approximately equimolar proportions (Pierotti and Harmar, 1985) and
the proportion of SS-28 released from the ME in vitro is also higher
(Kewley et al, 1981; Pierotti et al, 1985). Figure 3-4 shows that
the increase in total SS output was due to increased secretion of
both SS-28 and SS-14; the cross-reaction of antiserum 774 with
SS-28 on a molar basis is only 30 per cent (Kewley et al., 1981)
and, therefore, these results (Fig. 3-5), which underestimate the
amount of SS-28 secreted, suggest that, in vivo, SS-28 is probably
secreted in greater amounts than SS-14.
Srikant and Pate! (1981) suggested that the greater potency of
SS-28 compared with SS-14 in inhibiting hormone release (Meyers ^t
al., 1980; Brazeau et al, 1981; Rodrigues-Arno, Gomez-Pan, Rainbow
et al, 1981) was due, at least in part, to the fact that the
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pituitary binds SS-28 with an affinity that is 3.2 times greater
than that for SS—14. The longer half-life of SS-28 in plasma may
also contribute to its apparently greater potency in vivo (Patel and
Wheatley, 1983). The present data taken together with those of
Srikant and Patel raise the possibility that SS-28 is a major
hypothalamic factor that inhibits growth hormone release and that
SS-14 may be an active fragment. Some hormones such as ACTH,
although themselves highly active and functionally important, are
capable of being processed further to biologically active molecules
such as a-MSH. By analogy, SS-28 should therefore be regarded as a
potential precursor for SS-14 as well as an important hormone in its
own right. In view of the different potencies (Meyers et a!., 1980;
Schally et al♦, 1980; Rodrigues-Arno et al., 1981), actions (e.g.
SS-28 but not SS-14 inhibits the FSH response to LHRH; Millar,
Klaft, Barron, Levitt and Ling, 1982) and possibility of different
receptor populations (Srikant and Patel, 1981) for SS-14 and SS-28,
alterations in the relative production and secretion of the two
hormones may play a significant role in the physiological regulation
of pituitary hormone secretion.
Radioimmunoassay with the S320 antiserum, showed that like
SS-28 and SS-14, SS—28(1—12)—IR is present in hypophysial portal
blood in greater concentrations than in peripheral blood and that
its release into portal blood can be increased significantly by ME
stimulation. Although the S320 antiserum used in the radioimmuno¬
assay does not cross-react significantly with either SS-28 or SS-14,
it does recognize two other SS—28(1—12)—IR like peptides in the
hypothalamus, with higher molecular weights, 5K and 8K SS-28(1-12),
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(Benoit et al., 1982c; Benoit et al., 1984), and conceivably these
larger forms may also be released into portal vessel blood and may
account for up to 20 to 25 per cent of the immunoreactivity measured
in this study.
The reduced release of SS—28(1—12) into portal blood in
response to the second compared with the first ME stimulus is
similar to the result obtained in studies on LHRH (Fink and
Jamieson, 1976). The amount of SS—28(1—12) released during the
first stimulus (~ 170 pg/animal; Fig. 3-5) was small relative to the
hypothalamic content of the peptide (~ 45 ng; Benoit et al.,
1982b). Therefore, as in the case of LHRH (Sherwood, Chiappa,
Sarkar and Fink, 1980), the reduced response to the second stimulus
is likely to have been due to a decrease in the readily releasable
pool of SS—28(1—12) and/or a change in Ca channel permeability
(e.g. Nordmann, 1976) rather than a reduction in the total
hypothalamic content of SS-28(1-12).
The biological activity of SS—28(1—12) is still to be
determined. However, there is some evidence to suggest that the
processing and release of SS-28 (1-12) may be dissociated from that
of SS—14. The ratios of SS-28, SS-28 (1-12) and SS-14 vary in
different regions of the brain; results of immunohistochemical
studies taken together with other data reveal that, whilst all three
species are present in hypothalamic nerve terminals, in the
neocortex and hippocampus SS-28 is confined mostly to cell bodies,
and SS-28 (1-12) is preferentially located in the nerve terminals
(Morrison, Benoit, Magistretti, Ling and Bloom, 1982; Morrison,
Benoit, Magistretti and Bloom, 1983). Cysteamine (2-mercapto-
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ethylamine) produces a dose-dependent reduction in total SS
throughout the brain (Sagar, Landry, Mi 11ard et al, 1982) and
increases basal secretion of growth hormone (Millard, Sagar, Badger
and Martin, 1983). Bakhit, Koda, Benoit, Morrison and Bloom (1984)
have shown that administration of this compound to rats selectively
reduced both the hypothalamic content, and K+ evoked release in
vitro, of SS-14, but did not affect the content and release of SS28
(1-12), suggesting that selective release of SS-14 and SS—28(1—12)
may occur under certain conditions. However the specificity and
mechanism of action of cysteamine are controversial. Bakhit, Benoit
and Bloom (1983b) showed a selective depletion by cysteamine of the
brain content of SS-14, but not SS-28 and suggested that this effect
was produced by the release of SS-14 rather than by interference of
cysteamine with the SS radioimmunoassay. Sagar et al (1982)
reported a depletion of both SS-14 and SS-28 following cysteamine
administration and other studies have indicated that cysteamine may
render SS non-immunoreactive by an interaction with the disulphide
bond thereby apparently depleting both SS-14 and SS-28, but not
linear molecules such as SS—28(1—12) (Patel and Pierzchala, 1985).
Taken together the present results obtained in vivo confirm the
results obtained from release studies in vitro (Kewley et al., 1981;
Bakhit et al, 1983) in showing that, in addition to SS-14, SS-28 and
SS—28(1—12) are secreted into hypophysial portal vessel blood.
There is much evidence to support a physiological role of SS-28
independent of its possible role as a precursor of SS-14, however it
remains to be established whether SS-28(1-12) has any functional




Thyrotrophin Releasing Hormone in Hypophysial Portal Blood,
Hypothalamus and Pituitary Gland: Studies with High Performance
Liquid Chromatography
4.1 INTRODUCTION
The detailed mechanism for the synthesis of thyrotrophin
releasing hormone (TRH) in the mammalian brain remains to be
elucidated. An early report suggested that TRH might be synthesized
by the action of soluble enzymes in the cytoplasm rather than by
ribosomal synthesis (Mitnick and Reichlin, 1972) but these findings
were not substantiated by work in other laboratories (Bauer and
Lipmann, 1976; Rupnow, Hinkle and Dixon, 1979) and it is now
generally accepted that, like the larger peptide molecules, TRH is
derived by the cleavage and post-translational modification of a
ribosomally-synthesized precursor (McKelvy, 1983; Griffiths and
Millar, 1983). The in vitro incorporation of H proline into TRH
has been demonstrated in explants of guinea-pig hypothalamus
(McKelvy, 1974; McKelvy, Sheridan, Joseph, Phelps and Perrie, 1975)
and in newt hypothalamus and forebrain (Grimnv-Jorgensen and McKelvy,
1974). Using frog brain, which contains a high concentration of TRH
(Jackson and Reichlin, 1977b,1979), Rupnow, Hinkle and Dixon (1979)
demonstrated the presence of a macromolecule which yielded TRH after
chemical or enzymatic treatment.
Studies using complementary DNA-cloning techniques have now
resulted in the determination of the partial sequence of the amino
terminal of a pre pro-TRH isolated from the skin of Xenopus laevis
(Richter, Kawashima, Egger and Kreill, 1984) and, more recently, of
a pre pro-TRH isolated from rat hypothalamus (Lechan, Wu, Jackson et
al, 1986). The deduced rat TRH precursor, of 255 amino acids,
contained five copies of the sequence
Lys-Arg-Gln-His-Pro-Gly-Lys (or Arg)-Arg.
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The 123 amino acid polypeptide deduced from the partial sequence of
the frog precursor, contained three copies of the above sequence,
together with a fourth TRH-containing sequence at the carboxyl
terminal -
Lys-Arg-Gln-His-Pro
(Richter et al, 1984). Other than the repeating sequences encoding
TRH, there was no homology between the rat and frog precursors
(Lechan et al, 1986). The tetrapeptide, Gln-His-Pro-Gly, is
generated by cleavage at the pairs of Lys-Arg (or Arg-Arg) residues,
and from this intermediate, TRH can be formed by the spontaneous or
enzymatic modification of the glutamine residue to pGlu (Ortowski,
Richman and Meister, 1969; Abraham and Podell, 1981). The glycine
may be required for the enzymatic amidation of the proline residue
(Bradbury, Finnie and Smythe, 1982) and the enzymes required for
this conversion have been demonstrated in rat brain (Kizer, Busby,
Cottle and Youngblood, 1984); alternatively the amide group might be
transferred to pGlu-His-Pro by a transamidase (Griffiths and Millar,
1983).
There are no features of the TRH precursor isolated from frog
skin or rat brain which suggest the possibility of other known
biologically active peptides being generated during processing
(Richter et al, 1984; Lechan et al, 1986). In addition to TRH,
several non-TRH containing peptides ranging in size from 10 to 49
amino acids may also be generated from the rat precursor, but
whether these are released and are bioactive remains to be
determined (Lechan et al, 1986). Some of the TRH-like
immunoreactivity (IR) as measured by radioimmunoassay in
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extrahypothalamic sites and body fluids does not correspond to the
authentic tripeptide (e.g. Youngblood, Humm and Kizer, 1979; Busby,
Youngblood, Humm and Kizer, 1981b). The aims of the following
experiments were to use HPLC in conjunction with RIA to determine
whether the TRH-IR measured in portal vessel blood, the hypothalamus
and pituitary gland, was due to one or more peptides, and to examine
the release of TRH in response to electrical stimulation of the
hypothalamus. The electrical stimulus used in these studies was
applied to either the median eminence (ME), in order to stimulate
directly the terminals of the TRH neurones or the paraventricular
nuclei (PVN) in which are located the cell bodies of the TRH
neurones (Jackson and Reichlin, 1974; Lechan and Jackson, 1982).
4.2 MATERIALS AND METHODS
4.2.1 TRH-like immunoreactivity in hypophysial portal vessel blood
Hypophysial portal vessel blood was collected for 15 - 60 min
periods from adult male Wistar rats anaesthetized with urethane, as
described in Chapter 2. Since TRH is rapidly degraded in blood
samples at 37°C (Jackson, Papapetrou and Reichlin, 1979) blood from
the cut pituitary stalk was removed every 30 to 60 seconds
(depending upon the rate of flow of blood) and transferred to a
glass centrifuge tube containing 4 ml of ice-cold absolute alcohol
(Fink, Koch and Ben Aroya, 1982). The contents of the tube were
thoroughly mixed at regular intervals (generally with each addition
of blood to the tube) throughout the collection period. In some
experiments the pituitary gland was removed after the stalk had been
cut; after haemostasis had been achieved, heparin was injected, the
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stalk re-cut and pituitary stalk blood was collected into ethanol on
ice for either two consecutive periods of 30 min each or for a
single collection period of 60 min. Peripheral blood samples (0.5
ml) withdrawn from the external jugular vein (EJV) during collection
were extracted in the same manner as stalk blood. The blood samples
were centrifuged (3000 rpm at 4°C for 15 min) and the supernatants
removed. The precipitate was resuspended in a further 4 ml of
ice-cold ethanol, centrifuged again and the supernatant combined
with that from the first centrifugation. The ethanol extracts of
stalk or peripheral blood were stored at -40°C and subsequently
evaporated to dryness at 35°C under vacuum or under a stream of
nitrogen gas.
4.2.2 Immunoreactive TRH in the hypothalamus and pituitary gland
For studies on hypothalamic TRH-IR, blocks of hypothalamic
tissue were dissected (2.2.6) from the brains of animals which had
been killed by decapitation. The blocks of tissue were homogenised
and extracted in pairs in either 1 ml 0.1 N HC1 or in 4 ml ice-cold
ethanol. One to three whole pituitary glands were homogenized in 1
ml ethanol. After freeze or vacuum drying (acid and ethanol
extracts, respectively), extracts were prepared for HPLC as
described below. Some hypothalamic extracts were re-dissolved in
200 pi of distilled water, mixed for 30-60 sec with 1 ml peripheral
blood (taken from the EJV of a rat anesthetized with urethane and
injected with heparin) and then extracted for TRH as described for
stalk blood. In order to determine the recovery of the extraction
procedure a similar experiment was carried out in which synthetic
TRH (Penninsula Laboratories, California) was added to, and
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extracted from, peripheral blood. In a second series of experiments
hypothalami were homogenised in 200 ul of either 0.9% saline or
distilled water and either freeze-dried, or incubated for 5 min at
37°C with 5 ml peripheral blood or 5 ml distilled water. At the end
of the incubation period the blood was extracted with ice cold
ethanol and both the ethanol and aqueous extracts dried as described
above.
4.2.3 Release of TRH in response to electrical stimulation of the
hypothalamus
Hypophysial portal vessel blood, from male Wistar rats
anaesthetized with urethane (2.2.3), was collected for 3 or 4
consecutive 15 min periods and extracted in ice-cold ethanol as
described above. During the second and also (when collected) the
fourth collection period, an electrical stimulus was applied to
either the ME by way of a unipolar electrode positioned in the ME at
the time of the experiment or to the PVN using a bipolar electrode
which had been stereotaxically implanted 3-10 days previously
(2.2.4). In preliminary experiments with ME stimulation, the
collection of portal blood immediately followed the surgical
preparation of the animals, but in subsequent experiments with
either ME or PVN stimulation there was a 4 h delay between the
exposure of the dura and the later exposure of the portal vessels
(for rationale, see Chapter 5). The electrical stimulus was applied
for 15 min; in control animals the electrodes were implanted, but no
stimulating current was passed. Peripheral blood samples (0.5 ml)
were withdrawn from the EJV immediately before, and at the end of,
the first period of stimulation and were extracted in ice-cold
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ethanol. In order to relate the amount of TRH released into portal
blood to the hypothalamic TRH content, at the end of the experiment
the rats in which the ME had been stimulated, were decapitated, the
hypothalami dissected (2.2.6) and homogenized in 0.1 N hydrochloric
acid. For comparison, control hypothalami were removed from
unanaesthetized rats killed by decapitation. The heads of animals
bearing PVN electrodes were fixed in 4% phosphate buffered formalin
for confirmation of correct electrode placement (2.2.4). Extracts
of peripheral or portal blood were stored at -40°C until dried under
vacuum and reconstituted in either PBS/0.25% BSA for RIA (2.5.1) or
in 0.1% trifluoracetic acid (aqueous) for application to an HPLC
column.
4.2.4 High performance liquid chromatography and radioimmunoassay
The dried tissue or blood extracts were dissolved in 1.4 ml
0.1% TFA in water and centrifuged briefly. The supernatants were
applied to the HPLC column and eluted with a linear gradient
(2.4.1); the fractions eluting from the column were vacuum dried and
the TRH-IR content determined by RIA (2.5.1). In addition, TRH and
several synthetic analogues and related compounds, particularly
those (Lys^ TRH, Phe^ TRH and [3Me-His^] TRH) which showed
high cross-reactivity with the anti-TRH antiserum, were run on the
HPLC under identical conditions and their retention times determined.
4.3 RESULTS
HPLC resolved the TRH-IR of pituitary stalk blood into 3
components (Fig. 4-1) the first of which eluted in the same position
as synthetic TRH. Table 4-A shows that the stalk blood content of
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FIGURE 4-1: Representative HPLC profile of TRH-like immunoreactivity in
an ethanol extract of hypophysial portal blood. The blood was
collected for a single, 1 hour collection period. The arrow
indicates the position at which synthetic TRH eluted from the
HPLC column. The dotted line indicates the lower limit of
detection of the assay. Similar results were obtained in a
total of 39 separate HPLC runs.
TABLE 4-A Mean ± SEM content of TRH-IR in each of the three peaks
of material recovered after HPLC of 4 successive 15 min periods of
stalk blood collection. The first peak corresponded in retention
time to authentic TRH (n = 5).
Collection TRH-IR (pg/15 min collection period)
Period
Peak 1 Peak 2 Peak 3
0-15 min
15 - 30 min
30 - 45 min













each of the three components decreased in successive 15 min
collection periods. The mean total amount of TRH-IR released in 1
hour (Table 4-A) was 4556 pg of which 1667 pg (37%) corresponded to
authentic TRH. Efficiency of the extraction procedure, as assayed
by recovery of synthetic TRH from peripheral blood, was 70%. All
three immunoreactive peaks were present in extracts of stalk blood
collected from animals in which the pituitary gland had been removed
(Fig. 4-2A). In peripheral blood, levels of TRH were generally
below the limit of detection of the assay, but, when detectable, the
TRH-IR was also resolved into 3 components which eluted in a
position similar to those of stalk blood (not shown). By contrast,
the TRH-IR of extracts of pituitary tissue (Figure 4-2B) and of
hypothalamic extracts (Figure 4-3A) eluted as a single peak in an
identical position to that of authentic TRH. Only a single IR peak
was recovered when hypothalamic extracts or homogenates were added
to (Fig. 4-3B), or incubated with (Fig. 4-4), peripheral blood. In
addition to TRH the anti-TRH serum cross-reacted significantly with
Lys^ TRH, Phe^TRH (Chapter 2, Table 2-B) and at about 25% with
[3Me-His ]TRH (Fig. 4-5) there was no cross-reaction with
pGlu-His-Gly (Anorexigenic peptide; Trygstad, Foss, Edminson,
2
Johansen and Reichelt, 1978). Figures 4-3 and 4-6 show that Lys
2
TRH eluted in a similar position to TRH while Phe was retained
2
well beyond TRH; [3Me-His ]TRH eluted just before the second peak.
Figure 4-7 illustrates typical results from a preliminary study
of TRH release into hypophysial portal blood, before, during and
after electrical stimulation of the ME. In this experiment there
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FIGURE 4-2: A: HPLC profile of TRH-IR in an extract of stalk blood
obtained from an animal in which the pituitary had been
removed before stalk blood collection. Similar profiles
were obtained in three experiments.
B: HPLC profile of pituitary TRH-IR (similar results were
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FIGURE 4-4: HPLC profiles of TRH-IR in (A) rat hypothalamus homogenized
in 200 pi of water, (B) aqueous extract of hypothalamus





























FIGURE 4-4 (continued): HPLC profiles of TRH-IR in (C) aqueous extracts
of hypothalamus incubated with 5 ml of peripheral blood at
37°C for 5 minutes before extraction in ice-cold ethanol, or
(B) saline extracts of hypothalamus incubated with peripheral
blood and extracted as described above.
0^02512̂1£5? Concentration(ng/ml)
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FIGURE 4-7: HPLC profiles of TRH-IR in ethanol extracts of hypophysial
portal vessel blood. The blood was collected for four
consecutive 15 min collection periods. In (A) an electrode
was positioned in the median eminence, but no current was
passed; in (B) an electrical stimulus was applied to the
median eminence during the second and fourth collection
period. Arrows indicate the position at which synthetic TRH
eluted from the HPLC column; the dotted line shows the lower
limit of detection of the assay. Similar results were
obtained from a total of three stimulated and two unstimulated
rats.
the application of the stimulus. As shown above, HPLC resolved the
TRH-IR into three separate components, each of which decreased in
magnitude in each of the four successive collection periods.
Electrical stimulation did not alter the rate of release of any of
the three peaks of IR material. Similarly, there were no major
changes in total TRH-IR release into portal blood after stimulation
of the the PVN or the ME in rats in which there had been a 4 h delay
period between the initial surgical preparation of the animal and
cutting the pituitary stalk (Table 4-B). HPLC of extracts of portal
blood collected from PVN stimulated rats revealed a small increase
in the size of the first IR Peak (i.e. that which corresponded in
retention time to authentic TRH) in response to stimulation (Table
4-C); however, this was mainly related to the increase in the rate
of blood flow although the portal vessels during stimulation rather
than an increase in the concentration of TRH in hypophysial portal
vessel blood. The secretion of TRH-IR was lower in extracts of
portal blood collected after a 4 h delay period than in extracts of
blood collected from rats in which the pituitary stalk was sectioned
immediately after its exposure (Table 4-D). With the exception of
the PVN stimulated group of animals there was a significant decrease
in the TRH-IR content of portal blood extracts over the four 15 min
collection periods (P < 0.02-P < 0.05). Despite the relatively high
rate of TRH-IR release into portal blood, there were no major
changes in hypothalamic TRH content (Table 4-D). TRH-IR was not
detectable (< 30 pg/ml) in all extracts of peripheral blood except
for samples obtained from a total of eight rats from which portal
blood was collected immediately after the completion of surgery. In
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"^Valuesrecalculatedft rexc usionofnim liwhichTRH-IRcont ntthfi s15 minperiodwas>1000g;incontra ttheremaininganimals,TRH-IRe tf ll rapidlyduringsubsequentcollect ope iods.
Table 4-C Content of TRH-IR in each of the three peaks of material
recovered after HPLC of three successive 15 min periods of
hypophysial stalk blood collection. The first peak coincides in
retention time with authentic TRH. The data shown were obtained
from six individual rats all of which were previously implanted
with bipolar electrodes in the paraventricular nuclei (PVN). After
exposing the dura, animals were maintained under urethane
anaesthesia for 4 h before the exposure of the pituitary stalk and
blood collection. An electrical stimulus was applied to the PVN of
four of the animals (A-D) during the second collection period
(15-30 min).
Animal Collection Blood volume TRH-IR
Period (min) (yl) (pg/15 min collection
period)
Peak 1 Peak 2 Peak 3
A 0-15 550 57 48 43
15-30* 650 76 51 59
30-45 300 N/D 23 N/D
B 0-15 250 49 40 65
15-30* 400 144 39 99
30-45 210 41 44 67
C 0-15 100 23 N/D N/D
15-30* 200 46 N/D 17
30-45 100 N/D N/D N/D
D 0-15 100 49 46 76
15-30* 150 73 52 58
30-45 100 25 N/D 33
E 0-15 400 92 71 119
15-30 300 66 52 67
30-45 300 32 62 80
F 0-15 150 114 101 115
15-30 100 63 57 86
30-45 150 32 23 45
N/D Not detectable
* Electrical stimulus applied (for stimulus parameters see 2.2.4)































+1089±87ifexcludetheresultsfrom3ani aliwhichTRHr leasetnit5mincolle tionp riod remainedabov1000pg/15min.N/Aota plic ble
these eight animals peripheral blood TRH-IR concentrations were 198
± 19 pg/ml and 215 ± 29 pg/ml for the samples of blood withdrawn
from the EJV 15 and 30 minutes into the portal blood collection
period respectively; since when measurable there was no significant
difference in the TRH content of samples of peripheral blood from
stimulated and unstimulated rats, the data from both groups of
animals have been combined.
4.4 DISCUSSION
These results show that HPLC can resolve the TRH-IR in extracts
of rat pituitary stalk blood into three components, the first of
which has an identical retention time to the synthetic tripeptide.
Although only about 37% of total TRH-IR corresponded to authentic
TRH, the absolute amount of TRH released into stalk blood, 1667 pg/h
(Table 4-A), is in the same range as the values reported previously
(Eskay, Oliver, Ben-Jonathan and Porter 1975; Fink et al. 1982) and
is still very large relative to the amounts of LHRH (Sherwood,
Chiappa, Sarkar and Fink, 1980) and somatostatin (Chapter 3)
released. The amount of authentic TRH-IR in hypothalamus (about 5
ng; Fig. 4-3A) was also similar to that published before for crude
extracts (Reichlin, Saperstein, Jackson, Boyd and Patel, 1976; Vale,
Rivier and Brown, 1980; Fink et al. 1982). Thus the percentage of
neuropeptide released relative to that stored (Fig. 4-3A) was about
34% for authentic TRH compared with about 0.6% for LHRH and 0.3% for
somatostatin (Fink et al. 1982). The additional peaks of
immunoreactivity which were detected in the portal blood extracts
are unlikely to correspond to known metabolites of TRH since the
-74-
antiserum used for the radioimmunoassay does not cross-react
significantly with either the free acid derivative of TRH or the
cyclized dipeptide, diketopiperazine (Table 2.B). The antiserum
shows little or no cross-reaction with analogues of TRH in which
either of the terminal amino acids are modified or replaced, but
does cross-react with molecules in which the histidyl residue is
2
altered; the cross-reaction between Phe TRH and the TRH antiserum
was 100%, but Figs. 4-3 and 4-6 show that Phe^TRH is unlikely to
2
contribute significantly to the TRH-IR in stalk blood. Lys TRH,
which eluted in the same position as TRH, has not been reported to
be synthesised in the brain. [3Me-His ]TRH, which was tested
because of its relatively high cross-reaction with the anti-TRH
serum, could not account for the TRH-IR of stalk blood, and is in
any case not detectable in hypothalamus (Pekary, Morley and
Hershman, 1978).
In addition to its widespread distribution throughout the
central nervous system and spinal cord (Brownstein, Palkovits,
Saavedra, Bassiri, Utiger, 1974; Jackson and Reichlin, 1974; Winokur
and Utiger, 1974), TRH-IR has been detected by RIA in a variety of
peripheral organs and body fluids from a number of mammalian and
non-mammalian species. Thus the presence of TRH-IR has been
reported in the pancreas and gastrointestinal tract (Morley, Garvin,
Pekary and Hershman, 1977; Leppaluoto, Koivulsalo and Kraama, 1978),
the retina (Schaeffer, Brownstein and Axelrod, 1977), the pineal
gland (Kellokumpu, Vuolteenaho and Leppaluoto, 1980), reproductive
system (Pekary, Meyer, Vaillant and Hershman, 1980; Pekary, Richkind
and Hershman, 1983), breast milk (Baram, Koch and Hazum, 1977),
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peripheral blood and urine (Jackson and Reichlin, 1974; Oliver,
Charvet, Codaccioni and Vague, 1974), and frog skin and blood
(Jackson and Reichlin 1977b, 1979). Although most of the TRH-IR in
the mammalian CNS, as assessed by HPLC or other chromatographic
techniques, appears identical to the authentic tripeptide (Kreider,
Winokur and Utiger, 1979; Jackson, 1980; Kellokumpu, et al. 1980;
Parker, 1981; Emson, Bennett and Rossor, 1981), the identity of the
immunoreactive material found in some peripheral organs and body
fluids has been questioned (Emerson, Frohman, Szabo and Thakkar,
1977; Youngblood, Humm and Kizer, 1979; Youngblood, Humm, Lipton and
Kizer, 1980). In contrast, Engler, Scanlon and Jackson (1981) have
shown that TRH-IR in the peripheral blood of neonatal rats, which is
higher than in the adult, corresponds to authentic TRH, though it is
probably derived from the pancreas rather than the hypothalamus.
The TRH-IR in human peripheral blood has also been reported to be
identical to synthetic TRH (Mai 1ik, Wilber and Pegues, 1982). The
differences in the resolving power of the various chromatographic
techniques used to investigate TRH-IR in different tissues may
account for the discrepancies in the results obtained in different
laboratories (Busby, Youngblood, Humm and Kizer, 1981a) and to
overcome these difficulties the immunoreactive TRH in a number of
peripheral organs was re-examined using a multi-step purification
procedure followed by HPLC and thin layer chromatography [TLC]
(Busby, Youngblood, Humm and Kizer, 1981b). Using this procedure
Busby et al. (1981b) showed that (i) only about 10% of the TRH-IR in
partially purified peripheral blood extracts was similar to
authentic TRH, (ii) none of the TRH-IR present in human urine,
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placenta and in the sheep pineal corresponded to authentic TRH,
(iii) in the rat eye, only 57% of the total extracted TRH-IR had a
similar retention time to TRH in the HPLC system and of this only
90% was authentic when rechromatographed on TLC, (iv) 83% of the
TRH-IR extracted from the pancreas was chemically similar to TRH on
HPLC.
Using reverse phase HPLC run under isocratic conditions, Pekary
et al (1980) demonstrated the presence of TRH and at least one other
homologous peptide distributed throughout the reproductive system of
the male rat; the additional IR material co-eluted with TRH during
Sephadex G-10 chromatography. In a subsequent study (Pekary et al,
1983) most of the TRH-IR found in semen and extracts of canine
prostate;, epididymis and testis was due to at least three peptides
with an amino acid sequence similar to TRH (possibly in which the
histidyl residue was replaced by a neutral amino acid) rather than
the authentic peptide. A compound which cross-reacts with anti-TRH
serum, but which inhibits the release of prolactin from pituitary
explant cultures, (and was not diketopiperazine) has been
demonstrated in rat testicular and pituitary tumour tissue (Morley,
Meyer, Pekary et al, 1980). Whilst this compound co-eluted with TRH
on sephadex G-10 it showed non-identity with TRH on cation exchange
chromatography. HPLC has also revealed multiple peaks of TRH-IR in
human CSF samples (Biggins, Das, Dodd et al, 1983).
In previous studies, alcohol extracts of hypophysial portal
vessel blood were shown to contain a single species of TRH-IR using
gel filtration on Sephadex G-25 columns (Fink, Koch and Ben Aroya,
1983) or thin layer electrophoresis (Ching and Utiger, 1983);
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techniques which may not give optimal resolution of small TRH-like
peptides (Busby et al, 1981a). HPLC has also been used to examine
the TRH-IR released from rat hypothalamic and cerebral cortical
neurons in response to K+ depolarization (Scanlon, Robbins,
Bolaffi, Jackson and Reichlin, 1983) and, under isocratic
conditions, 95% of the IR material eluted in a broad peak in a
similar position to authentic TRH.
The present findings of multiple TRH-IR peaks in hypophysial
portal vessel blood extracts were not confirmed by a recent study
(de Greef, Klootwijk, Karels and Visser, 1985) in which, using HPLC
and elution under isocratic conditions, it was shown that all the IR
material appeared homogeneous with authentic TRH. One possible
explanation for this difference is that as suggested by de Greef et
al (1985), the resolution of their HPLC system was less than that
employed in the present study. Busby et al. (1981b) suggested that
substances were present in crude tissue extracts which caused the
appearance of multiple IR peaks and an alteration in the retention
time of authentic TRH. However, this cannot explain the multiple
TRH-IR peaks shown in stalk blood in the present study, since only
one peak of TRH-IR corresponding to authentic TRH was found in
hypothalamic extracts whether or not they were mixed or incubated
with peripheral blood.
TRH is present in high concentrations in the posterior
pituitary gland and to a lesser degree in the anterior pituitary
gland (Jackson and Reichlin, 1977a). Figure 4-2 shows that the
pituitary TRH-IR is homogeneous, and that the profile of IR in stalk
blood was unchanged in animals in which, because the pituitary had
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been removed before stalk blood collection, there was no
contamination with back-flow blood from the pituitary sinusoids.
Thus, the pituitary gland is not a likely source of the two
additional peaks.
Early experiments showed that electrical stimulation of the
anterior hypothalamus resulted in the increased ability of
hypophysial portal blood to stimulate the release of thyrotrophin in in
vivo or in vitro bioassay systems (Averill, Salamin and Worthington,
1966; Wilbur and Porter, 1970). The electrical stimulus used in the
present experiments has been shown to result in a 6-7 fold increase
in the concentrations in hypophysial portal vessel blood of LHRH
(Fink and Jamieson, 1976; Chiappa et al, 1977; Sherwood et al, 1980)
and SS-14, SS-28(1-12) and SS28 (Chapter 3). Despite the effects of
the stimulus on thyrotrophin and prolactin release (see Chapter 5),
in the present experiments there was no apparent increase in total
TRH-IR release into portal blood after ME or PVN stimulation (Table
4-B). The relatively small increase in TRH in response to
stimulation (approximately 2 fold) apparent after HPLC of portal
blood extracts collected during stimulation of the PVN of rats in
which there was a 4 h delay between surgery and cutting the
pituitary stalk (Table 4-C) was largely due to the increased flow of
hypophysial portal blood during stimulation rather than a change in
TRH concentration.
Using the same stimulus as was applied in the present
experiments, stimulation of either the ME or PVN did not result in
increased release into portal blood of vasoactive intestinal peptide
(Brar, Fink, Maletti and Rostene, 1985a) or oxytocin and vasopressin
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(Horn, Robinson and Fink, 1985c), although the latter study did show
that the stimulus was effective in increasing oxytocin and
vasopressin concentrations in systemic plasma. Since the stimulus
was effective in releasing thyrotrophin from the anterior pituitary
gland it is clear that the apparent lack of a major effect of the
stimulus on TRH secretion is not due to either inappropriate
stimulation parameters or to 'fatigue' caused by the frequency of
stimulation or the length of the trains of pulses (Boer, Cransberg
and Dogterom, 1980; Bicknell and Leng, 1981). As noted earlier, the
TRH content of portal blood is high relative to hypothalamic
content, and decreases rapidly in successive periods of blood
collection. Therefore, it is most likely that, as discussed for VIP
(Brar et al, 1985a) and oxytocin and vasopressin (Horn et al,
1985c), the lack of any major effect of hypothalamic stimulation on
the release of TRH into portal blood is the result of maximal
secretion of TRH following sectioning of the pituitary stalk thus
rendering it impossible to drive the system further by electrical
stimulation.
In conclusion, the source of the two peaks in addition to
authentic TRH in hypophysial portal blood remains unclear. Doubt
has been expressed as to the ability of an anti-TRH, such as was
used in the present study, to recognise the Glu (or Gln)-His-Pro
sequence in a larger precursor due to the specificity of these
antisera for the modified amino and carboxy termini (Spindel and
Wurtman, 1980; McKelvy, 1983). Chemical analysis, and the
determination of the biological potency, of the additional IR peaks
was not possible because of the relatively small amount of material
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present in portal blood. Conceivably, there may be a precursor
which does not react with the antiserum, but on release into stalk
blood gives rise to intermediates in TRH synthesis which do
cross-react with the antiserum. Alternatively, when TRH enters
blood some of it might be changed in a minor way by reactions which
may alter the retention time on HPLC. However, at least under these
experimental conditions, the studies carried out with peripheral
blood to which had been added synthetic TRH or hypothalamic extracts
(Fig. 4-4) make the possibility of the generation of the additional
IR material by the action of blood borne enzymes appear unlikely.
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CHAPTER 5
Effect of Anti-TRH Serum on the Release of Thyrotrophin and Prolactin
during Suckling or in Response to Electrical Stimulation of the
Hypothalamus
5.1 INTRODUCTION
The stimulation of the nipples during suckling generates a
neural signal which is conveyed by the mammary nerves and an
ascending pathway to the magnocel1ular neurons of the
paraventricular and supraoptic nuclei resulting in the reflex
release of oxytocin and subsequent milk ejection (e.g. Wakerley and
Lincoln, 1973; Cross, Dyball, Dyer et al, 1975). In addition, the
suckling stimulus also induces a reflex release of prolactin from
the anterior pituitary gland (Amenomori, Chen and Meites, 1970).
The release of both oxytocin and prolactin may also be evoked in
lactating rats by the direct electrical stimulation of the mammary
nerve (Mena, Pacheco, Aguayo, Clapp and Grosvenor, 1978; Mena,
Pacheco and Grosvenor, 1980). Anaesthesia with urethane does not
abolish either the milk ejection reflex (Lincoln, Hill and Wakerley,
1973), nor the prolactin response to suckling (Burnet and Wakerley,
1976; Wakerley, O'Neill and ter Haar, 1978) though in anaesthetized
rats the rise in plasma prolactin concentrations occurs much later
after the onset of suckling than occurs in conscious animals (Burnet
and Wakerley, 1976). Although during suckling, oxytocin release was
seen in the absence of prolactin release, the reverse was not
observed, suggesting that some component of the milk ejection reflex
is necessary to trigger suckling induced prolactin release (Wakerley
et al, 1978). The precise details of the neural pathways which
mediate these reflexes are not established (Urban, Moss and Cross,
1971; Tindal, Knaggs and Turvey, 1969; Tindal and Knaggs, 1972,
1977; Sutherland and Fink, 1983).
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Thyrotrophin releasing hormone (TRH) in addition to its role in
regulating the release of thyrotrophin from the anterior pituitary
gland, has been shown to release prolactin in a number of species
(Bowers, Friesen, Hwang, Guyda and Folkers, 1971; Jacobs, Snyder-,
Wilber, Utiger and Daughaday, 1971; Convey, Tucker, Smith and
Zolman, 1973; Fell, Findlay, Cumming and Goding, 1973; Kelly,
Bedirian, Baker and Friesen, 1973; Rivier and Vale, 1974; Deis and
Alonso, 1975). Although low concentrations of TRH are effective for
the release of prolactin in vitro from rat pituitary tumour cells
(Tashjian, Barowsky and Jensen, 1971) or pituitary cells obtained
from hypothyroid rats (Vale, Blackwell, Grant and Guillemin, 1973)
the doses of TRH required for the in vivo release of prolactin from
the rat anterior gland are high (Blake, 1974; Burnet and Wakerly,
1976) and it has not been established whether TRH is physiologically
involved in the regulation of prolactin release in this species
(Leong, Frawley and Neill, 1983).
The technique of immunoneutralization of a peptide by the
administration of a specific antiserum (passive immunization) has
been used previously in many studies to examine the physiological
function of hypothalamic peptides including TRH (e.g. Szabo &
Frohman, 1977; Fraser & McNeilly, 1982; Wehrenberg, Brazeau, Luben,
Bohlen and Guillemin, 1982; Tannenbaum and Ling, 1984). The aims of
the following experiments were to determine the effect of electrical
stimulation of the hypothalamus on the release of thyrotrophin and
prolactin from the anterior pituitary gland and using passive
immunization with anti-TRH serum to investigate the role of TRH in
mediating these responses and also the prolactin response to the
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suckling stimulus in anaesthetized lactating rats.
5.2 MATERIALS AND METHODS
The animals used for the electrical stimulation studies were
male or female Wistar rats (Edinburgh University Centre for
Laboratory Animals). The female rats had exhibited at least two
successive regular 4-day oestrous cycles immediately before the
experiment (2.1). Lactating female Wistar Cob rats were supplied by
Charles River U.K. Ltd. At the time of their arrival in the animal
house, these animals were 4-5 days post partum and were then allowed
a further 5 days to acclimatize to the conditions of the animals
house. All animals were maintained as described in Chapter 2.
5.2.1 Electrical stimulation and the release of prolactin and
thyrotrophin
Adult male Wistar rats (180-300 g body weight) were
anaesthetized with urethane and the ME and pituitary stalk exposed
(2.2.3). After exposure of the dura, some animals were maintained
under anaesthesia for a 4 h delay period during which the body
temperature was regularly monitored by way of a rectal thermometer
and maintained at 36-37°C with the aid of a warming lamp. The 4 h
delay enabled the plasma concentrations of thyrotrophin and
prolactin to return to a low, steady baseline after the stress of
surgery, and also allowed comparison with the model used for the
suckling studies described below (5.2.3). At the end of the 4 h
delay the dura was cut and the ME and pituitary stalk exposed. An
electrical stimulus (2.2.4) was applied for 15 min either to the ME
or the PVN. In order to maintain the PVN stimulated animals under
*(1-1.2 g/kg body weight i.p.)
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the same conditions as animals in which the ME was stimulated, and
also to facilitate comparison with the results of the study of TRH
release into portal vessel blood (4.2.3), the ME and pituitary stalk
were also exposed for 4 h in the PVN stimulated rats before applying
the stimulus. In control animals the stimulating electrodes were
positioned but no stimulating current was passed. Blood samples
(0.5 ml) for subsequent hormone assay were withdrawn from the EJV at
15 min intervals during the 30 min necessary for the surgical
preparation of the animal and before and after the 15 min period of
stimulation. At the end of the experiment the heads were removed
from animals with PVN electrode implants and fixed in phosphate
buffered formaldehyde in order subsequently to determine whether the
electrode had been correctly placed (2.2.4).
5.2.2 Effect of anti-TRH serum on the responses to electrical
stimulation
Male, or pro-oestrous female rats were anaesthetized with
urethane and the median eminence (ME) and pituitary stalk exposed
using the transpharyngeal approach (2.2.3). In female rats, the
anaesthetic was administered and the surgical preparation completed
between 06.00 and 08.00 h of pro-oestrus. After the exposure of the
dura, all animals were maintained under anaesthesia for a 4 h delay
period (as described above) during which animals were slowly
injected by way of the external jugular vein with 1 ml of ovine
anti-TRH serum (antiserum no. 420; described in section 2.5.1).
Control animals were treated similarly with either ovine non-immune
serum or ovine anti-BSA-serum. At the end of the 4 h delay period
the dura was cut, the ME and pituitary stalk exposed and the
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electrical stimulus was applied to the ME or PVN. Blood samples
(0.5 ml) for subsequent hormone assay were withdrawn from the
external jugular vein 15 min before, and at 15 min intervals after a
15 min period of stimulation. The correct placement of the
electrodes in the PVN was confirmed at the end of the experiment and
the results obtained from one animal were excluded from the results
because of incorrect electrode placement.
5.2.3 Suckling induced prolactin release
The experimental protocol of this study was based on that of
Burnet & Wakerley (1976) who showed that in lactating rats
anaesthetized with urethane, a good prolactin surge occurred 2.5-3 h
after the beginning of suckling in animals anaesthetized for a total
of about 6 h. Lactating female rats 9 to 11 days post-partum were
separated from all but one of their young overnight. On the
following morning, the mother was anaesthetized with urethane and an
hour later was injected intravenously with anti-TRH or anti-BSA
serum. Three hours after induction of anaesthesia, a blood sample
was withdrawn from the external jugular vein and 7 to 10 pups were
then applied to the mother's teats. Further blood samples were then
removed at 30 min intervals throughout the period of suckling and
the plasma stored at -40°C until assayed for prolactin and
thyrotrophin.
5.2.4 Radioimmunoassays and analysis of results
Plasma samples were stored at -40°C until assayed for
thyrotrophin (2.5.3) and prolactin (2.5.4). In cases where the
values for thyrotrophin or prolactin were below the lower limit of
detection of the assay the lower limit, 15-50 ng/ml for prolactin
*(1-1.2 g/kg body weight i.p.)
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and 0.3 ng/ml for thyrotrophin, was ascribed to the sample and used
in subsequent calculations. The significance of differences between
groups was determined by the Mann-Whitney U test (Siege!, 1956).
5.3 RESULTS
5.3.1 Electrically stimulated thyrotrophin and prolactin release
The plasma concentration of thyrotrophin did not alter
significantly in rats in which the electrical stimulus was applied
to the ME within an hour after the administration of the anaesthetic
(Fig. 5-1). However, in the same animals, there was an increase in
the plasma prolactin concentration 15 min after the end of the
stimulation period (P < 0.005 compared with pre-stimulation value; P
< 0.05 compared with unstimulated control). In rats in which the
final exposure of the ME was delayed for 4 h, electrical stimulation
of either the ME (Fig. 5-2) or PVN (Fig. 5-3) resulted in
significant increases in the plasma concentrations of both
thyrotrophin and prolactin. Whilst the thyrotrophin response to
stimulation occurred immediately, the peak prolactin response to
stimulation of the ME occurred 15 min after the termination of the
stimulus. In all treatment groups plasma prolactin concentrations
were high after induction of anaesthesia, but declined towards the
end of the 30 min period of surgery; the decrease was significant (P
< 0.02-P < 0.005) in all except the ME stimulated (no delay) group.
Plasma thyrotrophin concentrations did not alter appreciably during
the surgery, but decreased significantly during the 4 h delay period
(P < 0.001-P < 0.005).




FIGURE 5-1: Mean (± SEM) plasma concentrations of (A) prolactin and (B)
thyrotrophin (TSH) in rats in which an electrical stimulus was
applied to the median eminence (•) or in control rats (0) in
which the electrode was positioned, but no current was passed.
The initial blood samples (0, 15 and 30 min) were taken during
the exposure of the median eminence and placement of the
electrode. The electrical stimulus was applied for 15 min as
indicated by the horizontal bars. Seven animals in each
treatment group. *P < 0.05, **P < 0.005 compared with the pre-
stimulation concentration.
FIGURE 5-2: Effect of electrical stimulation of the median
eminence on the plasma concentrations of (A)
prolactin and (B) thyrotrophin (TSH). Stimulated
animals are denoted by closed circles; open
circles indicate animals in which the electrode
was positioned, but no stimulating current was
passed. The initial blood samples (0, 15 and 30
min) were taken during the exposure of the dura,
animals were maintained under anaesthesia for 4 h
before exposure of the median eminence and the
placement of the electrode. The electrical
stimulus was applied for 15 min as indicated by
the horizontal bar. Five-seven animals in each
treatment group. *P < 0.05, **P < 0.01, ***P <
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FIGURE 5-3: Effect of electrical stimulation of the paraventricular nuclei
on the plasma concentrations of (A) prolactin and (B) thyro¬
trophs (TSH). Stimulated animals are denoted by (•); (0)
indicates animals in which electrodes were implanted, but no
stimulating current was passed. The electrical stimulus was
applied for 15 min as indicated by the horizontal bars. Seven
animals in each treatment group. *P < 0.02, **P < 0.001
compared with pre-stimulation concentration.
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FIGURE 5-5: Mean (± SEM) plasma concentrations of TSH in response to
electrical stimulation (horizontal line) of the median eminence
in pro-oestrous female rats (n = 5-7/group) injected with
control (anti-bovine serum albumin) serum 2 h previously. The
blood sample at 285 min was taken immediately before the
application of the stimulus. The broken line indicates the
lower limit of detection of the assay; in all samples from
anti-thyrotrophin-releasing hormone-treated animals the plasma
TSH concentration was below the limit throughout the experiment.
Time (mins )
FIGURE 5-6: Plasma prolactin concentrations before and after electrical
stimulation (horizontal lines) of the median eminence on
the morning of pro-oestrus of individual female rats
previously injected with either (A) anti-TRH serum or (B)
control (anti-bovine serum albumin) serum. The plasma
prolactin concentrations are expressed on a 1ogiq scale;



























FIGURE 5-7: Mean (± SEM) plasma concentrations (n = 12) of TSH before and
during suckling in lactating rats anaesthetized with urethane
which had been injected 2 h previously with control (anti-
bovine serum albumin) serum. The broken line indicates the
lower limit of detection of the assay; in all samples from
anti-TRH serum treated animals the plasma TSH concentration
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FIGURE 5-8: Plasma prolactin concentrations before and during suckling
in individual lactating rats (n = 8) injected with either
(a) anti-TRH serum or (b) with control (anti-BSA) serum. The
four animals in each group which did not show a significant
prolactin reponse to suckling are not included. A log-^
scale has been used for the ordinate; the dotted line on
each graph indicates the geometric mean of the prolactin
concentrations.
Table5-A.Mean(±S.E.M.)maximalincreme ts(maxim lconcentrationsupre-stim lationrpr -suckling concentrations)fthplasmathyrotroph na dprolac iconcentrationsf ll wi gr calti ulationfi herh medianeminence(ME)orparaventricularnuclei(PVN)rir spo setos kling.Fivighta imalsrtr t nt group. Meanmaximalincr me ts( g/ l) PlasmathyrotrophinPlasmapr lactin ControlAntise umtreatedControlAntis rumr ated MaleR ts-Estimulation3.46±0 705.13**223.061.6170 4 PVNstimulation2.68±1 200.15.08*240.55 .81 7.452 0 FemaleRats-MEstimulation2.10±0 57NC**341.7 (2.530 22)487.6 (2.69 ) SucklingNC2004.5a(3.30±1 )1235.9a(3.109 NC=nochangedetected;(a)V luesrg ometricmeanswi hean±S.E.M.log^gincr tg v npar theses;*p<0.005;* 1comparedwithn olvalu s(Mann-W itneyUtes )
electrically stimulated release of thyrotrophin, but not prolactin
(Fig. 5-4; Table 5-A). Similar results were obtained in response to
ME stimulation in pro-oestrous rats (Figs. 5-5 and 5-6; Table 5-A),
although the prolactin response to stimulation in the pro-oestrous
rats was more variable than in the male animals. As in male rats,
in female animals the thyrotrophin response to stimulation of the ME
was immediate, but the prolactin response was delayed relative to
the onset of the stimulus.
5.3.2 Prolactin release in response to suckling
In lactating female rats injected with anti-BSA serum the
plasma thyrotrophin concentration did not alter significantly during
a period of suckling; in animals treated with anti-TRH serum, plasma
thyrotrophin concentrations remained below the detectable limits of
the assay throughout (Fig. 5-7). In contrast, plasma prolactin
concentrations were increased well above a value of 100 ng/ml or
more by suckling in eight out of twelve animals in each of the
groups of animals treated with anti-BSA or anti-TRH serum (Fig.
5-8). The peak prolactin response occurred approximately 2.5 h
after pups were applied to teats. The mean prolactin response to
suckling was lower in the animals treated with anti-TRH serum, but
the difference between the responses in these animals was not
significantly different from those in animals treated with anti-BSA
serum (Table 5-A).
5.4 DISCUSSION
Martin and Reichlin (1972) showed that electrical stimulation
of either the ME or PVN resulted in elevated plasma concentrations
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of thyrotrophin. This was confirmed by the present experiments in
which there was a 4 h delay period between the completion of surgery
and the application of the stimulus (Figs. 5-2 and 5-3). However, a
thyrotrophin response to stimulation could not be demonstrated in
rats in which the stimulus was applied 15 min after the exposure of
ME and pituitary gland, although these animals still showed a good
prolactin response to stimulation (Fig. 5-1). Stressful stimuli
have long been known to inhibit thyrotrophin secretion (e.g.
Brown-Grant, Harris and Reichlin, 1954; Ducommun, Vale, Sakiz and
Guillemin, 1967) and in the group of animals in which the stimulus
was applied (15 min after the completion of surgery), the surgical
trauma and stress of anaesthesia may have inhibited the initial
response to stimulation.
The results of several studies which used lesion or electrical
stimulation of the hypothalamus suggested several hypothalamic areas
which may mediate the prolactin responses to stimuli such as mating
or suckling. The dorsomedial-ventromedial areas of the hypothalamus
facilitate prolactin release, whilst the medial pre-optic area
(mPOA) may contain both inhibitory and facilitatory neurones
governing prolactin release (e.g. Tindal and Knaggs, 1977; Smith and
Gala, 1978; Freeman and Banks, 1980; Gunnet and Freeman, 1985). The
present study shows that the ME and PVN are also both effective
sites for the electrical stimulation of prolactin release. Tindal
and Knaggs (1977) used partially decorticate rats with brain stem
transsections (to reduce the requirement for anaesthesia) to show
prolactin release in response to stimulation of the mPOA, but failed
to show prolactin release after stimulation of sites in or near the
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ME or PVN. However, the stimulus used by Tindal and Knaggs (1977)
was of lower intensity than that used in the present experiments and
was applied as a single train of pulses, 30 seconds in duration.
Malvern (1975) showed release of prolactin in response to
stimulation of the anterior ME in 3 conscious sheep, whilst
stimulation of the posterior ME in a fourth animal appeared
ineffective.
In Chapter 4 it was shown that it was not possible to
demonstrate an increase in the concentration of TRH in hypophysial
portal blood in response to electrical stimulation of the
hypothalamus. However, the fact that the i.v. injection of anti-TRH
serum blocked the thyrotrophin response to electrical stimulation of
either the ME or PVN and suppressed the plasma concentrations of
thyrotrophin in lactating female rats, does provides direct evidence
in support of the role of TRH as the principal mediator of the
neural control of thyrotrophin release from the pituitary gland. In
contrast, injections of anti-TRH serum did not block the prolactin
response to either electrical stimulation or suckling, although
plasma prolactin concentrations were lower (but not significantly
so) in some circumstances. These results are similar to those
obtained in sheep actively immunized against TRH in which plasma
tri-iodothyronine and thyroxine concentrations were suppressed, but
in which the seasonal changes in prolactin and the prolactin
response to suckling were not significantly reduced. The prolactin
response to heat stress, however, was significantly lower in the
actively immunized compared with the control ewes (Fraser &
McNeilly, 1982). In rats, passive immunization with the ovine
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anti-TRH serum used here did not affect significantly the prolactin
response to heat stress (Fraser & McNeilly, 1983).
The suckling stimulus resulted in significant increases in the
plasma prolactin concentration in the majority of the lactating rats
in a manner similar to that described by Burnet & Wakerley (1976).
In previous studies using conscious rats (Blake, 1974) or rats
anaesthetized with urethane (Burnet and Wakerley, 1976) the
prolactin response to suckling was associated with an increase in
the plasma concentration of thyrotrophin, although in both studies
the magnitude of the thyrotrophin response was much lower than the
prolactin response. The present results are in agreement with the
results of a recent study (Riskind, Millard and Martin, 1984) in
that plasma thyrotrophin concentrations in animals injected with
non-immune or anti-BSA serum did not increase during the period of
suckling. Several studies have indicated that in man also, the
prolactin response to suckling is not accompanied by any change in
circulating thyrotrophin concentrations (Gautvik, Weintraub,
Graeber, Maloof, Zuckerman and Tashjian, 1973; Jeppsson, Nilsson,
Rannevik & Wide, 1976) and Riskind et al. (1984) suggested that
thyrotrophin release may be an occasional and unpredictable
component of the suckling response. Oxytocin reduced the
effectiveness of TRH in releasing thyrotrophin from cultured rat
pituitary cells and this led to the suggestion that oxytocin may
modulate thyrotrophin release during suckling (Frawley, Leong and
Nei11, 1985).
Doses of TRH which significantly increased thyrotrophin release
in lactating rats did not increase plasma prolactin concentrations
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to the values achieved during suckling (Burnet & Wakerley 1976; de
Greet & Visser 1981). Grosvenor, Mena and Whitworth (1979a)
proposed that suckling induced release of prolactin proceeds in two
distinct phases. Initially prolactin is not released directly into
the circulation, but the pituitary prolactin stores are rapidly
depleted and transformed into a releasable form which is slowly
released into the circulation whilst the pituitary stores are
repleted (Mena, Pacheco and Grosvenor, 1980). The
depletion-transformation stage, which is accompanied by
morphological changes in the appearance of the lactotrophs (Shiino,
Williams and Rennels, 1972; Chang and Nikitovitch-Winer, 1976;
Farquhar, Reid and Daniel!, 1976), can be initiated by suckling but
not by exposure to ether (Grosvenor, Mena and Whitworth, 1979b) or
by TRH (Grosvenor and Mena, 1980). However, once the
transformation-depletion stage has been produced by a brief period
of suckling both agents could evoke prolactin release.
Administration of extracts of stalk-median eminence (SME), dopamine
or the dopamine agonist bromocriptine, before the period of suckling
prevented both the depletion of prolactin in the pituitary and the
rise in plasma prolactin concentration in response to suckling, but
neither the SME extract or bromocriptine prevented suckling-induced
prolactin release when administered after an initial 10 minute
period of suckling had already occurred (Grosvenor, Mena and
Whitworth, 1980). Electrical stimulation of the mammary nerve of
lactating rats, or suckling, resulted in a brief decrease in the
concentrations of dopamine in hypophysial portal blood (de Greef,
Plotsky and Nei11, 1981; Plotsky and Neill, 1982a) although the
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dopamine concentration returned to pre-stimulation values before the
maximum prolactin response and the magnitude of the reduction of
dopamine release alone was insufficient to fully account for the
prolactin release (de Greef et al. 1981; Plotsky and Neill, 1982b).
As a result of the foregoing studies it has been proposed that a
transient decrease in the secretion of dopamine (DA) into the
hypophysial portal vessel blood at the onset of suckling may
increase the sensitivity of the pituitary to the prolactin releasing
action of TRH (Grosvenor & Mena 1980; de Greef & Visser 1981;
Plotsky & Neill 1982). However, Riskind et al. (1984) found no
increase in pituitary responsiveness to exogenous TRH after a period
of suckling.
Previous studies which have used the technique of passive
immunization with anti-TRH serum to investigate the role of TRH in
the release of prolactin have produced conflicting results. Koch,
Goldhaber, Fireman, Zor, Shani and Tal (1977) showed that passive
immunization significantly reduced the prolactin surge on the
afternoon of pro-oestrus, but Harris, Christianson, Smith, Fang,
Braverman and Vagenakis (1978) reported no change in prolactin
despite a suppression of basal thyrotrophin release. However, there
are several differences in method which may have contributed to the
difference between the results of these two studies. First,
different volumes of antisera (which possibly differed in affinity
and titre) were injected in the two studies. Harris et al. (1978)
used only 0.1 ml whereas Koch et al (1977) used 1.0 ml of
antiserum. Secondly, Koch et al (1977) exposed their animals to
ether before blood sampling (Koch et al. 1977), and thirdly, Harris
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et al (1978) withdrew blood samples at 1300 h, 1500 h and 1700 h
whilst Koch et al (1977) sampled blood at 1500 h only. Recent
studies, in which hourly blood samples were withdrawn from conscious
rats throughout the afternoon of pro-oestrus, have shown that the
administration of the same anti-TRH serum as was used in the present
study did not affect the magnitude of the spontaneous surge of
prolactin on pro-oestrus. However, the onset of the prolactin surge
was delayed by approximately 1 h (Horn, Fraser & Fink 1985b)
suggesting that TRH might be involved in the initiation, but not the
maintenance of the pro-oestrous prolactin surge.
A possible criticism of the passive immunization technique,
which may be invoked to explain some of the discrepancies between
the data reviewed above, is that under some circumstances the
anti-TRH-serum may not act quickly enough to quench all the TRH
released into hypophysial portal blood. However, the results
presented in this Chapter show that in animals injected with the
anti-TRH-serum, plasma thyrotroph!'n concentrations remained
undetectable during electrical stimulation of the ME in pro-oestrous
rats (Fig. 5-2) and suckling in lactating rats (Fig. 5-4).
In sum these results provide direct evidence that TRH mediates
the neural control of thyrotrophin release. Several data suggest
that under certain conditions TRH may play a role in either
initiating and/or maintaining the release of prolactin (e.g. Koch et^
al. 1977; de Greef & Visser, 1981; Fraser & McNeilly, 1982, 1983;
Fink, Koch & Ben Aroya, 1982; Leong et al. 1983, Horn et al.
1985b). While the present data do not exclude such a role for TRH,
they do show that TRH is not crucial for the neural control of
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prolactin release in the rat. The increase in plasma prolactin
concentrations in response to electrical stimulation or the suckling
stimulus could be mediated either by the inhibition of inhibitory
influences or by the release of a specific prolactin releasing
factor (1.5).
The decreased secretion of dopamine into portal blood may
provide a powerful stimulus for prolactin release (Leong et al,
1983). There is no direct evidence on the effects of electrical
stimulation of the hypothalamus on dopamine release into hypophysial
portal blood, but on the basis of studies of electrical stimulation
of ME slices in vitro (Sarkar, Gottshall, Meites et al, 1983) it
would seem likely that, if anything, the release of dopamine into
portal blood would be increased by ME stimulation. In an
examination of the prolactin inhibiting activity of porcine ME
extracts, a significant portion of the activity found could be
accounted for by y-aminobutyric acid (GABA) (Schally, Redding,
Arimura, Dupont and Linthicum, 1977). Anatomical studies have shown
that GABA and the enzyme, glutamic acid decarboxylase (GAD)
responsible for its synthesis are present throughout different
regions of the hypothalamus (Tappaz, Brownstein and Kopin, 1977);
immunohistochemical studies with anti-GAD antibodies indicate a
plexus of presumed GABA terminals in the ME (Vincent, Hokfelt and
Wu, 1982). Receptors for GABA are present in the anterior pituitary
and evidence is accumulating in support of a regulatory role of
GABA in hormone secretion (e.g. Anderson and Mitchell, 1986). GABA
is present in hypophysial portal blood and its release was found to
increase 7-8 fold after ME stimulation (Mitchell, Grieve, Dow and
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Fink, 1983). The 56 amino acid, GnRH-associated peptide (GAP)
identified at the C-terminus of the human placental LHRH precursor,
has been reported to inhibit prolactin release in vitro (Nikolics,
Mason, Szonyi, Ramachandran and Seeburg, 1985). Conceivably the
release of GAP as a result of stimulation of the cell bodies of LHRH
neurons in the preoptic area could account for the observations
[e.g. Gunnet and Freeman (1985)] of neurons in this area which
inhibit prolactin release. However, in the absence of direct
measurements of the GAP content of hypophysial portal blood, it
seems likely that as for LHRH (Sherwood, Chiappa and Fink, 1976) the
secretion of GAP would increase rather than decrease during
electrical stimulation of the ME. Nikolics et al (1985) suggested
that GAP could account for the inverse relationship between
gonadotrophs and prolactin secretion which occurs, for example,
during lactation (see Chapter 9). However, there are several lines
of evidence which suggest that GAP is unlikely to function as a
physiological regulatory of prolactin secretion under all
circumstances (Fink, 1985). For example, a surge of prolactin
occurs simultaneously with some steroid-induced LH surges and during
the spontaneously occurring pre-ovulatory LH surge during the
afternoon of pro-oestrus (e.g. Smith, Freeman and Nei11, 1975; Horn
and Fink, 1985a; de Greef et al, 1985). In addition, it would be
predicted that if GAP was the major prolactin inhibiting factor then
hpg mice should have elevated pituitary and plasma concentrations of
prolactin, but in fact pituitary and plasma prolactin concentrations
in hpg mice are similar to those measured in normal male mice and
lower than those measured in normal female mice (Charlton, Speight,
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Hal pin et al, 1983). Thus it seems likely that the increase in
plasma prolactin in response to ME stimulation is due to the
increased release into hypophysial portal blood of a prolactin
releasing factor rather than a decrease in the release into portal
blood of transmitters (dopamine and GABA) known to inhibit prolactin
release.
Several studies have indicated the presence in the hypothalamus
of factors, other than TRH, which may stimulate prolactin release
(Valverde, Chieffo & Reichlin, 1972; Dular, LaBella, Vivian & Eddie,
1974; Boyd, Spencer, Jackson <5 Reichlin, 1976; Szabo & Frohman 1976;
Yasuda, Yasuda & Greer, 1984) but the nature of the prolactin
releasing factor remains to be determined. However, several studies
have suggested that, in some circumstances, vasoactive intestinal
peptide (VIP) and peptide histidine isoleucine amide (PHI) may be
involved in the physiological regulation of prolactin secretion.
VIP and PHI are peptides (containing 28 and 27 amino acid residues
respectively) which were originally isolated from porcine intestine,
but were subsequently identified in the brain (e.g. Rostene,
Leranth, Maletti et al, 1982; Tatemoto, Carlquist, McDonald and
Mutt, 1983) and shown to stimulate prolactin release (e.g. Kato,
Iwasaki, Iwasaki et al, 1978; Frawley and Neill, 1981; Hokfelt,
Fahrenkrug, Tatemoto et al, 1983; Kaji, Chihara, Abe et al, 1984).
Cell bodies and fibres containing immunoreactive PHI have been
demonstrated in the PVN and external layer of the ME respectively
(Hokfelt, Fahrenkrug, Tatemoto, Mutt, Werner, 1982). VIP-containing
fibres in the external layer of the ME are normally reported to be
scarce but many such fibres were visible in adrenalectomized rats or
-97-
lactating rats (Mezey and Kiss, 1985). VIP is present in
hypophysial portal blood in concentrations which are sufficient to
release prolactin in vitro (Said and Porter, 1978; Brar, Fink,
Maletti and Rostene, 1985a). When injected into lactating rats at
the start of a period of suckling, anti-VIP serum delayed the onset
of the prolactin response without diminishing the magnitude of the
response; when injected during the period of suckling the antiserum
produced a partial and transient decrease in the plasma
concentration of prolactin (Abe, Engler, Molitch, Bol1inger-Gruber
and Reichlin, 1985). The prolactin response to ether exposure was
completely blocked by administration of anti-VIP serum to lactating
rats (Abe et al, 1985) and was partly blocked in male rats by
anti-VIP or anti-PHI sera either when administered alone or in
combination (Kaji, Chihara, Kita et al, 1985a). Passive
immunization of male rats with a combination of anti-PHI and
anti-VIP sera also resulted in a reduced prolactin response to the
injection of 5-hydroxy-tryptophan and completely blocked this
response when dopaminergic control was eliminated by sulpiride
administration (Kaji, Chihara, Abe et al, 1985b). Thus, both VIP
and PHI may participate in the control of prolactin release, but




Chromatographic Studies of Immunoreactive LHRH in the Rat and Mouse
Hypothalamus and in Rat Hypophysial Portal Blood
6.1 INTRODUCTION
Several chromatographic studies have indicated the presence in
hypothalamic extracts of higher molecular weight material with
LHRH-like immunoreactivity which may represent either the LHRH
precursor or intermediate derivatives of the LHRH precursor
(Kerdelhue, Jutisz, Gillessen and Studer, 1973; Fawcett, Beezley and
Wheaton, 1975; Barnea and Porter, 1975; Millar, Achnett and Rossier,
1977; Gautron, Pattou and Kordon, 1981). The in vitro translation
of mRNA from rat, human or mouse hypothalamus resulted in the
production of a single polypeptide which was immunologically similar
to LHRH and had a molecular weight (in all three species) of 28,000
(Curtis and Fink, 1983; Curtis, Lyons and Fink, 1983). The
structure of a smaller sized precursor (molecular weight 10,000 and
92 amino acids in length) was deduced from the cloned complementary
DNA sequence derived from human placental messenger RNA (Seeburg and
Adelman, 1984). As yet there is no explanation for the discrepancy
between the size of precursor described by Seeburg and Adelman
(1984) and that reported by Gautron et al (1981) and Curtis et al,
(1983).
Many previous studies have demonstrated the presence of LHRH-IR
in hypophysial portal vessel blood and the variation in its release
under different physiological conditions, consistent with its role
in mediating the neural control of gonadotrophin release (Fink,
1979a; Fink, Stanley and Watts, 1983). There have, however, been no
chromatographic studies in which it has been demonstrated that the
LHRH-IR of portal blood is similar to the authentic decapeptide,
although this was suggested by the fact that serial dilutions of
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portal plasma inhibited binding of I-LHRH in parallel with
serial dilutions of the synthetic decapeptide (Fink and Jamieson,
1976; Eskay et al, 1977). The following series of experiments was
undertaken to determine (i) whether as assessed by HPLC the LHRH-IR
of hypophysial portal blood is due entirely to the decapeptide, and
(ii) the characteristics of LHRH-IR in extracts of hypothalami from
rats, from normal mice and also from mutant, hypogonadal (hpg)
mice. The hypogonadism of the hpg mouse is inherited as an
autosomal recessive trait. The hpg mice have low plasma and
pituitary concentrations of gonadotrophins and underdeveloped gonads
and accessory sexual organs (Cattanach, Iddon, Charlton, Chiappa and
Fink, 1977). In the male the penis remains small, the scrotum
underdeveloped, and the minute testes remain undescended and the
anogenital distance is reduced. In the female, the vagina does not
usually open, the uterus appears thread- like and the ovaries are
barely discernible without the aid of a microscope. Although data
obtained by RIA of crude hypothalamic extracts suggested that the
mutant is totally deficient in LHRH, as for the immunoreactive LHRH
in portal blood, this point has not been proven with the aid of HPLC.
6.2 MATERIALS AND METHODS
The animals used were male and female hpg and normal mice and
adult male and female Wistar rats. The female rats had shown at
least two consecutive 4-day oestrous cycles immediately before
experimentation (2.1).
6.2.1. LHRH-like immunoreactivity in hypophysial portal vessel blood
Hypophysial portal blood was collected, from a total of 13 male
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rats anaesthetized with urethane (2.2.3), for periods of 45 to 60
minutes. In order to increase the amount of LHRH in hypophysial
portal blood, the median eminence was electrically stimulated by way
of a unipolar electrode (2.2.4) for 10 minutes during each 15 minute
period of blood collection. The blood which issued from the cut
pituitary stalk was transferred at 30-60 s intervals to ice-cold
tubes and subsequently centrifuged at 4°C. The plasma was then
immediately mixed with 4 volumes ethanol/lN HC1 (95/5; v/v) and
stored at -40°C. Immediately before HPLC the plasma extracts were
centrifuged and the supernatants pooled and then dried by rotary
evaporation.
6.2.2. Hypothalamic LHRH-like immunoreactivity
For studies of hypothalamic LHRH, blocks of hypothalamic tissue
(2.2.6) were removed from animals killed by decapitation. Blocks of
tissue were taken in two separate batches; the first from 4
pro-oestrous female (animals killed at 13.00 h) and the second from
5 male rats. The tissues were homogenized in a total of 3 ml of
ice-cold 0.1 N HC1. Similarly dissected blocks of hypothalamic
tissue were removed from 10 normal or 60 hpg mice and homogenized in
2.5 or 12 ml of ice-cold 0.1 N HC1, respectively. The testes or
ovaries of each mouse were carefully checked before the hypothalamus
was added to the tissue pool in the homogenizer tube to ensure that
the hypothalamus had been placed in the correct category. All
hypothalamic extracts were stored at -40°C until dried while frozen.
6.2.3. High performance liquid chromatography
The dried blood or hypothalamic extracts were reconstituted in
1.4 ml of 0.1% trifluoroacetic acid in water and centrifuged
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briefly. The supernatants were applied to the HPLC column and
eluted with a linear gradient (2.4.1). The fractions eluting from
the HPLC column were vacuum dried over phosphorous pentoxide,
redissolved in assay buffer and assayed for LHRH using double
antibody radioimmunoassays (2.5.2) in which the primary antiserum
was either the R-42 or the HC-6 anti-LHRH serum.
6.3 RESULTS
Radioimmunoassay using the R-42 antiserum showed that the
LHRH-like immunoreactivity in extracts of rat hypophysial portal
vessel plasma (Fig. 6-1A) or of acid extracts of hypothalami from
male rats (Fig. 6-2A) or normal mice (Fig. 6-2B) eluted from the
HPLC column as a single peak which corresponded in retention time to
the synthetic decapeptide (Fig. 6—IB). Similar HPLC profiles of
LHRH-like immunoreactivity in extracts of either hypophysial portal
plasma (Fig. 6-3) or extracts of hypothalami from male or
pro-oestrous female rats (Fig. 6-4) were obtained when assayed with
the HC-6 anti-LHRH serum. No immunoreactive LHRH was detectable in
any of the HPLC fractions from the hypothalami of hpg mice. The
recovery of the HPLC system for synthetic LHRH was greater than 90%,
and for hypothalamic LHRH was 75-90%. The recovery of the whole
system (that is, the extraction of plasma with acid ethanol and
subsequent HPLC) for synthetic LHRH added to synthetic plasma was
50%.
6.4 DISCUSSION
The development of sensitive radioimmunoassays for LHRH has















FIGURE 6-1: A: HPLC profile of LHRH-like immunoreactivity, assayed using
the R42 antiserum, in an extract of rat hypophysial portal
piasma.
B: Elution profile of synthetic LHRH under the same conditions.
The broken line in each trace indicates the lower limit of
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FIGURE 6-2: HPLC profiles of immunoreactive LHRH, assayed using the R42-
anti-LHRH serum, in hypothalamic extracts from (A) pro-
oestrous female rats and (B) normal mice. The broken line
indicates the lower limit of detection of the assay for
these samples. The dotted line at the bottom of B is the
limit of detection for LHRH in extracts of hpg mouse






















FIGURE 6-3: HPLC profile of LHRH-like immunoreactivity, assayed using
the HC-6 antiserum, in an extract of rat hypophysial portal
plasma. The broken line indicates the lower limit of






































FIGURE 6-4: HPLC profiles of immunoreactive LHRH, assayed using the HC-6
anti-LHRH serum, in hypothalamic extracts from (A) male rats
(B) pro-oestrous female rats. The broken line indicates the
lower limit of detection of the assay for these samples.
release into hypophysial portal vessel blood (Fink, 1979a; Fink,
Stanley and Watts, 1983). Such studies included, for example,
investigations of hypothalamic LHRH content in male and female rats
(Chiappa and Fink, 1977), the release of LHRH in response to
electrical stimulation of the hypothalamus (Fink and Jamieson, 1976;
Chiappa, Fink and Sherwood, 1977; Eskay, Mica! and Porter, 1977),
the preovulatory surge of LHRH during the afternoon of pro-oestrus
(Sarkar, Chiappa, Fink and Sherwood, 1976; Sherwood, Chiappa, Sarkar
and Fink, 1980) and the steroid modulation of LHRH output (Sarkar
and Fink, 1979a, 1980). The present results show that in contrast
to somatostatin (Chapter 3) and TRH (Chapter 4) only one peak of
LHRH-IR was detected in extracts of hypophysial portal blood or
hypothalamus and indicate that the LHRH-IR measured in the previous
studies described above was in fact due to the authentic decapeptide.
Previous gel filtration studies of extracts of sheep
hypothalami revealed the presence of three peaks of LHRH-IR, which
corresponded to the authentic decapeptide and two higher molecular
weight (H.M.W.) forms - the largest with a molecular weight greater
than 5,000 daltons (Millar, Achnett and Rossier, 1977). By
examining the interactions between LHRH-HMW and various antisera
raised against differing portions of the LHRH molecule, and also by
studying the LHRH-IR formed after digestion of the HMW material with
either carboxy- or aminopeptidase, it was concluded that these HMW
forms consisted of the LHRH molecule extended at both the N and
C-termini (Millar, Wegener and Schally, 1981). Similar gel
filtration studies using rat hypothalamic extracts, showed the
presence of LHRH and two C-terminally extended forms with molecular
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weights of 1,800 and 26,000 daltons (Gautron et al, 1981). Allowing
for the removal of a signal peptide the latter value is in agreement
with the 28,000 dalton precursor demonstrated by the in vitro
translation of poly A+mRNA from rat, human or normal mouse brain
(Curtis et al, 1983). Subcellular fractionation of crude
hypothalamic extracts revealed that only authentic LHRH was present
in the synaptosomal fraction, whereas the HMW material was present
in the microsomal fraction (Millar et al, 1981; Gautron et al,
1981). Similarly, the LHRH decapeptide was released from
synaptosomes in response to a K+ depolarizing stimulus (Millar e^t
al, 1981). The present results, taken together with the above
evidence obtained in synaptosomal preparations, might be taken to
suggest that LHRH is processed to completion before entering the
portal vessels. However, the possibility remains that under the
conditions used in the present study for the extraction and HPLC of
LHRH, small quantities of either the LHRH precursor or of
intermediate forms of LHRH derived from the precursor may not have
been detected.
Radioimmunoassay of crude extracts of hypothalami from hpg mice
indicated the absence of detectable LHRH-IR (Cattanach et al, 1977),
a finding also shown, indirectly, by the inability of electrical
stimulation of the median eminence of hpg mice to raise the plasma
concentration of LH (Iddon, Charlton and Fink, 1980), even though
administration of exogenous LHRH is an effective stimulus for the
release of some of the small amount of LH present in the hpg
pituitary (Chapter 7). The present findings confirm the results
obtained previously that this mutant does not synthesize any
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LHRH-like material. In contrast to normal mice, no polypeptides
which were immunoprecipitable with the HC-6 antiserum were produced
by the cell free translation of poly A+ mRNA extracted from the
hypothalami from hpg mice (Curtis et al, 1983) suggesting that the
lack of LHRH in the mutant was due to a defect in the LHRH gene,
transcription or mRNA translation. Recently it has been possible to
correct the hpg deficit by the grafting of tissue taken from the
pre-optic area of foetal, normal mice into the third ventricle of
adult hpg animals, thus resulting in the innervation of the host
median eminence with immunohistochemically identified processes from
the LHRH-containing cell bodies (Krieger, Perlow, Gibson et al,
1982; Gibson, Charlton, Perlow et al, 1984a). Although these
transplants did not fully restitute a normal hypothalamic content of
LHRH, the grafts were sufficient to result in increases in plasma
testosterone concentrations and weight of the seminal vesicles ,
full spermatogenesis and some development of the interstitial cells
of the testes (Krieger et al, 1982). Similarly, transplantation of
pre-optic area tissue taken from normal foetuses (of either sex)
into female hpg mice, resulted in vaginal opening and a persistent
cornified vaginal smear, enlargement and development of the uteri
and ovaries and an increase in pituitary FSH content and plasma LH
concentrations (Gibson et al, 1984a). Such animals have been mated
and pregnancy maintained for its full duration. Ovulation in hpg
mice bearing a graft of normal hypothalamic tissue would appear to





The Priming Effect of LHRH, and Determination of the Biological
Activity of LH in the Hypoqonadal (hpq) Mouse
7.1 INTRODUCTION
The mechanism of the priming effect of LHRH, the capacity of
the decapeptide to increase pituitary responsiveness to itself
(Aiyer, Chiappa and Fink, 1974; Fink, Chiappa and Aiyer, 1976) is
not known. The priming, but not the releasing, action of LHRH is
dependent upon protein synthesis (Edwardson and Gilbert, 1976; de
Koning, van Dieten and van Rees, 1976; Pickering and Fink, 1976a,
1977; Curtis, Lyons and Fink, 1985), but the new protein is unlikely
to be gonadotroph!n since measurements of the amount of LH released
compared with that remaining in the pituitary gland suggest that
little or no new gonadotrophin is synthesized after the initial
exposure to LHRH (de Koning et al. 1976; Pickering and Fink, 1979;
Speight and Fink, 1981). Curtis et al (1985) demonstrated the
association of the priming effect with the synthesis of a protein
(with molecular weight approximately 69,000) and changes in the
isoelectric point of two other proteins. In vitro, the priming
effect is blocked by treatment with cytochalasin B suggesting that
priming may involve a change in contractile proteins (Pickering and
Fink, 1979a; Lewis, Morris and Fink, 1985). Conceivably, the
priming effect might depend upon an increase in specific LHRH
receptors. However, this seems unlikely because the density of the
LHRH receptors on anterior pituitary cells decreases at the time of
the spontaneous surge of luteinizing hormone (Clayton, Solano,
Garcia-Vila, Dufau and Catt, 1980) and once the anterior pituitary
gland has been exposed to LHRH a massive amount of LH, equivalent to
that released by a second exposure to LHRH, can be released by
exposure to either high extracellular K+ (Pickering and Fink,
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1976b) or Ca++ ionophores (Pickering and Fink, 1979a). Although
steroids do not mediate the priming effect of LHRH, the magnitude of
the effect is increased by oestradiol-17e (Aiyer et al. 1974;
Meidan, Fink and Koch, 1981).
The absence of hypothalamic LHRH from the hypogonadal mouse
(Chapter 6) makes this mutant an ideal model for investigations of
the effects of exogenous LHRH in animals which have had no previous
exposure to LHRH. The following experiments were designed in order
to determine whether previous exposure of the pituitary gland to
normal levels of LHRH, and a normal pituitary content of LH, are
necessary for the LH releasing action, and the priming effect, of
LHRH and for the facilitation of pituitary responsiveness by
oestradiol-17e. A second series of experiments was carried out to
determine whether the small amount of LH present in the pituitary
gland of the hpg mouse was biologically active as assessed by the in
vitro production of testosterone by mouse Leydig cells.
7.2 MATERIALS AND METHODS
The animals used were adult hpg or normal mice maintained as
described in Chapter 2.
7.2.1 Demonstration of the priming effect of LHRH
At the start of the experiment 4-5 mm silicone elastomer
capsules packed with oestradiol-17e were prepared, preincubated, and
then implanted subcutaneously (2.2.5) into recipient female hpg or
normal mice. In the rat, capsules of this size produced plasma
concentrations of oestradiol-17e of about 30-50 pg/ml and when left
implanted for 12-48 h produced a marked and sustained increase in
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pituitary responsiveness to LHRH (Henderson, Baker and Fink, 1977).
Insufficient blood remained after assay for LH for estimation of
plasma oestradiol-17g in the present study, but in both normal and
hpg mice implanted with oestradiol-containing capsules the weights
of the uteri were significantly increased (Table 7-A). Control
groups of animals received similarly constructed capsules without
the oestradiol. In normal mice the capsules were implanted mostly
two days, but in a few three days, after the last cornified vaginal
smear. At the time of capsule implantation the smear was
leucocytic. Pituitary responsiveness to LHRH was tested 48 h later
at which time the smear was comprised of cornified cells in all
animals bearing oestradiol-containing capsules and either cornified
or cornified plus nucleated epithelial cells in animals bearing
empty capsules. In the hpg mice the vagina had opened and the
vaginal smear cornified at 48 h after implantation of an oestradiol-
containing capsule in most animals. In hpg mice implanted with an
empty capsule the vagina was closed in about 50% and the smear
leucocytic when the vagina was open.
To test the pituitary responsiveness to LHRH, the mice were
anaesthetized with urethane (120 mg/100 g body weight, administered
i.p. as a 10% solution in 0.9% NaCl (w/v) solution) and, after
withdrawal of an initial blood sample (0.2 ml) from the external
jugular vein, the mice were injected with 400 ng synthetic LHRH (ICI
Pharmaceuticals, Cheshire) (about 1.2 yg/100 g body weight) i.v. in
0.2 ml 0.9% NaCl. A second injection of the same dose of LHRH was
administered one hour later. This relatively high dose of LHRH was
used because at the time that these studies were begun, preliminary
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experiments had shown that with the sampling regime used in this
study, 400 ng LHRH/mouse were required to produce clear-cut and
reproducible LH release. Venous blood samples were withdrawn from
the external jugular vein at 30, 59, 90 and 120 min after the first
injection of LHRH. At the end of the experiment, animals were
killed and the anterior pituitary gland rapidly removed, weighed and
homogenized in ice cold 0.09% NaCl (w/v) solution (2.2.6). The
uterus was dissected out, freed from all adhering tissue, blotted
and weighed using a torsion balance. Pituitary and plasma samples
were stored at -40°C until assayed for LH (2.2.5). Previous studies
(Cattanach, Iddon, Charlton, Chiappa and Fink, 1977) showed that in
this assay, saline extracts of mouse pituitary gland inhibited
binding in parallel with LH standard. The plasma samples were
assayed in duplicate usually in volumes of 50 or 20 pi. For a 50 pi
volume the lower limit of the sensitivity of the assay was usually
0.8 ng LH/ml but in one assay the sensitivity was 2 ng/ml. The
significance of differences between groups was assessed by the Mann
Whitney U test.
7.2.2 Assay of the biological activity of LH in the hpg pituitary
The anterior pituitary glands from 10 normal and 30 hpq mice
were separately homogenized in 2 or 6 ml ice-cold 0.9% saline
respectively and freeze-dried. The testes and seminal vesicles of
each animal were checked carefully before the pituitary gland was
added to the pool in the homogenizer tube to ensure that the
pituitary glands had been placed in the correct category. The
freeze-dried extracts were subsequently redissolved in assay buffer
to provide stock solutions containing 1 normal or 10 hpq pituitary
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glands/ml; the solutions were stored at -40°C until dispatched
(frozen) to Dr. Tony Plant (University of Pittsburgh) for assay of
LH bioactivity by the in vitro production of testosterone by mouse
Leydig cells (Van Damme, Robertson and Diczfaluzy, 1974). A total
of four assays were carried out in which serial dilutions of 1-11 yl
of the diluted pituitary extracts were assayed in triplicate. In
the absence of a readily available standard preparation of murine
LH, a rhesus LH standard (WP-XV-20:NICHD-rLH) was included in three
of the assays mainly to check that the characteristics of the assays
were similar to those previously carried out in Pittsburgh. The
potency of the WP-XV-20 was approximately 0.5 NIH-LH-S1 (Plant,
1982; Monroe, Peckham, Neill and Knobil, 1970; Karsch, Weick, Butler
et al, 1973).
Testosterone released into the incubation medium was estimated
by radioimmunoassay (Plant, Hess, Hotchkiss and Knobil, 1978) of
50 ul samples of the unextracted medium. The specificity of the
antiserum (S250, provided by Dr. G.D. Niswender) and the accuracy of
the assay were as described in detail by Plant et al. (1978). The
sensitivity of the assay was 2 pg/tube and the intra-assay
coefficients of variation of the two assays used in this study were
9% and 11% respectively. The statistical analyses of the slopes and
relative potencies were calculated according to Bliss (1952).
7.3 RESULTS
7.3.1 The priming effect of LHRH and the effect of oestrogen implants
The plasma concentrations of LH are shown in Figure 7-1 and the
mean maximal increments, pituitary LH contents and concentrations
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FIGURE 7-1: Mean plasma concentrations of LH before and after the i.v.
injection of LH releasing hormone (LHRH; arrows) in normal
mice bearing either empty (A) or oestradiol-containing silicone
elastomer capsules (A) or in hypogonadal (hpg) mice bearing
either empty (O) or oestradiol-containing capsules (•). The
vertical lines indicate S.E.M. These are not shown for the
concentrations of LH in some samples taken before the first
injection of LHRH because some of these values were below the
limit of detection of the assay. For the purpose of calculating
the mean LH concentrations in the preinjection samples of plasma,
the undetectable samples were mostly assigned values of 0.8 ng/ml,
the lower limit of detection of most of the assays for 50 ul
plasma samples. A few samples were assigned a value of 2.0 ng/ml,
the lower limit of detection of one assay. Nine to eleven
animals were included in each treatment group.
Table7-AMeanmaximalincr me tsofplas aLHaft rHRHinjection,pi uitaryglandcontent concentrationa dut rinew ightihyp gon dal( p )a m lm cimplant dwi ht er oestradiol-containingrmptyi1icone-elastomercap ules.Va ueea s*S.E.M.;ninetel v animalspergroup. TreatmentMaximalincre tsnplasmaLHPi uit ryU eri ew ght concentration(ng/ml)after:(mg MiceCapsulefir tinjectionsecondinje tionCon e tCon entration ofLHRH(ng/gland)(ng/mg NormalEmpty NormalOestradiol hpgEmpty hpgOestradiol4.4*0.6 2.1*0.5 5.0*0.5 4.4*0.234.8*6.5** 13.5*3.1** 19.4*4.4* 15.9*3.2*468.3*55.9 340.2*37.1 76.0*7.8 110.1*16.7
333.3*54.4 218.3*32.5 63.3*6.0 79.3*14.9
89.2*14.0 170.7*15.4 5.9*1.2 31.8*3.0
*P<0.01,*.00comparedwithincrementaft rfi stLHRHinj c ion.
and uterine weights are shown in Table 7-A. The maximal increments
were taken as the differences between the plasma LH concentrations
before and the maximal LH concentrations after the injection of
LHRH. In all treatment groups the mean maximal increments after the
second injection of LHRH were greater than after the first
injection. In animals implanted with an empty capsule the maximal
increments after the second LHRH injection in the hpg mice were
lower, but not significantly compared with those in normal mice.
Implantation of an oestradiol-containing capsule significantly (P <
0.01) reduced the LH response to both the first and second injection
of LHRH in normal mice, but had no significant effect on the
responses in the hpg mice. Pituitary LH contents in the hpg mice
were significantly (P < 0.001) lower than in the normal mice.
Implantation of an oestradiol-containing capsule had no significant
effect on pituitary LH content or concentration in either hpg or
normal mice.
7.3.2 The bioactivity of LH
Assays 1-3 (Table 7-B) were performed to determine the optimal
starting dilutions of the pituitary extracts for potency
comparisons; these proved to be 0.01 pituitary/ml for normal glands
and 0.1 pituitary/ml for glands from hpg mice. The linear parts of
the dose response curves for normal and hpg pituitary extracts did
not diverge significantly (assay 3, Table 7-B; assay 4, Fig. 7-2 and
Table 7-B). Normal mouse pituitary gland was about 20-times as
potent as hpg pituitary gland (Table 7-B) a value similar to that
obtained by radioimmunoassay (Cattanach et al. 1977; Iddon et al.
1980; McDowell, Morris and Charlton, 1982a). The divergence in
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FIGURE 7-2: Testosterone production assay (number 4 in Table 7-B) showing
log dose-response curves produced by extracts of pituitary
glands from normal (▼) and hpg (O) mice and the WP-XV-20 LH
standard (■). Each point is the mean of 3 estimations. The
amount of testosterone produced in the absence of pituitary
extracts or LH standard was 0.431 ng/ml medium.
slopes between the WP-XV-20 preparation and the mouse pituitary
extracts made it impossible to determine relative potency of mouse
pituitary gland in terms of a known standard preparation of LH.
7.4 DISCUSSION
Whilst the pituitary content of LH of hpg mice implanted with
empty capsules was only 16% of that of normal animals (Table 7-A),
the hpg animals have the capacity to respond to the injection of
LHRH by releasing LH, as shown previously (Iddon, Charlton and Fink,
1980; McDowell, Morris, Charlton and Fink, 1982b). Furthermore, the
data contained in Table 7-A and Figure 7-1 demonstrate that the
priming effect in hpg mice was similar to that in normal animals and
also that the magnitude of the priming effect is not directly
proportional to pituitary LH content. In the rat, plasma LH
concentrations reach a peak 20-30 minutes after each injection of
LHRH and decline subsequently (Aiyer et al, 1974); in mice, the
response to the second injection of LHRH was slower and consequently
the plasma concentration of LH was greater 60 minutes after this
injection than at 30 minutes (Fig. 7-1). It was not possible to
carry out further experiments to examine the release of LH over a
longer time period because of a lack of sufficient animals. More
recently, in vitro studies have confirmed that the priming effect of
LHRH can be elicited from pituitary glands from both normal and hpg
mice (Lewis et al, 1985; Lewis, Morris, Fink and Johnson, 1986).
The present data also showed that the primed response to LHRH was
similar in magnitude in hpg and normal mice, and this was confirmed
in vitro by Lewis et al (1986). In order to economize on animals in
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the present experiments, control groups in which animals were
injected with LHRH followed by saline, and vice versa, were not
included because previous studies in mice showed that sequential
blood sampling either in untreated or saline injected animals did
not significantly alter plasma LH concentrations (Iddon, Charlton
and Fink, 1980), and, in rats, the priming effect of LHRH could not
be elicited by injecting LHRH followed by saline or vice versa
(Aiyer et al. 1974; Fink and Pickering, 1980). The dose of LHRH
used by Iddon et al (1980) to evoke LH release was lower than that
used in the present study, but Iddon et al. used male mice and
removed the first blood sample after LHRH injection 5 minutes after
the injection.
Since the primary deficit in the hpg animals is related to the
lack of hypothalamic LHRH (Chapter 6), it is clear that neither the
releasing, nor the priming, actions of LHRH depend upon previous
exposure to LHRH. The LHRH receptor density in hpg male and female
mice is about 30% of that of normal mice (Young, Speight, Charlton
and Clayton, 1983) and this shows that LHRH receptors are present in
the pituitary gland in the absence of endogenous LHRH, albeit at
lower concentrations. The present findings add to the evidence
cited in the introduction to this chapter that LHRH receptor density
may not play a critical role in the priming effect of LHRH.
The dependence of the priming effect upon the integrity of
microfilaments was shown by in vitro studies in which the priming
but not the releasing action of LHRH was blocked by cytochalasin B
(Pickering and Fink, 1979; Lewis et al, 1985). Ultrastructural
studies of the gonadotrophs of normal mice demonstrated that the
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priming effect was associated with an increase in the length of the
microfilaments and a change in their orientation, together with a
migration of secretory granules towards the marginal zone of the
cytoplasm adjacent to the cell membrane (Lewis et al, 1985).
Although the total number of secretory granules was less in the
gonadotrophs of hpg than normal mice, the number of granules present
in the outer 500 nm wide band of cytoplasm closest to the cell
membrane was similar in both strains of mice and was increased by
exposure to LHRH (Lewis et al, 1986).
The increase in plasma oestradiol-17g concentrations on the
morning of pro-oestrus is a major factor in the development of the
enhanced responsiveness of the anterior pituitary gland to LHRH
which precedes and accompanies the pre-ovulatory surge of LH in the
rat. This action of oestradiol may be exerted, in part, by a direct
effect on the gonadotroph, as is suggested by studies of the
pituitary responsiveness to exogenous LHRH in vivo, in animals in
which the pituitary stalk has been sectioned (Greeley, Allen and
Mahesh, 1975; Fink and Henderson, 1977a; Greeley, Volcan and Mahesh,
1978), and in vitro, using dispersed cell systems (Drouin, Lagace
and Labrie, 1976; Speight and Fink, 1981). Other data, however,
indicate that a functionally intact hypothalamic-pituitary system is
necessary for oestrogen to exert its full effect. Henderson, Baker
and Fink (1977), for example, showed that the increased pituitary
responsiveness to LHRH was apparent in rats 12 h after the
implantation of an oestradiol-17e containing capsule, an effect
which was blocked by sodium pentobarbitone administered 8 h after
capsule implantation (Henderson et al, 1977; Speight, Popkin, Watts
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and Fink, 1981); the barbiturate-induced blockade could be overcome
by the infusion of LHRH at a low dose which, by itself, was
insufficient to evoke a large release of LH (Speight et al, 1981).
Furthermore, the increased concentrations of LHRH in rat hypophysial
portal blood which follow immediately after ovariectomy (Sarkar and
Fink, 1980) were maintained for 12 h in animals implanted with
oestradiol capsules, whereas LHRH concentrations declined in control
animals with empty capsules (Speight et al, 1981). From the
foregoing studies it is apparent that in the rat a major component
of the augmentation of pituitary responsiveness to LHRH by
oestradiol involves either an increase in or a maintenance of LHRH
release into hypophysial portal blood at a rate which is not
sufficiently high to produce a surge of LH. In relation to the
regulation of pituitary LRHH receptors and the control of the
release of pituitary gonadotrophins, the mouse, however, differs
markedly from the rat (Bronson, 1981; Naik, Young, Charlton and
Clayton, 1984a,b). In the normal mice of the present experiment
continuous exposure to oestradiol-170 reduced rather than
facilitated gonadotrophin function. Previous studies (Bronson and
vom Saal, 1979) showed that in contrast to female rats and hamsters,
long-term implantation of oestradiol-170-containing capsules did not
produce spontaneous daily LH surges. In contrast to the effect of
oestradiol on the priming effect of LHRH in normal mice,
oestradiol-170 had no significant effect on the priming effect in
the hpg mice suggesting that a normal LHRH mechanism may be
necessary for the inhibitory effect of oestradiol seen in normal
mice. A direct inhibitory effect of oestradiol on the gonadotroph
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has been demonstrated by Charlton et al (1983) in experiments which
showed that implantation of capsules containing oestradiol benzoate
into hpg mice abolished the large increase in pituitary FSH content
which was induced by daily administration of LHRH.
LHRH stimulates the synthesis of gonadotrophins as well as
stimulating their release. This could be inferred from the results
of early experiments in which it was noted with the aid of
cytological staining techniques that there was a progressive loss in
ability to detect gonadotrophs in pituitary glands which had been
transplanted from the hypothalamus to the kidney capsule
(Nikitovitch-Winer and Everett, 1958, 1959); normal pituitary
cytology was restored by the retransplantation of the pituitaries to
the median eminence (Nikitovitch-Winer and Everett, 1959) or by the
infusion of hypothalamic extracts (Evans and Nikitovitch-Winer,
1969). Direct evidence for the stimulation of the synthesis of
bioactive LH in response to LHRH was provided by studies of LH
synthesis by cell cultures or pituitary gland fragments in vitro
(e.g. Redding, Schally, Arimura and Matsuo, 1972; Ishikawa and
Nagayama, 1973; Liu and Jackson, 1979) and LHRH may also stimulate
the glycosylation of LH (Azhar, Reel, Pastushok and Menon, 1978; Liu
and Jackson, 1978). The data shown in Figure 7-2 and Table 7-B show
that the small amount of LH in the pituitary gland of the hpg mouse
is capable of stimulating testosterone production from Leydig cells
and is therefore biologically active. McDowell et al (1982a) found
that gonadotrophs which were stained by an antiserum raised against
the e subunit of LH were present in the pituitary gland of the hpg
mouse and that the frequency of occurrence of the gonadotrophs was
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72% of that in the pituitary glands of normal mice, though the LH-e
staining cells in hpg animals were smaller and possessed fewer and
smaller granules. The present results taken together with those of
McDowell et al (1982a) show that both differentiation of the
gonadotrophs and the synthesis of some bioactive LH can occur in the
absence of LHRH, even though LHRH is essential for the full
synthesis of normal amounts of pituitary LH. Treatment of hpg
animals with either single or multiple daily injections of LHRH
administered over a period of 10-20 days resulted in increased
pituitary content of both LH and FSH, although the effect was most
marked in the case of FSH for which there was a several-fold
increase to amounts greater than those in normal animals (Charlton
et al, 1983). Long-term LHRH administration also resulted in
increases in the number and size of the pituitary cells which
reacted with anti-LH-e serum, and an increase in the size of their
granules to values within the normal range (McDowell, Morris,
Charlton and Fink, 1982b).
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CHAPTER 8
Effect of A^-Tetrahydrocannabinol, Naloxone, or the Sucking
Stimulus on the Release of LHRH into Hypophysial Portal Vessel Blood.
8.1 INTRODUCTION
The following series of experiments were carried out to examine
the secretion of LHRH and LH during suckling in lactating rats and
after the administration of naloxone or tetrahydrocannabinol to
female rats at different times during the oestrous cycle.
8.1.1. Effects of A^-tetrahydrocannabinol on hormone secretion
A number of studies have indicated that following the
administration of ^-tetrahydrocannabinol (THC) the principal
psychoactive component of marijhuana (Mechoulam, Shani, Edery and
Grunfeld, 1970), the secretion of a number of pituitary hormones is
altered. These endocrine effects include an increase in ACTH
secretion (Dewey, Peng and Harris, 1970; Kokka and Garcia, 1974) and
decreased secretion of growth hormone (Kokka and Garcia, 1974),
prolactin (Kramer and Ben-David, 1974; Steger, Silverman, Johns and
Asch, 1981; Chakravarty, Sheth and Ghosh, 1975) and LH (Marks, 1973;
Collu, Letarte, Leboeuf and Ducharme, 1975). The high serum
concentrations of LH measured in ovariectomized rats or monkeys were
reduced by THC (Steger, Silverman, Siler-Khodr and Asch, 1980;
Smith, Besch, Smith and Besch, 1979), and Tyrey (1978) showed this
reduction was a consequence of a central inhibition of pulsatile LH
release. When administered to rats early in the afternoon of
pro-oestrus, THC blocked the spontaneous surge of LH and inhibited
subsequent ovulation (Nir, Ayalon, Tsafriri, Cordova and Lindner,
1973; Ayalon, Nir, Cordova et al, 1977); similarly, pretreatment of
rabbits with THC also blocks the reflex ovulation following mating
(Asch, Fernandez, Smith and Pauerstein, 1979). Although in many of
the above studies the anti-ovulatory effects of THC were suggested
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to be centrally mediated, there is no proof that THC inhibits the
release of LHRH. Therefore, the effect of THC, administered at a
dosage which blocked ovulation, was determined on the release of
LHRH into hypophysial portal vessel blood during the period of the
pro-oestrous LHRH surge.
8.1.2 Effect of continuous infusion of naloxone on the release of
LHRH
The inhibition of gonadotrophs release by morphine has long
been known (Barraclough and Sawyer, 1955) and there is much evidence
in support of a functional role of the endogenous opioid peptides in
the regulation of LHRH secretion (Kalra and Kalra, 1983, 1984;
Bicknell, 1985). Thus, the administration of morphine or opioid
peptides in vivo inhibited the basal secretion of LH (Bruni, Van
Vugt, Marshall and Meites, 1977; Cicero, Badger, Wilcox, Bell and
Meyer, 1977; Cicero, Schainker and Meyer, 1979) and the pro-oestrous
LH surge (Muraki, Nakadate, Tokunaga, Kato and Makino, 1979; Ieiri,
Chen, Campbell and Meites, 1980) and the surge of LH induced in
long-term ovariectomized rats by the administration of oestrogen and
progesterone (Adler and Crowley, 1984; Akabori and Barraclough,
1986b). Conversely in many of the foregoing preparations the
administration of the opiate receptor antagonist, naloxone, resulted
in enhanced LH secretion.
In a number of physiological situations, LH is secreted from
the pituitary gland in a pulsatile manner. In the rat these pulses
are most clearly demonstrated following gonadectomy (Gay and Sheth,
1972; Gallo, 1980), but regular pulses of LH have been shown to
occur with varying frequency and amplitude throughout the oestrous
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cycle (Gallo, 1981a,b). Several lines of evidence indicate that
pulsatile LH release is mediated by central mechanisms involving the
pulsatile release of LHRH. Although in the rat it is not possible
to measure simultaneously LH and LHRH output in the same animal,
discrete pulses of LHRH (which were consistent with the frequency of
LH pulses) have been detected in hypophysial portal blood (Sarkar
and Fink, 1980) and pulsatile LH secretion was suppressed after
passive immunoneutralization with anti-LHRH serum (Snabes and Kelch,
1979). Gallo (1981a) reported that the low plasma concentrations of
LH measured on the morning of oestrus were associated with the
slowest frequency of pulsatile LH release when compared with other
times of the oestrous cycle. Fox and Smith (1985) were unable to
detect measurable pulses of LH during the day of oestrus, but
demonstrated that regular pulses could be induced by the continuous
infusion of naloxone. In the second series of experiments described
below, LHRH secretion into portal blood was measured in rats
anaesthetized with alphaxalone and infused with naloxone or saline
on either the afternoon of pro-oestrus or the morning of oestrus.
In each case an attempt was made to correlate LHRH secretion with
the pattern of LH release during the hour of infusion which preceded
the section of the pituitary stalk for the collection of portal
blood.
8.1.3 Effect of the suckling stimulus on the release of LHRH in
lactating rats
The plasma and pituitary concentrations of the gonadotrophins
are reduced during lactation and the oestrous cycle suppressed
(Minaguchi and Meites, 1967; Lu, Chen, Huang et al, 1976a; Smith and
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Neill, 1977). The magnitude of the reduction of plasma LH and FSH
concentrations is directly related to the intensity of the suckling
stimulus (Hammonds, Velasco and Rothchild, 1973; Ford and Melampy,
1973; Smith, 1978a). Suckling also prevents the increased plasma
concentration of LH observed after ovariectomy (Ford and Melampy,
1973; Hammonds et al, 1973; Harms, Fleeger and Owens, 1977). The
suppressive effect of suckling on plasma gonadotrophin concentration
and ovulation may be mediated directly by a neural pathway activated
by suckling which inhibits LHRH release, or may be a secondary
consequence of the effects, at the hypothalamus and/or pituitary
gland, of the increased plasma prolactin concentration. The aims of
the final series of experiments which are described in this chapter
were two-fold. Firstly, LHRH secretion was compared in suckled and
non-suckled lactating rats. Secondly, since oxytocin was shown to
be released into hypophysial portal blood from nerve terminals in
the external layer of the median eminence (Gibbs, 1984; Sarkar and
Gibbs, 1984; Horn, Robinson and Fink, 1985c) and since synthetic
oxytocin is reported to release prolactin from the anterior
pituitary gland both in vivo and in vitro (Salisbury, Krieg and
Seibel, 1980; Lumpkin, Samson and McCann, 1983) the effect of the
suckling stimulus on the secretion of oxytocin into portal blood was
also investigated.
8.1.4 Rationale for the use of alphaxalone as an anaesthetic
In contrast to the effects of many other anaesthetics, the
steroidal anaesthetic, alphaxalone (Saffan, formerly available as
Althesin, 2.2.1) does not block (although it does reduce) either the
spontaneous pro-oestrous surge of LH and LHRH in adult rats (Sarkar,
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Chiappa, Fink and Sherwood, 1976; Sherwood, Chiappa, Sarkar and
Fink, 1980; Ching, 1982), or the surges of LH and LHRH induced by
the administration of pregnant mare serum gonadotrophin in immature
rats (Sarkar and Fink, 1979b). Similarly, unlike sodium
pentobarbitone, alphaxalone did not block the pulsatile release of
LH in ovariectomized rats (Watts and Fink, 1981) or the diurnal
rhythm of LH secretion in long-term ovariectomized rats treated with
oestrogen (Sarkar and Fink, 1980). Thus, alphaxalone proved to be
the anaesthetic of choice for studies of the regulation of LHRH and
LH release and was therefore used in the following investigations of
some aspects of the pharmacological and physiological control of the
release of LHRH into hypophysial portal vessel blood.
8.2 MATERIALS AND METHODS
Samples of hypophysial and peripheral blood were obtained and
assayed for LHRH (using the HC6 antiserum), LH and prolactin
respectively, using the methods and assays described in Chapter 2.
Samples of hypophysial portal blood from lactating rats were sent to
Dr. I.C.A.F. Robinson at Mill Hill for determination of oxytocin
concentration by radioimmunoassay using a specific antiserum (R^)
raised in rabbits against oxytocin conjugated to porcine
thyroglobulin (Robinson, 1980). The significance of differences
between means was determined using the Mann-Whitney U test.
8.2.1 Effect of ^^-tetrahydrocannabinol on LHRH and LH release
Tetrahydrocannabinol was purchased from Sigma, U.K. as a
solution in ethanol containing 10 or 25 mg/ml. The oily residue
which remained after evaporating the alcohol under a stream of
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nitrogen gas was suspended in vehicle [0.9% saline, propylene glycol
(Sigma) and polyoxyethylene sorbitan mono-oleate (Tween 80; Sigma)
(78:20:2 v/v)] to produce a 5 mg/ml solution. Adult female rats
were injected at 13.30 h on the afternoon of pro-oestrus with THC
(10 mg/kg) or with vehicle. At 15.30 h (Group A) or 17.00 h (Group
B) animals were anaesthetized with Saffan (5 ml/kg body wt) and the
hypophysial portal vessels exposed (2.2.3). Samples (0.2 ml) of
peripheral blood were withdrawn (for plasma LH determination) from
the EJV at the time of induction of anaesthesia; further blood
samples were withdrawn an hour later (0.5 ml, for LH and LHRH
determination). Immediately after removing the second peripheral
sample, animals were injected with heparin, and after cutting the
pituitary stalk, hypophysial portal vessel blood was collected for
four 30 min collection periods. At the end of the final collection
period, a further sample of peripheral blood (0.5 ml) was removed
for LHRH determination.
8.2.2 Effect of naloxone infusions
Female rats were anaesthetized with alphaxalone (5 ml/kg b.w.)
at 17.00 h on the afternoon of pro-oestrous at 10.00 h on the
morning of oestrus. After the withdrawal of an initial sample of
peripheral blood (0.2 ml) animals were injected with 1 mg naloxone
hydrochloride (Sigma UK; 2 mg/ml solution in 0.9% saline, i.v.) and
for the remainder of the experiment naloxone hydrochloride was
infused into the contralateral EJV at a rate of 0.7 mg/h. The
infusions were made through a 25 gauge hypodermic needle which was
connected to a 2 ml syringe by way of a length of polythene tubing
(Portex PP20). The piston of the syringe was driven by a six-speed
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continuous slow injection pump (Model 6130, C.F. Palmer Ltd.,
London) to give an infusion rate of 0.54 ml/h. Control animals were
injected and infused with saline. Further peripheral blood samples
were removed at 15 min intervals during the first hour of the
infusion, while the hypophysial portal vessels were exposed.
Hypophysial blood was collected for four 30 min periods and at the
end of the last collection period a 0.5 ml sample of peripheral
blood was withdrawn for determination of LHRH.
8.2.3 Effect of the suckling stimulus on LHRH release
Lactating female rats, 9-11 days post partum, were separated
overnight from all of their pups (6.2.2). The following morning the
mother was anaesthetized with alphaxalone (7 ml/kg b.w.) and the
dura overlying the portal vessels exposed, but not cut (2.2.3).
Animals were maintained under anaesthesia for 7 h during which the
rectal temperature was closely monitored and maintained at 37° ± 1°C
with the aid of a warming lamp. During the first 3 h, supplementary
doses of anaesthetic (0.5 ml) were administered at approximately
hourly intervals as required. Three hours after the exposure of the
dura, peripheral blood samples were withdrawn and 10 pups attached
to the mother's teats in the suckled group; no pups were returned to
the control group. After a further hour a further peripheral blood
sample was taken, the dura cut and hypophysial portal vessel blood
collected for four consecutive 30 min collection periods. A final
peripheral sample was taken at the end of the last collection period.
In a parallel series of experiments in which all the animals
were suckled, the portal vessels were exposed, but not cut, a series
of samples (0.5 ml) of peripheral blood were withdrawn from the EJV
at 30 min intervals throughout the period of suckling.
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8.3 RESULTS
8.3.1 Effects of tetrahydrocannabinol
The concentration of LH in the plasma of rats which had been
injected with THC at 13.30 h and anaesthetized with alphaxalone at
15.30 h did not differ significantly from the plasma concentrations
in vehicle treated rats (Table 8—A; group A). There was a small,
but significant increase in plasma LH concentration (P < 0.05) in
vehicle treated rats only, between 15.30 and 16.30 h. In the second
group of rats which were injected at 13.30 h with either THC or with
vehicle and anaesthetized at 17.00 h (Table 8-A, group B), vehicle
treated rats showed a significant pro-oestrous surge of LH (P < 0.05
- 0.01 compared with plasma LH concentrations in group A) which was
completely blocked in THC treated animals. Figures 8-1 and 8-2 show
the concentration (pg/ml) and content (pg released/30 min collection
period) of LHRH in samples of portal blood obtained from the rats in
groups A and B respectively. In both groups of animals the LHRH
content and concentration in hypophysial portal blood was lower in
blood samples collected from THC treated animals though these
differences were significant (P < 0.05) only during the first 30 min
collection period. A progressive decline in LHRH release over the
four successive collection periods occurred over the 2 h of blood
collection. The concentration of LHRH in all the samples of
peripheral plasma (including samples from the naloxone-treated and
lactating rats, described below) was below the limit of detection of
the assay, i.e. less than 30 pg/ml.
8.3.2 Effects of continuous naloxone infusion
During the first hour of the infusion of naloxone there was no
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Table 8-A Mean ± SEM concentrations of LH in peripheral plasma of
female rats, injected at 13.30 h on the afternoon of pro-oestrus
with A^-tetrahydrocannabinol (THC) or with vehicle and
anaesthetized with alphaxalone at either 15.30 h (Group A) or
17.00 h (Group B). 6-9 animals in each treatment group. The
hypophysial portal vessels were exposed for the subsequent
collection of portal blood, commencing at either 16.30 (Group A; see
Figure 8.1) or 18.00 h (Group B; see Figure 8.2).
Time of Sampling Plasma LH concentration (ng/ml)
THC Vehicle
Group A 15.30 2.9 ± 1.1 1.8 ± 0.2
16.30 2.5 ± 0.3 2.5 ± 0.2
Group B 17.00 2.1 ± 0.3* 31.3 ± 9.4
18.00 1.6 ± 0.1* 23.7 ± 5.3
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FIGURE 8-1: Mean (± SEM) concentration and content of LHRH in hypophysial
portal vessel plasma, together with volume of blood collected
during four successive 30 min periods of collection from
female rats injected with either 10 mg/kg of tetrahydro¬
cannabinol (\//\ ) or vehicle ( □ ) at 13.30 h on the afternoon
of pro-oestrus. Rats were later anaesthetized with alphaxalone
and collection of blood commenced at 16.30 h. 6-8 animals in
each treatment group. *P < 0.05; N/S, not significant:

















FIGURE 8-2: Mean (± SEM) concentration and content of LHRH in hypophysial
portal vessel plasma, together with volume of blood collected
during four successive 30 min periods of collection from
female rats injected with either 10 mg/kg of tetrahydro¬
cannabinol (X/A ) or vehicle ( □ ) at 13.30 h on the afternoon
of pro-oestrus. Rats were later anaesthetized with alphaxalone
and collection of blood commenced at 18.00 h. 7-9 animals in
each treatment group. *P <0.05: significance of difference
between means determined by Mann-Whitney U test.
change in the magnitude of the LH surge which occurred on the
afternoon of pro-oestrus (Table 8-B) and no differences were
apparent between the profiles of LH secretion in individual rats
infused with either naloxone or saline (Table 8-C). After the
withdrawal of the final sample of peripheral blood the infusions
were continued for a further 2 h period during which time
hypophysial portal blood was collected. The infusion of naloxone
did not result in significant changes in the release of LHRH (Fig.
8-3). Over the 2 h period there was a progressive decrease in both
the content (P < 0.001) and concentration (P < 0.01-0.02) of LHRH in
portal blood from both naloxone and saline infused animals; the
pattern of LHRH secretion in individual rats is summarized in Table
8—D).
In rats infused during the morning of oestrus the mean plasma
concentrations of LH did not differ between the naloxone and saline
infused groups (Table 8-B), but in both these treatment groups,
plasma LH increased significantly after the start of the infusion.
Concentrations of LH in the plasma of individual rats during the
first hour of the infusions are shown in Table 8-E, and the data
suggest that in the majority of both naloxone and saline infused
rats a small amplitude pulse of LH was secreted during the sampling
period. For LHRH release in these animals, there were no significant
differences between naloxone and saline treated groups, however, in
both groups there was a decrease in LHRH content (P < 0.001) and
concentration (P < 0.005-0.001) over the 2 h period of portal blood
collection (Fig. 8-4). A pulsatile pattern of LHRH secretion into
portal vessel blood was not seen in any of the individual animals
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Table 8-C Plasma concentrations of LH (ng/ml) in individual female
rats anaesthetized with alphaxalone at 17.00 h on the afternoon of
pro-oestrus. Peripheral blood samples were withdrawn before (0 min
sample), and at 15 min intervals during, the intravenous infusion of
either naloxone or saline. The hypophysial portal vessels were also
exposed for the subsequent collection of portal blood (see Figure
8-3).
Infusion Animal Number Duration of Infusion (min)
0 15 30 45 60
1 12.9 20.0 30.4 19.9 15.0
2 3.1 3.4 5.8 3.3 2.6
3 27.5 37.1 47.4 95.3 14.0
4 125.2 98.4 113.3 33.6 47.8
5 27.0 44.0 61.4 48.8 33.3
6 23.0 27.6 43.1 15.8 10.4
7 1.6 1.5 2.5 2.9 2.8
8 29.0 21.4 26.3 16.4 10.9
9 8.0 21.2 11.9 11.6 6.4









13.0 29.4 35.9 7.2
26.2 18.3 9.4 7.5
56.4 36.9 49.0 36.7
106.5 77.3 63.6 25.2
9.4 16.3 10.9 7.6
41.0 50.3 24.5 18.5
80.6 87.4 88.1 50.6





FIGURE 8-3: Mean (± SEM) concentration and content of LHRH in hypophysial
portal vessel plasma, together with volume of blood collected
during four successive 30 min periods of collection from
female rats anaesthetized with alphaxalone at 17.00 h on the
afternoon of pro-oestrus and injected and infused with either
naloxone (f'/A ) or saline ( □ ). The infusions commenced at
17.00 h and the collection of portal blood started at 18.00 h.























































Naloxone1162863947 1297503425 137498655 14783712362 156822714 167039127 17594823420 18118474553
Table 8-E Plasma concentrations of LH (ng/ml) in individual female
rats anaesthetized with alphaxalone at 10.00 h on the morning of
oestrus. Peripheral blood samples were withdrawn before, and at 15
min intervals during, the intravenous infusion of either naloxone or
saline. The hypophysial portal vessels were also exposed for the
subsequent collection of portal blood (see Figure 8-4).
Infusion Animal Number Duration of Infusion (min)
0 15 30 45 60
21 1.2 1.5 2.9 2.1 2.0
22 1.0 2.9 3.3 2.5 2.6
23 0.6 0.7 1.6 1.6 1.2
24 0.7 6.0 6.5 4.2 2.7
25 0.9 3.5 10.5 4.9 3.4
26 1.0 0.8 1.1 3.3 2.8










0.6 3.0 1.3 1.2
8.1 4.1 2.5 3.7
3.1 3.6 2.6 1.8
3.9 2.6 2.6
4.4 6.2 3.7 3.0
3.9 2.6 1.6 1.0
1.1 1.3 1.3 0.5
5.3 6.9 4.1 2.9
2.7 6.5 4.3 2.8
Applying the criteria of Watts and Fink (1984) an LH pulse is
indicated by a rise in plasma LH concentration which exceeded 4 x
standard deviation of the appropriate quality control assay pool
(i.e. for present data, with a 50 yl assay sample a > 0.8 ng/ml


























FIGURE 8-4: Mean (± SEM) concentration and content of LHRH in hypophysial
portal vessel plasma, together with the volume of blood
collected, during four consecutive 30 min periods of
collection from female rats anaesthetized with alphaxalone
at 10.00 h on the morning of oestrus and injected and
infused with either naloxone (§\j§ ) or saline (Q ). The
infusions commenced at 10.00 h and collection of portal
blood started at 11.00 h.
(Table 8-F).
8.3.3 Effects of the suckling stimulus
In lactating rats in which the ME and pituitary were exposed
ready for the subsequent collection of portal blood, a 1 h period of
suckling did not result in a significant increase in the plasma
concentration of prolactin (Table 8-G). The concentration of LH in
the plasma of lactating rats was low and no decrease in plasma LH
concentration could be detected after a period of suckling (Table
8-G). Immediately after the second sample of peripheral blood had
been withdrawn, both suckled and non-suckled animals were injected
with heparin and the pituitary stalk sectioned for the collection of
portal blood. There were no significant differences between either
the content or the concentration of LHRH in hypophysial portal
plasma from suckled and non-suckled animals except that the
concentration of LHRH in the plasma collected during the final
collection periods was lower (P < 0.05) in non-suckled compared with
suckled rats (Fig. 8-5). For both groups of rats there was a
significant decrease in LHRH concentration (P < 0.02) and content (P
< 0.005) over the two hours of blood collection. Similarly, for
oxytocin measured in hypophysial portal blood, there were no
differences in either content or concentration between suckled and
non-suckled rats, but in both groups the concentration of oxytocin
decreased over the 2 h period and, for the suckled group only, there
was also a significant decrease in plasma content of oxytocin (P <
0.001) (Fig. 8-6). Oxytocin was undetectable (< 5 pg/ml) in samples
of peripheral blood withdrawn from suckled and non-suckled rats
either before or after cutting the pituitary stalk.
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Saline Naloxone3110473584632133652473316051485413413643812415351 0574338252367544322916 377262418038897455322903911408835352721
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Figure 8-5. Mean (± S.E.M.) plasma concentration and content
of LHRH in hypophysial portal vessel plasma
together with the volume of blood collected
during four consecutive 30 min periods of
collection from lactating female rats either
) or non-suckled ( □ ). Rats
were separated from all but one of their litter
overnight and were anaesthetized with alphaxalone
for 4 h before commencement of the collection of
portal blood. In the group of suckled animals,
10 pups were applied to the nipples 1 h before
the start of portal blood collection and suckling
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FIGURE 8-6: Mean (± SEM) plasma concentration and content of oxytocin in
hypophysial portal vessel plasma collected during four
consecutive 30 min periods of collection from lactating
female rats either suckled (E8&1 ) or non-suckled <□>.
Rats were separated from all but one of their litter overnight
and were anaesthetized with alphaxalone for 4 h before
commencement of the collection of portal blood. In the group
of suckled animals, 10 pups were applied to the nipples 1 h
before the start of portal blood collection and suckling
then continued throughout the 2 h collection period.
Samples of peripheral blood were also withdrawn, throughout a
3.5 h period of suckling, from a small number of lactating rats in
which the pituitary stalk was not sectioned. Two (of three) rats
anaesthetized with alphaxalone, but not subjected to surgical
manipulation, showed an increased plasma concentration of prolactin
in response to the suckling stimulus (Table 8-H). An increase in
plasma prolactin concentration was observed after 3.5 h of suckling
in one (number 45) of the three rats in which the ME and pituitary
had been exposed. In all animals the plasma concentrations of LH
were low throughout the experiment and no further decrease could be
detected in response to suckling (Table 8-H).
8.4 DISCUSSION
In confirmation of previously reported observations (Nir et al,
1973; Ayalon et al, 1977), the administration of THC, to female rats
at 13.30 h on the afternoon of pro-oestrus, blocked the pro-oestrous
LH surge (Table 8-A). In addition, Ayalon et al (1977) showed that
when THC was administered between 12.00 and 16.00 h on the afternoon
of pro-oestrus, the subsequent ovulation was delayed by 24 h;
earlier or later administration resulted in only a partial block of
ovulation. As well as these effects on the pro-oestrous LH surge
and ovulation, THC has also been shown to inhibit the
progesterone-induced LH surge in long-term ovariectomized rats
primed with oestrogen (Steger, De Paolo, Asch and Silverman, 1983).
These effects of THC might be mediated by an action within the
hypothalamus to inhibit the secretion of LHRH and/or a reduction in
the pituitary responsiveness to LHRH. Figures 8-1 and 8-2 show that
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Table 8-H Concentrations (ng/ml) of LH and prolactin in the
peripheral plasma of individual lactating female rats which were
anaesthetized with alphaxalone. Three rats (41-43) were not
subjected to surgery (except for exposure of the EJV) whereas in the
remainder (44-46) the hypophysial portal vessels were exposed but the
pituitary stalk was left intact throughout the experiment. All
animals were maintained under anaesthesia for 3 h before the removal
of 0.5 ml of peripheral blood (sample I) after which 10 pups were
applied to the nipples Further blood samples (11—VIII) were removed
at 30 min intervals during the period of suckling.
Plasma LH Concentration
I II III IV V VI VII VIII
41 0.55 0.35 0.60 0.45 0.40 0.44 0.82 < 0.25
42 0.78 0.46 0.45 0.46 0.45 0.40 0.70 N/A
43 0.55 0.61 0.60 0.30 N/A 0.45 0.42 0.60
44 0.57 0.60 0.46 0.48 0.46 0.46 0.45 0.50
45 0.37 0.33 0.29 0.35 0.37 < 0.25 0.35 0.49
46 0.22 0.19 0.22 < 0.25 0.22 < 0.25 0.17 0.34
Plasma Prolactin Concentration
I II III IV V VI VII VIII
41 458 288 408 460 508 1162 1108 907
42 489 496 399 877 641 543 480 N/A
43 48 58 59 61 N/A 92 65 59
44 352 126 168 125 133 119 152 188
45 110 119 132 159 149 248 320 521
46 < 50 < 50 < 50 < 50 < 50 < 50 < 50 < 50
N/A, not assayed.
the secretion of LHRH was lower in the rats injected with THC than
those treated with vehicle and taken together with several other
data these results are consistent with a central inhibition of LHRH
release by THC. In rats, the blockade of ovulation may be overcome
by the administration of exogenous LHRH (Ayalon et al, 1977) and
similarly, in rabbits in which the reflex ovulation in response to
mating was blocked by pre-treatment with THC, the later
administration of LHRH or human chorionic gonadotrophs resulted in
ovulation (Asch et al, 1979). Normal pituitary responsiveness to
exogenous LHRH has been shown in THC-treated rats in several studies
(e.g. Ayalon et al, 1977; Tyrey, 1978). In long term ovariectomized
rats primed with oestrogen, 4 h after progesterone administration,
the LHRH content of the medio-basal hypothalamus was higher in
THC-treated than in vehicle-treated rats (Steger et al, 1983).
Since there was no difference in the release of LH in response to
LHRH in the vehicle or THC-treated rats, this was interpreted as
suggesting that the effect of THC on steroid-induced LH surges might
be mediated through inhibition of LHRH release. In this context,
Sarkar and Fink (1980) could not demonstrate a surge of LHRH in
hypophysial stalk plasma in steroid primed ovariectomized rats and
concluded that in this model the LHRH surge is brought about mainly
by a large increase in pituitary responsiveness to LHRH.
Early experiments showed that dibenamine or atropine blocked
ovulation if administered before 14.00 h (but not after 16.00 h) on
the day of pro-oestrus (Everett, Sawyer and Markee, 1949). This and
similar observations led to the development of the concept of a
critical period during the afternoon of pro-oestrus when the
-129-
administration of a number of drugs (e.g. barbiturates and opiates)
blocks the gonadotrophin surge and subseqent ovulation (Everett,
1964). As shown also for barbiturates (Barraclough and Wise, 1982;
Kalra and Simpkins, 1981), the turnover of noradrenaline in the
mediobasal and anterior hypothalamus was reduced by THC
administration (Steger et al, 1983) and ovulation was delayed by 24
h (Nir et al, 1973). In contrast to the barbiturates however, THC
was reported still to be partially effective in blocking ovulation
when the drug was given after the end of the critical period (Ayalon
et al, 1977).
A direct action of THC upon the ovary may contribute to the
ovulation blocking effect. This was suggested by the observation
that THC was still partially effective in blocking ovulation when
administered at the end of the critical period (Ayalon et al, 1977)
and the finding that higher doses of LH were required to induce
ovulation in THC-blocked than in pentobarbitone-blocked rats (Nir et^
al, 1973; Ayalon et al, 1977). Progressively higher doses of LH
were also shown to reverse the reduction in ovarian prostaglandin (E
series) content which occurred following administration of THC
(Ayalon et al, 1977).
Data from many studies have suggested that the release of LHRH
is controlled by central stimulatory NA neurons and inhibitory DA
and opioid (principally the $-endorphin neurons in the arcuate
nucleus which project to the preoptic area) neurons (see reviews by
Bicknell, 1985; Ferin, Van Vugt and Wardlaw, 1984; Kalra and Kalra,
1983, 1984; Ramirez, Feder and Sawyer, 1984). Interactions between
central opioid and CA neurons may result in the generation of
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steroid induced LH surges in ovariectomized rats (Adler and Crowley,
1984; Akabori and Barraclough, 1986a,b) and opioid-containing
neurons may also mediate some of the feedback effects of gonadal
steroids on LHRH release (Van Vugt, Sylvester, Aylesworth and
Meites, 1982; Bhanot and Wilkinson, 1984). Whilst LHRH neurons
themselves do not appear to possess oestrogen receptors (Shivers,
Harlan, Morrell and Pfaff, 1983), studies using combined immuno-
cytochemical and autoradiographic techniques have shown that a small
proportion (4-10%) of B-endorphin- or dynorphin-immunoreactive cells
in the mediobasal hypothalamus concentrate oestradiol (Morrell,
McGinty and Pfaff, 1985). Some NA neurons in the lower brainstem
and arcuate DA neurons also appear to concentrate oestradiol (Sar,
1984; Sar and Stumpf, 1981). Some of the possible interactions
between opioid, CA and steroids in the control of LHRH release in
the female rat are summarized in Figure 8-7.
Continuous infusion of naloxone during the time of the
pro-oestrous surge of LH did not affect either the plasma
concentration of LH measured during the first hour of infusion
(Tables 8-B and 8-C) or the release of LHRH into portal blood during
the following two hours (Figure 8-3). These results suggest that at
the time of the infusion the inhibitory influence of the opioid
system was already completely suppressed and it was therefore
impossible to augment further the magnitude of the LH surge or the
output of LHRH. This is supported by the data of Sarkar and Yen
(1985a) who showed that in the rats anaesthetized with alphaxalone
the concentration of immunoreactive B-endorphin in hypophysial
portal plasma fell sharply during the afternoon of pro-oestrus,
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FIGURE 8-7: Schematic diagram to illustrate possible opioid-catecholaminergic
interactions and their effects on the activity of LHRH neurons
in the female rat. The possible sites of the feedback effects
of oestradiol are arrowed and + and - signs indicate stimulatory
and inhibitory effects, respectively, of oestradiol, opioids
and amines; PV denotes the hypophysial portal vessels.
1. Oestradiol stimulates LHRH release either by the stimulation
of noradrenergic neurons or by inhibition of opioid neurons.
2. Oestradiol inhibition of opioid neurons resulting in the
disinhibition of NA neurons which then facilitate LHRH release.
3. Inhibitory actions of dopamine and opioids exerted at the
terminals of the LHRH neurons in the median eminence.
secretion being minimal at the time of the LHRH surge. The
inability of naloxone infusion to elevate plasma LH concentrations
in oestrous rats (see below) cannot be explained in terms of an
inhibition of the opioid system at this stage of the cycle.
Gabriel, Simpkins and Kalra (1983) reported that naloxone stimulated
LH secretion at all stages of the oestrous cycle including during
the pro-oestrous surge. The LH responses to naloxone treatment were
similar in dioestrous and in pro-oestrous rats at the onset of the
preovulatory LH surge, and Gabriel et al (1983) argued that, since
the pituitary sensitivity to LHRH is lower on the day of dioestrus,
naloxone had a greater stimulatory effect on LHRH release on the day
of dioestrus. Muraki et al (1979) showed that, in conscious rats,
whilst naloxone reversed the morphine-induced blockade of the
pro-oestrous surge, the administration of naloxone at 14.00 h by
itself did not alter the magnitude of the surge at 18.00 h.
Similarly, a single intravenous injection of naloxone at 14.00 h on
the afternoon of pro-oestrus suppressed the prolactin surge, but did
not alter the magnitude of the LH surge although the duration of the
surge was prolonged (Ieiri, Chen, Campbell and Meites, 1980; Gabriel
et al, 1983; Akabori and Barraclough, 1986a,b). Naloxone
administration did not affect either the magnitude or the time of
the onset of the LHRH surge induced in immature female rats by the
administration of pregnant mare serum gonadotrophs (Blank, Panerai
and Friesen, 1980).
Pulses of LH were shown in the plasma at 50-60 minute intervals
on the days of met- and dioestrus and on the morning of pro-oestrus
(Gallo, 1981a) and higher frequency pulses, occurring approximately
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every 15-30 minutes, were detected during the surge of LH on the
afternoon of pro-oestrus (Gallo, 1981b); Gallo (1981a) also showed
pulses of LH occurring about once every two hours on the day of
oestrus. Fox and Smith (1985) were not able to detect pulses of LH
secreted during the day of oestrus, but showed that a rapid release
of LH could be induced on that day by a single injection of
naloxone, and that continuous intravenous infusion of naloxone
initiated a pulsatile pattern of LH release in 12 out of 17 oestrous
rats. The frequency of the pulses induced by naloxone infusion was
similar to that observed during the other days of the oestrous cycle
(Fox and Smith, 1985). In the present experiments, in which
peripheral blood samples were withdrawn from anaesthetized oestrous
rats at 15 minute intervals during the infusion of naloxone
(compared with a 10 minute sampling interval from conscious rats,
Fox and Smith, 1985), the pattern of LH secretion was unchanged by
the naloxone treatment (Tables 8-B and 8-E). Similarly, LHRH output
during the subsequent two hours of infusion also remained unaltered
by naloxone (Figure 8-4) and there was no evidence of pulsatile
release of LHRH during this period (Table 8-F). Using a RIA for
LHRH which used the R-42 antiserum (Nett, Akbar, Niswender, Hedlund
and White, 1973) and 15 minute blood collection periods, Sarkar and
Fink (1980) were able to demonstrate the pulsatile release of LHRH
in ovariectomized rats. It is possible that if in the present
experiments naloxone had induced pulsatile release of LHRH, the
amplitude of the pulses may have been smaller than those apparent in
ovariectomized rats and thus not detected or that the HC-6 antiserum
used here is less sensitive than the R-42 antiserum in
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discriminating small fluctuations in LHRH concentration. In this
context, although the profiles of LHRH-IR recovered after HPLC of
hypothalamic or portal plasma extracts are similar when assayed by
each of the two anti-LHRH sera (Chapter 6), there are several
qualitative and quantitative differences in the results obtained by
direct measurement of portal plasma LHRH concentration by the two
assays. In comparison with the results obtained in previous studies
which used the R-42 antiserum (Sarkar et al, 1976; Sherwood et al,
1980), the present results obtained with the HC-6 antiserum showed
much higher concentrations of LHRH in portal plasma, and did not
show a difference between the LHRH concentrations measured in portal
plasma collected from pro-oestrous or oestrous rats (Figs. 8-3 and
8-4). For example, data taken from Sarkar et al (1974) show
concentrations of 120 pg/ml (during the pro-oestrous surge) and 30
pg/ml (oestrous) compared with the 500 pg/ml measured here in both
pro-oestrous and oestrous rats. Finally, in contrast to the data of
Sherwood et al (1980) in which in some animals the portal blood
content of LHRH increased during successive collection periods
during the time of the expected pro-oestrous surge, in the present
studies LHRH content declined in all animals after cutting the
pituitary stalk.
In lactating animals there were no significant differences
between LHRH output in suckled or non-suckled animals (Fig. 8-5).
LHRH concentrations were lower in portal plasma from lactating
compared with pro-oestrous or oestrous rats. However, since in
comparison with cycling rats the lactating animals were maintained
under anaesthesia for an extended period before the pituitary stalk
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was cut, the data from these animals may not be comparable. Plasma
concentrations of LH were low in lactating rats and were not reduced
in response to suckling (Table 8-G) and such a decrease may have
been more readily apparent if ovariectomized animals had been used.
As shown for urethane-anaesthetized rats (Chapter 5, Burnet and
Wakerley, 1976; Isherwood and Cross, 1980) anaesthesia with
alphaxalone delayed the onset of the prolactin response to suckling
(Table 8-G). At the time of cutting the pituitary stalk for the
collection of portal blood, plasma concentrations of prolactin were
higher in suckled than non-suckled rats (though this reflected
largely the higher initial prolactin concentration in the suckled
group), but prolactin concentration at this time was low compared
with the high concentrations measured after longer periods of
suckling in animals anaesthetized with urethane (Chapter 5) or in
other hyperprolactinaemic conditions (see below).
Other than lactation, there are many physiological and
experimental situations in which the plasma concentrations of
gonadotrophins are reduced in the presence of a high prolactin
concentration; for example, pseudopregnancy (Smith, Freeman and
Nei11, 1975), after grafting anterior pituitary gland tissue under
the kidney capsule (McNeilly, Sharpe and Fraser, 1980) or injection
of prolactin (Cohen-Becker, Selmanoff and Wise, 1986). However,
this inverse relationship between the secretion of prolactin and
gonadotrophins does not always apply as is shown by the concurrent
release of LH and prolactin during the afternoon of pro-oestrus
(e.g. Horn, Fraser and Fink, 1985b) or in ovariectomized rats
injected with oestradiol (e.g. Horn and Fink, 1985a).
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The suppression of LH release during lactation may be mediated
by the direct inhibition of LHRH release by the suckling stimulus or
may be secondary to the hyperprolactinaemia induced by suckling.
Elevated plasma concentrations of prolactin may decrease the
pituitary responsiveness to LHRH and/or reduce LHRH output either by
direct inhibition of the LHRH neurons or by increased release of DA
from the tuberoinfundibular DA system (Fig. 8-7).
Since in conscious rats the secretion of LH was apparently
suppressed virtually instantaneously at the start of the period of
suckling, Isherwood and Cross (1980) suggested that the suckling
stimulus alone, rather than the associated hyperprolactinaemia,
accounted for the inhibition of LH secretion. In support of this,
plasma LH concentrations were also suppressed in lactating rats when
prolactin secretion was inhibited pharmacologically by the
administration of dopamine-agonists (Lu, Chen, Huang et al, 1976a;
Smith, 1978b). Smith (1978b) suggested that although in the early
days of lactation the suckling stimulus alone was principally
responsible for blocking the post-ovariectomy increase in plasma LH
concentrations, in the later stages of lactation (around day 12 and
onwards) it is the hyperprolactinaemia (in the presence of the
suckling stimulus) which accounts for the inhibition of
gonadotrophs secretion.
The long-term hyperprolactinaemia induced by the implantation
of anterior pituitary gland tissue under the kidney capsule results
in the suppression of plasma concentrations of LH and FSH (McNeilly,
et al, 1980). However, Brar, McNeilly and Fink (1985b) showed that
LHRH output was unchanged in this model suggesting that at least in
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the male rat, the effects of hyperprolactinaemia on gonadotrophs
secretion are mediated largely by an action at the level of the
pituitary gland e.g. by a reduction in either pituitary
responsiveness to LHRH or LHRH receptor number. In male rats
bearing a tumour which secreted both prolactin and
adrenocorticotrophin (ACTH) the secretion of LH and FSH was reduced
by 45% and 70%, respectively, the concentration of LHRH in
hypophysial portal blood reduced by approximately 50%, and the
portal blood concentration of dopamine increased three-fold (Weber,
de Greef, de Koning, Vreeburgh, 1983). However after adrenalectomy
only the change in dopamine output was apparent, suggesting that the
altered secretion of LHRH and the gonadotrophins was related to the
hypersecretion of ACTH rather than prolactin. A four-fold decrease
in the portal blood concentration of LHRH was reported in
ovariectomized rats which had pituitary tissue implanted under the
kidney capsule (Sarkar and Yen, 1985b). Sarkar and Yen (1985b) also
suggested that this inhibitory effect of prolactin on LHRH secretion
may be mediated by an opioid mechanism, since the concentration of
e-endorphin in portal blood was raised in hyperprolactinaemic rats
and the administration of naloxone resulted in increased portal
blood LHRH and peripheral blood LH concentrations in
hyperprolactinaemic but not in control rats.
In vivo and in vitro evidence suggests that in lactating rats
the pituitary responsiveness to LHRH is decreased (Lu, Chen,
Grandison, Huang and Meites, 1976b; Smith, 1985). Fox and Smith
(1984) showed that the suckling stimulus which was provided by two
pups was sufficient to inhibit pulsatile LH secretion without a
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reduction in pituitary responsiveness to LHRH, though pituitary
responsiveness was reduced when the size of the suckling stimulus
was increased to 8 pups. In contrast, in ovariectomized,
non-suckling rats, a series of injections of ovine prolactin was
sufficient to decrease both the frequency and amplitude of the LH
pulses without decreasing pituitary responsiveness (Cohen-Becker et
al, 1986). A direct effect of prolactin on the anterior pituitary
gland to decrease its responsiveness to LHRH has been demonstrated
in vitro (Cheung, 1983).
Immunohistochemical studies have shown an oxytocin-containing
fibre system which originates in the PVN and terminates in the
external layer of the ME, adjacent to the portal vessels
(Vandesande, Dierickx and de Mey, 1977; Burlet, Chateau and
Czernichow, 1979). Synthetic oxytocin can stimulate prolactin
secretion from the anterior pituitary gland in vivo and in vitro
(Lumpkin et al, 1983) and may be a factor involved in the regulation
of prolactin secretion. The present results (Fig. 8-6) confirm
previous findings which showed that oxytocin is present in higher
concentrations in hypophysial portal blood than in peripheral blood
(Gibbs, 1984; Sarkar and Gibbs, 1984; Horn, Robinson and Fink,
1985c). It is unlikely that a significant amount of the oxytocin
content of portal blood was due to contamination by the backflow of
blood from the posterior pituitary gland as the concentration of
oxytocin measured in portal blood was not altered by the removal of
the pituitary gland before the start of blood collection (Sarkar and
Gibbs, 1984; Horn et al, 1985c). Similarly, the concentration of
oxytocin in C.S.F. was too low to account for the oxytocin in portal
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blood (Horn et al, 1985c).
In the present study there were no significant differences
between the concentration of oxytocin in hypophysial portal blood
collected from suckled or non-suckled lactating rats (Fig. 8-6).
However these results must be interpreted with caution since in
urethane anaesthetized male rats, Horn et al (1985c) were unable to
increase oxytocin output by electrical stimulation of the ME and
concluded that the secretion of oxytocin was maximal following the
exposure and section of the pituitary stalk. Nonetheless, using
female rats anaesthetized with alphaxalone, Sarkar and Gibbs (1984)
showed that oxytocin release into portal blood varied during the
oestrous cycle; the highest concentrations were measured during the
afternoon of pro-oestrus and corresponded with the prolactin surge.
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CHAPTER 9
The Effects of Intravenously Administered 6-Hydroxydopamine
on the Content of Monoamines in the Median Eminence and
Neurointermediate Lobe, and on Pituitary Hormone Secretion
in the Male Rat
9.1 INTRODUCTION
The neurotoxic drug, 6-hydroxydopamine (6-OHDA) has been widely
used in studies of the anatomy and function of catecholaminergic
(CA) neurons in both the peripheral and central nervous systems.
The neurodegenerative action of 6-OHDA depends upon both its
accumulation in CA containing terminals as a result of its uptake by
the high affinity amine uptake mechanism (hence the specificity for
CA neurons) and on its auto-oxidation to form quinone derivatives,
and oxidation products such as hydrogen peroxide, which may be
responsible for the cytotoxic effects (see reviews by Breese, 1975;
Jonsson, 1983). As it does not readily penetrate the blood-brain
barrier (Sachs, 1973; Garver, Cedarbaum and Mass, 1975), for studies
of the function of central CA pathways, 6-OHDA has usually been
administered by intraventricular or intracisternal injection or
applied locally to specific brain areas (e.g. Iversen and Uretsky,
1970; Uretsky and Iversen, 1970; Breese and Traylor, 1971;
Ungerstedt, 1971; Breese, Smith, Cooper and Grant, 1973). Since the
median eminence lies outside the blood-brain barrier (Wislocki and
King, 1936), in the majority of such studies, no marked effect on
the CA content of the median eminence was reported. In addition to
producing a lesion of the sympathetic neurons in the peripheral
nervous system, systemic administration of 6-OHDA results in a
depletion of CA in brain areas outside the blood-brain barrier
including the area postrema (Klara, Kostrezewa and Brizzee, 1976)
and the median eminence (Cuello, Shoemaker and Ganong, 1974; Smith
and Helme, 1974; Smith Courtney, Wreford and Walker, 1982). The
spinal cord is also affected by systemic 6-OHDA (Wong and Tan, 1974)
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and since a small amount of 6-OHDA may penetrate the blood-brain
barrier (Garver et al. 1975) some changes in whole brain CA turnover
have also been reported (Clark, Corrodi and Masuoka, 1971; Kawa,
Kamisaki, Ariyama et al, 1979). As assessed by fluorescence
histochemistry, the intravenous injection of 150 mg/kg 6-OHDA
resulted in a complete depletion of CA in the median eminence within
24 h, whilst the remainder of the hypothalamus is relatively
unaffected (Smith et al. 1982); although there was some depletion of
CA in the mediobasal hypothalamus at 24 h, the fluorescence
appearance of this region appeared normal 48 h after injection
whereas the return of fluorescence to the median eminence was slower
and occurred over a 5 week period.
The following experiments were carried out to determine the
effect of lesions of the CA neurons of the ME and NIL produced by
intravenous 6-OHDA administration on the plasma concentrations of
prolactin, thyrotrophin, LH, FSH and corticosterone. In the initial
experiments the extent of the depletion of CA was monitored by
fluorescence histochemistry, in a later series of experiments, NA,
DA, DOPAC, 5-HT and 5-HIAA were measured directly, with the aid of
HPLC with electrochemical detection, in the median eminence and
neurointermediate lobe of control animals, 6-OHDA lesioned animals
and of animals in which the lesion had been modified by pretreatment
with desipramine (DMI) in order to produce a more selective
depletion of DA (Smith, Cooper and Breese, 1973; Kelly and Iversen,
1976).
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9.2 MATERIALS AND METHODS
The animals used were adult male Wistar rats maintained as
described in Chapter 2 and which had had at least 3 weeks to become
accustomed to the conditions of the animal house before the time of
the experiment.
9.2.1 Effects of 6-OHDA on pituitary hormone secretion
The animals were lightly anaesthetized with anaesthetic ether
and slowly injected intravenously with either 150 mg/kg 6-0HDA-HC1
(Labkemi, Stockholm; 50 mg/ml in 0.1% ascorbic acid in 0.9% saline
[vehicle]) or with vehicle alone. The 6-OHDA solutions were freshly
prepared immediately before the time of injection. All injections
were administered between 17.00 and 18.00 h. One group of animals
(untreated control) were not injected. At 1, 2, 7, 14, 21 and 36
days after the injection the animals were killed by decapitation at
17.30 h in batches of six at one time. No more than two minutes
elapsed between the time that a cage of six animals were removed
quietly from the animal housing room and the time that the last
animal in the group was decapitated. The trunk blood was collected
into ice-cooled 10 ml heparinized plastic tubes with the aid of a
glass filter funnel which had also previously been heparinized.
After centrifugation of the blood samples, the plasma was stored at
-40°C until the time of assay. The anterior pituitary gland was
removed from each animal, weighed and homogenized (2.2.6). The
plasma concentration of corticosterone and plasma and pituitary
concentrations of LH, FSH, prolactin and thyrotrophin were
determined as described in Chapter 2. The significance of the
differences between groups was determined by unpaired t-tests.
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9.2.2 Fluorescence histochemistry
Two animals from each of the experimental groups described
above were perfused with fixative, the brains removed and processed
for catecholaminergic fluorescence histochemistry using the 'FAGLU'
technique (2.3).
9.2.3 Assay of tissue monoamines
Male rats were injected with 150 mg/kg 6-0HDA (Sigma, U.K.) or
vehicle as described above. A third group of rats was also injected
with 30 mg/kg DMI-HC1 (Geigy, Macclesfield; 12 mg/ml w/v in 0.9%
saline i.p.) which was administered 30 min before the injection of
6-OHDA. As in the previous experiments a group of untreated,
control animals was not injected with either vehicle or drugs.
Forty-eight hours after drug treatment the animals were killed by
decapitation and the brain rapidly removed, placed on an ice-cold
glass microscope slide and the stalk median eminence (SME) and the
neurointermediate lobe of the pituitary (NIL) dissected (2.2.6).
The mean (± S.E.M.) weights of the ME and NIL samples taken were
0.44 ± 0.07 mg and 1.39 ± 0.39 mg respectively.
NIL and SME samples were stored in liquid nitrogen until the
contents of amines were determined by LCED (2.4.1). The
significance of differences between means was calculated using
unpaired t-tests.
9.3 RESULTS
9.3.1 Pituitary hormone secretion
Figure 9-1 shows that in the group injected with 6-OHDA the
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FIGURE 9-1: Mean (isEM) plasma concentrations of prolactin,
thyrotropin (TSH), corticosterone, LH and FSH in male rats
killed by decapitation 1-36 days after the i.v. injection
of either 6-OHDA^ or vehicle Also shown are
hormone concentrations in animals which had not been
injected with either 6-OHDA or vehicle alone. The number
of animals in each group are shown at the base of each
column.
from those in the untreated control group. However, in animals
injected with vehicle alone the concentrations of prolactin were
significantly elevated above the values in the untreated control
group at 1 and 2 days and at 14 and 21 days after treatment (P <
0.05, 0.001, 0.01 and 0.025, respectively). The plasma
concentration of thyrotrophin was significantly (P < 0.01) elevated
24 h after injecting 6-0HDA compared with the concentrations in
either untreated control animals or animals injected with vehicle
alone. The plasma concentrations of corticosterone were
significantly elevated (P < 0.02) 24 h after injecting 6-0HDA
compared with those in untreated control animals. On days 2 and 7
the concentration of corticosterone in animals injected with 6-OHDA
were lower (P < 0.01 and 0.02, respectively) than in vehicle-treated
animals. In animals treated with vehicle the concentrations of
corticosterone were higher (P < 0.05-0.001) than in untreated
control animals for all days except day 1 after injection.
Treatment with either 6-0HDA or vehicle had no significant effect on
the plasma concentrations of LH or FSH, except that at day 36 plasma
FSH concentrations in both of these treatment groups were lower than
those in the untreated control group (P < 0.005 and P < 0.001,
respectively).
For LH, FSH and thyrotrophin there were no major changes in
pituitary content (Fig. 9-2) or concentration (Fig. 9-3) in the
treated animals compared with those in the untreated control animals
other than reduced values for LH and FSH on day 36 (P < 0.005-
0.001). The pituitary content and concentration of prolactin in the
treated animals were mostly lower than in the untreated, control
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FIGURE 9-2: Mean (±SEM) pituitary hormone content in male rats killed
by decapitation 1-36 days after i.v. injection of either
6-OHDA^ , or ascorbic acid vehicle Q . Values from
I are also shown. Number of animals peruntreated ratsfS
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FIGURE 9-3: Mean (iSEM) pituitary hormone concentration in male rats
killed by decapitation 1-36 days after i.v. injection of
either 6-0HDA^ , or ascorbic acid vehicle □ alone.
Values from untreated rats are. also shown. Number of
animals per group given at the base of each column.
animals, significantly on days 1 and 7 (P < 0.025-0.005). The
pituitary content and concentrations of prolactin were lower (P <
0.02-0.005) at 14 and 21 days in the animals treated with 6-OHDA
compared with those in animals treated with vehicle alone.
Full details of all the statistical comparisons of plasma and
pituitary gland hormone concentrations, and ME and NIL amine and
metabolite contents (9.3.3), in 6-OHDA treated and control group
animals are shown in Table 9-C at the end of the chapter.
9.3.2 Fluorescence histochemistry
The fluorescence histochemical findings, which are illustrated
in Figures 9-4 to 9-6 and are summarized in Table 9-A, showed that
terminals in the ME-NIL were depleted of CA fluorescence 24 h after
injection of 6-OHDA. The adjacent mediobasal hypothalamus was
moderately depleted at 24 h, but was of normal appearance at 48 h as
was the rest of the hypothalamus at all times studied. Regenerating
terminals in the median eminence were seen by day 7 after injecting
6-OHDA, and by day 36, the fluorescence appearance of this region
could not be distinguished from that in untreated animals or animals
treated with vehicle alone.
9.3.3 Monoamine content of neurointermediate lobe and median
eminence
Table 9-B shows the amine and metabolite content of the SEM and
NIL after drug treatment; typical LCED traces of SME samples from
drug-treated or control animals are shown in Figures 9-7a-d.
Forty-eight hours after 6-OHDA administration there was a
significant decrease in the contents of both NA (P < 0.005 and P <
0.02, SME and NIL, respectively) and DA (P < 0.001 and P < 0.005)
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FIGURE 9-4: Fluorescence photomicrographs of coronal sections
through the median eminence of adult male Wistar rats
treated with ascorbic acid 24 h previously and prepared
by the FAGLU perfusion technique. The fluorescence
histochemical appearance is indistinguishable from that
of untreated control rats prepared similarly.
A: Mid POlf showing the fine varicose nature of
terminals of catechol amine-containing fibres in the
external layer (EXL) and the larger varicose fibres of
the intermediate layer (IL). 3V, third ventricle; PV,
portal vessel.
B: Anterior POI, showing a distinct varicose fluorescent
fibre (arrowed) passing from the arcuate nucleus of the
hypothalamus through the ependymal layer (EL) of the
median eminence.
*pars oralis infundibuli
FIGURE 9-5: Fluorescence photomicrographs of sections from the
diencephalon of male Wistar rats previously injected
with ascorbic acid.
(A) Arcuate nucleus demonstrating numerous
dopamine-containing cell bodies of the A12 group and
showing the presence of fine varicose fluorescent
fibres. 3V, third ventricle.






FIGURE 9-6: Fluorescence photomicrographs of coronal sections from
male rats injected previously with 6-hydroxydopamine and
prepared by the FAGLU technique. (A) Median eminence of
a male rat treated 24 h previously with 6-OHDA (150
mg/kg i.v.). Specific catecholamine fluorescence is
absent, except for occasional fluorescent masses in the
intermediate layer (IL). Compare with Fig. 9-4A. 3V,
third ventricle; EXL, external layer; PV, portal
vessel. (B) Median eminence of an adult male rat
treated 7 days previously with 6-OHDA (150 mg/kg i.v.).
A large number of fluorescent masses, produced by
accumulations of catecholamines in fibres proximal to
degeneration, are seen in the IL and EXL. Some
re-innervation of the EXL has occurred. (C) Junction of
the arcuate nucleus (AN) and median eminence (ME), from
a Wistar rat treated 48 h previously with 6-OHDA (150
mg/kg i.v.). Accumulation of catecholamine induced
fluorescence (arrowed) in axons proximal to degeneration
marks the boundary of the lesion. ME fluorescence is
still depleted. (D) Swollen preterminal axon in the
lateral hypothalamus of the same animal as seen in Fig.
C.
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compared with the contents in untreated or vehicle-treated control
groups. In animals treated with DMI 30 min before 6-OHDA
administration there was also a significant depletion of DA after
48 h (P < 0.001, both areas) but NA content remained similar to the
values in the control animals. DOPAC was reduced in the SME in both
6-OHDA and DMI plus 6-OHDA treated groups compared with the values
in controls (P < 0.05 - P < 0.005). 5-HT and 5-HIAA content
remained unchanged in all treatment groups.
9.4 DISCUSSION
The data obtained with the aid of fluorescence histochemistry
(Table 9.A) were similar to those previously published (Smith and
Helme, 1974; Smith et al. 1982) and showed a maximum depletion of CA
fluorescence in the ME 1-2 days after the injection of 6-OHDA with a
gradual recovery of fluorescence intensity to that of control
animals over a subsequent 4-5 week period. The CA terminals in the
NIL were not examined with the FAGLU technique in the present study,
but Smith et al. (1982) have shown that in the first 2 days after
the 6-OHDA treatment there was a depletion of fluorescent
varicosities in the intermediate lobe of the pituitary gland, and
also showed that only a few fluorescent fibres remained in the
neural lobe.
Fluorescence histochemistry only yields semi-quantitative data
and does not distinguish between NA and DA containing structures,
and, therefore, the second series of experiments were carried out to
measure the amine content of the ME and NIL directly. The results
obtained with the aid of LCED confirmed the depletion of both
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catecholamines from the ME and NIL of lesioned animals (Table
10.B). The magnitude of depletion (= 50% of the catecholamine
content of the control animals) was, however, much lower than
suggested by the apparent completeness of the lesion at 48 h after
6-OHDA revealed by histochemistry. The most likely explanation for
the discrepancy in these results is that in the assay of
catecholamines the extent of the lesion had been underestimated as a
result of the inclusion in the dissected areas of regions in which,
as a result of continued synthesis and axoplasmic transport,
catecholamines had accumulated behind the lesioned nerve terminals
(Ungerstedt, 1971a). Cuello et al. (1974) showed a 37% reduction in
the hypothalamic content of NA, but no change in DA content 24 h
after 6-OHDA treatment. However, the latter study differs in two
respects from the present investigation in which amine concentration
was measured in more discrete areas and a higher dose of 6-OHDA was
administered (in the study of Cuello et al, the amine content of the
whole hypothalamus was measured after the intraperitoneal injection
of two, 50 mg/kg doses of 6-OHDA). The NA containing nerve
terminals are reported to be more susceptible than DA terminals to
the neurotoxic action of 6-OHDA (Ungerstedt, 1971b), but with the
high dose used in the present study the relative magnitude of the
depletion appeared similar for both types of nerve terminals.
The uptake mechanism for 5-HT has some affinity for
catecholamines and a few studies have noted a degree of depletion of
5-HT after 6-OHDA administration in some species (e.g. Laguzzi,
Petitjean, Pujol and Jouvet, 1971; de Montigny, Wang, Reader and
Aghajanian, 1980). The present study, in agreement with the results
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of the majority of previous studies of the effects of 6-OHDA in the
rat (see review by Breese, 1975) showed that 5-HT-containing
terminals in the ME or NIL were not affected.
DMI blocks the uptake mechanism in NA terminals and, therefore,
pretreatment with DMI prevents the subsequent uptake of 6-OHDA into
these terminals, thus resulting in a more specific lesion of the DA
terminals (Kelly and Iversen, 1976). Within the ME, the depletion
of fluorescence after 6-OHDA and DMI administration has been shown
to be confined to the midline of the external layer; fluorescence
intensity was reduced in the NIL and appeared unaffected in the
mediobasal hypothalamus, and in the intermediate layer and lateral
parts of the external layer of the ME (Sarkar, Smith and Fink, 1981;
Smith et al. 1982). The turnover of dopamine in the
tuberoinfundibular neurons which project to the lateral palisade
zone is slower than in those neurons which project to the portal
vessels in the midline of the external layer (Lofstrom, Jonsson,
Wiesel and Fuxe, 1976b) and this may result in an apparent
difference in the sensitivity of the DA terminals to 6-OHDA in these
two regions. The data obtained in the present study with the aid of
LCED confirmed that a more selective lesion of DA terminals occurred
when 6-OHDA was administered after pretreatment with DMI.
In sum, the data obtained with fluorescence histochemistry or
by HPLC, confirm that treatment with 6-OHDA depleted terminals in
the ME of DA and NA but a 'masking' effect by the accumulation of
amines proximal to the lesion made it impossible to assess fully the
magnitude of the NA and DA deficit in these animals. From this
arises one of several difficulties in attempting to interpret the
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effects of this lesion on hormone release as the data give no
indication of the extent to which the functioning of the CA
terminals are affected by the lesion (i.e. the amount of transmitter
which may still be released by any undamaged neurons is not known).
The administration of 6-OHDA alone, results in lesions of both DA
and NA terminals, possibly to differing degrees and, as will be
discussed below, these two transmitters often have opposing actions
in the central control of hormone release (Weiner and Ganong,
1978). Although histochemistry reveals the loss of fluorescence,
there may be residual functioning in CA terminals which are depleted
of their amine content, but not damaged by the 6-OHDA (Day and
Willoughby, 1980). A further complication arises from the
possibility of the development of receptor supersensitivity
following the denervation induced by 6-OHDA. The release of amines
from a few remaining undamaged CA neurons combined with an increased
sensitivity of the receptors on either the pituitary cells or the
terminals of peptidergic neurons in the ME, may be sufficient to
maintain a relatively unchanged basal release of the pituitary
hormones. It is also possible that, once developed, the receptor
supersensitivity may outlast the time required for regeneration of
the damaged CA terminals resulting in a period when the inhibitory
or facilitatory effects of the amines are potentiated.
The plasma corticosterone concentrations (Fig. 9-1) in the
untreated control animals were similar to those reported by Chiappa
and Fink (1977) and suggest that the plasma samples from these
animals were obtained under relatively unstressed conditions. That
is, in agreement with the results of studies on the prolactin
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response to stress (Mattheij and Van Pijkeren, 1977; Seggie and
Brown, 1976) the time interval between the removal of the animals
from the room in which they were housed and their subsequent
decapitation was too short for a significant endocrine response to
stress. The increases in the plasma concentration of prolactin
which occurred in animals injected with vehicle alone may, however,
have been due to the long term effects of the stress of the
injection as several studies have indicated a similar effect in
animals subjected to surgical manipulations (Ajika, Kalra, Fawcett,
Krulich and McCann, 1972; Fenske and Wuttke, 1976; Harms, Langlier
and McCann, 1975; Nei11, 1972). Such a long term effect may require
the functional integrity of ME-NIL CA terminals since, as shown in
Figure 9-1, injection of 6-OHDA prevented the increase in the plasma
concentration of prolactin which occurred in animals injected with
vehicle alone. In support of this there is some evidence to suggest
that NA neurons may be involved in the stress-induced (and also
oestrogen-induced) release of prolactin (Weiner and Ganong, 1978).
For example, Fenske and Wuttke (1976) showed the absence of a
prolactin response to stress in animals in which 6-OHDA had been
injected into the lateral ventricles 12 days previously; the basal
secretion of prolactin in these animals was elevated. If, as
discussed earlier (Chapter 5), DA is the principal prolactin
inhibitory factor (PIF) then an increase in prolactin secretion
would have been expected in the animals injected with 6-OHDA in the
present experiment. That this was not observed suggests that either
the normal inhibition of prolactin was maintained by an alternative
PIF or that the lesion of the DA terminals was incomplete. This
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question could partly be resolved by the direct measurement of DA
concentrations in hypophysial portal blood.
The stress of injection may also explain the increased
concentrations of plasma corticosterone in animals treated with
vehicle compared with those in untreated animals, although in this
case 6-OHDA prevented the increase only on days 2 and 7. The
findings of an increase in the plasma concentration of
corticosterone 24 h after injection of 6-OHDA is in agreement with
the data obtained by Cuello et al. (1974) who interpreted this as
indicating that ACTH secretion is inhibited by the influence of NA
terminals within the ME. However, the data from a number of studies
in both rats and dogs, whilst indicating an inhibition of ACTH by
central NA neurons, suggest that these inhibitory neurons terminate
not in the ME but in a hypothalamic site inside the blood-brain
barrier (Weiner and Ganong, 1978). In the dog intraventricular, but
not systemic administration of NA results in the inhibition of the
release of ACTH in response to stress (Van Loon, Hilger, King,
Boryczka and Ganong, 1971; Van Loon, Scapagnini, Cohen and Ganong,
1971) and data from pharmacological studies suggest that
a-adrenergic receptors in the dorsal hypothalamus are involved in
this inhibitory mechanism (Ganong, Kramer, Salmon et al, 1976).
Earlier studies (Halasz, Slusher and Gorski, 1967) also demonstrated
that plasma corticosterone concentrations were elevated after the
removal of the NA input to the rat hypothalamus as a result of total
hypothalamic deafferentation.
Central CA neurons appear to play an important role in the
mechanism of the spontaneous (Fink and Geffen, 1978; Ramirez, Feder
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and Sawyer, 1984) and steroid-induced gonadotropin surge (Wise,
Ranee and Barraclough, 1981; Ranee, Wise and Barraclough, 1981a).
In studies in which amine turnover was assessed by the disappearance
of CA fluorescence after the inhibition of tyrosine hydroxylase it
was shown that DA turnover in the lateral palisade zone (LPZ) of the
ME was lower on pro-oestrus than at all other times during the
oestrous cycle; NA turnover in the subependymal layer was increased
during pro-oestrus (Lofstrom, 1977). Similar results were obtained
using a radioenzymatic assay (Ranee, Wise, Selmanoff and
Barraclough, 1981b), although Ranee et al. (1981b) also showed a
small but significant increase in DA turnover before the surge. The
turnover rates of DA and NA were shown to decrease and increase
respectively in the median eminence of pre-pubertal rats in which an
LH surge was induced by the administration of pregnant mare serum
gonadotrophin [PMSG] (Agnati, Fuxe, Lofstrom and Hokfelt, 1977); the
intravenous injection of 6-OHDA after pretreatment with DMI resulted
in an enhancement of the LH surge in PMSG-treated animals (Sarkar et
al. 1981). Thus while there is considerable evidence that in the
female rat the tuberoinfundibular DA system inhibits gonadotrophin
secretion, the present data indicate that the terminals in the
ME-NIL may have little to do with controlling the basal secretion of
the gonadotrophins in the male, though transient changes in the
median eminence content of NA and DA may occur during the first 8 h
after orchidectomy (Chiocchio, Negro-Vilar and Tramezzani, 1976).
The central control of thyrotrophin secretion may also be
mediated by facilitatory NA and inhibitory DA neurons (Krulich,
1979). Following thyroidectomy, tyrosine hydroxylase activity was
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significantly increased in the periventricular, arcuate and
dorsomedial nuclei, the medial forebrain bundle and in the ME
(Kizer, Muth and Jacobowitz, 1976). In the studies of Kizer et al.
(1976), bilateral lesion of the ventral NA tracts prevented the
increase in tyrosine hydroxylase in all of the areas examined with
the exception of the ME and, since this lesion had resulted in a
greater than 85% fall in dopamine e-hydroxylase activity in the ME,
it was concluded that the majority of the endocrine responsive
neurons in the ME were dopaminergic. However, in another study, no
change in DA turnover in the ME was observed 4 weeks after
thyroidectomy (Fuxe, Hokfelt, Andersson et al, 1978). The
physiological significance of the direct effects of DA and NA on the
basal and TRH-stimulated release of thyrotrophin seen in some
(Peters, Foord, Dieguez, Scanlon and Hall, 1983; Dieguez, Foord,
Peters, Hall and Scanlon, 1984), but not all, in vitro studies
(Price, Grossman, Besser and Rees, 1983) remains to be elucidated.
The marked increase in the plasma concentration of thyrotrophin seen
in the present studies 24 h after 6-OHDA administration suggest that
the ME-NIL CA system does moderate the secretion of thyrotrophin.
Although several studies have shown that, under stress, the
secretion of thyrotrophin is inversely related to the secretion of
ACTH (Brown-Grant, Harris and Reichlin, 1954; Brown-Grant, 1960;
Guillemin, 1968), the release of the two hormones is not always
inversely related (Pamenter and Hedge, 1980) and this is illustrated
by the present results in which the secretion of both thyrotrophin
and corticosterone were increased 24 h after 6-OHDA administration.
Similarly, although stress stimulates the release of both prolactin
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and ACTH (Harms, Langlier and McCann, 1975) the present data
indicate that under relatively unstressed conditions the secretion
of these two hormones is dissociated.
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Table 9-C Summary of statistical analysis. All
comparisons not shown were non-significant (unpaired t test)
Plasma hormone concentrations
Hormone Day Comparison P
Prolactin 1 Vehicle vs untreated < 0.05
2 Vehicle vs untreated < 0.001
14 Vehicle vs untreated < 0.01
21 Vehicle vs untreated < 0.025
TSH 1 6-OHDA vs untreated < 0.01
1 6-OHDA vs vehicle < 0.01
Corticosterone 1 6-OHDA vs untreated < 0.02
2 6-OHDA vs vehicle < 0.01
2 Vehicle vs untreated < 0.01
7 6-OHDA vs vehicle < 0.02
7 Vehicle vs untreated < 0.05
14 Vehicle vs untreated < 0.01
21 Vehicle vs untreated < 0.001
36 Vehicle vs untreated < 0.001
FSH 36 6-OHDA vs untreated < 0.005
36 Vehicle vs untreated < 0.001
Pituitary hormone content
Prolactin 1 6-OHDA vs untreated < 0.05
1 Vehicle vs untreated < 0.05
7 6-OHDA vs untreated < 0.005
7 Vehicle vs untreated < 0.005
14 6-OHDA vs vehicle < 0.001
21 6-OHDA vs vehicle < 0.01
FSH 36 6-OHDA vs untreated < 0.005
36 Vehicle vs untreated < 0.001
LH 36 6-OHDA vs untreated < 0.005
36 Vehicle vs untreated < 0.005
Pituitary hormone concentrations
Prolactin 1 6-OHDA vs untreated < 0.025
1 Vehicle vs untreated < 0.005
7 6-OHDA vs untreated < 0.001
7 Vehicle vs untreated < 0.001
14 6-OHDA vs vehicle < 0.005
21 6-OHDA vs vehicle < 0.02
FSH 36 6-OHDA vs untreated < 0.001
36 Vehicle vs untreated < 0.001
LH 36 6-OHDA vs untreated < 0.005
36 Vehicle vs untreated < 0.001
Table 9-C (cont.) Summary of statistical analysis. All
comparisons not shown were non-significant.




Noradrenaline 2 6-OHDA vs vehicle < 0.005
2 6-OHDA vs untreated < 0.005
2 6-OHDA vs 6-OHDA + DMI < 0.05
Dopamine 2 6-OHDA vs vehicle < 0.001
2 6-OHDA vs untreated < 0.001
2 6-OHDA + DMI vs vehicle < 0.001
2 6-OHDA + DMI vs untreated < 0.001
DOPAC 2 6-OHDA vs vehicle < 0.05
2 6-OHDA vs untreated < 0.005
2 6-OHDA + DMI vs vehicle < 0.05
2 6-OHDA + DMI vs untreated < 0.01
Neurointermedi ate lobe
Day Comparison P
Noradrenaline 2 6-OHDA vs vehicle < 0.02
2 6-OHDA vs untreated < 0.01
2 6-OHDA vs 6-OHDA + DMI < 0.005
Dopamine 2 6-OHDA vs vehicle < 0.005
2 6-OHDA vs untreated < 0.005
2 6-OHDA + DMI vs vehicle < 0.001
2 6-OHDA + DMI vs untreated < 0.001
CHAPTER 10
Summary and Conclusions
Many biologically active peptides are synthesized as components
of a larger precursor molecule. These precursors may contain
multiple copies of the same peptide (e.g. TRH and met-enkephalin)
or, as a result of enzymatic cleavage at different sites within the
molecule, may generate extended forms of the peptide (e.g.
somatostatin-28) which may also show biological activity. The main
aims of this thesis were to investigate (i) the immunoreactive forms
of somatostatin (SS), TRH and LHRH which are released into
hypophysial portal vessel blood, (ii) the role of TRH in the control
of thyrotrophin and prolactin release, (iii) some aspects of the
mechanism of action of LHRH on the pituitary gland of hypogonadal
(hpg) mice, (iv) some aspects of the effects of cannabinoids,
opioids and suckling on the release of LHRH and LH, and (v) some
aspects of the role of catecholamines in the control of pituitary
hormone secretion.
The application of an electrical stimulus to the ME of male rats
anaesthetized with urethane resulted in a 6 to 7-fold increase in
both the concentration and the total amount of somatostatin released
into portal blood. High performance liquid chromatography (HPLC)
followed by radioimmunoassay using an antiserum directed against the
mid-region of the SS-14 molecule showed the presence of two peaks of
immunoreactivity in extracts of portal plasma, and these peaks
corresponded with SS-14 and SS-28 respectively. The amount of SS-28
to
in portal plasma was, on a molar basis, similar^or greater than that
of SS-14. These findings are supported by in vitro studies showing
the release of both forms of SS from the median eminence in response
to depolarizing stimuli (Kewley etal, 1981; Pierotti etal, 1985).
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However, in contrast to the ME, SS-14 was the predominant form of SS
released from blocks of hypothalamic tissue in vitro suggesting the
possibility of at least two types of SS-containing neurons which
process the SS-precursor in a different manner (Pierotti et al,
1985). The fact that both SS-14 and SS-28 are released into portal
blood, and SS-28 is as or more potent than SS-14 in inhibiting the
release of growth hormone, insulin and glucagon and the different
pituitary receptor affinities for the two peptides suggests that
SS-28 as well as SS-14 is an hormonally active peptide. Further
studies are necessary to define the physiological functions of SS-14
and SS-28 and to correlate variations in the release of these
peptides with varying secretion rates of growth hormone (and
thyrotrophin) under different experimental conditions.
Radioimmunoassay of extracts of portal plasma using an antiserum
which recognizes the C-terminus of SS—28(1—12) but which does not
recognize either SS-14 or SS-28, showed the presence of
SS—28(1—12)—IR in portal blood in higher concentrations than were
present in peripheral blood. The release of SS-28(1-12) into portal
blood was also increased 4 to 5-fold by electrical stimulation of
the ME. No biological activity of SS- 28(1-12) has yet been found
and possibly it may be a non-functional fragment which is
co-secreted with SS-14.
High performance liquid chromatography revealed the presence of
a single peak IR form of TRH in acid or ethanolic extracts of rat
hypothalami which corresponded in retention time to synthetic TRH.
In contrast, chromatography resolved the TRH-IR in ethanol extracts
of rat hypophysial portal vessel blood into three components, the
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first of which corresponded in retention time to the authentic
tripeptide. The additional peaks of IR material did not correspond
to the major metabolites of TRH since the anti-TRH serum used for
the RIA does not cross-react with either diketopiperazine or with
the free acid form of TRH. Two synthetic analogues of TRH, which
showed high cross-reactivity with the antiserum, were also excluded
as potential sources of the additional IR material. The additional
IR peaks did not originate from the pituitary gland since HPLC of
pituitary gland extracts revealed the presence of only a single IR
peak corresponding to TRH, and all three IR components were present
in extracts of hypophysial portal blood collected from rats from
which the pituitary gland had been removed. The concentration of
TRH-IR in peripheral blood was generally too low to be detected in
the RIA, however when present in measurable quantities, traces of
all three IR peaks were detected. Only a single IR peak was
obtained after addition of either synthetic TRH or hypothalamic
extracts to peripheral blood and no additional peaks of IR material
were generated by incubating hypothalamic extracts with peripheral
blood. It is possible that a precursor of TRH, which itself is not
immunoreactive, could on release into portal blood generate
intermediates of TRH biosynthesis which are immunoreactive, or
alternatively on release TRH may undergo some minor modification by
reactions which might alter its retention time on HPLC. However, in
the light of the above observations of the effect of incubating
hypothalamic extracts with peripheral blood it appears unlikely that
the additional IR material is formed by the action of blood-borne
enzymes; rather these conversions may occur during the release
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process itself.
Using the same HPLC system as used for the TRH studies and RIAs
with two highly specific anti-LHRH sera, only a single peak of
LHRH-IR was present in extracts of hypophysial portal blood. The
LHRH-IR peak corresponded in retention time to synthetic LHRH. This
may suggest that LHRH is processed to completion before entering the
portal vessels, but a possiblity remains that due to losses during
the extraction and chromatography of LHRH-IR, small quantities of a
precursor or intermediate form of LHRH may not have been detected.
The nature of the IR forms of LHRH in extracts of hypothalami
from rats and from 'normal' and hypogonadal (hpg) mice was also
examined, and as shown for rat hypophysial portal blood a single IR
peak was present in hypothalamic extracts from both rats and
'normal' mice. This peak corresponded in retention time to
synthetic LHRH. No LHRH-IR was detected in hypothalamic extracts
from the hpg strain of mice which confirms the results of previous
studies of crude hypothalamic extracts (Cattanach et al, 1977). In
spite of the total LHRH deficit in the hpg mice a small amount of
gonadotrophin is synthesized in the anterior pituitary gland of the
mutant. Saline extracts of pituitary glands from normal and hpg
mice were assayed for LH by the testosterone production assay. The
extract of hpg pituitary tissue stimulated testosterone production
by mouse Leydig cells in a dose-dependent manner which paralleled
that of normal mouse pituitary. Extracts of normal mouse pituitary
were about 20 times as potent as those of hpg pituitary, a relative
potency similar to that determined by RIA. The hpg gonadotrophes
have receptors for LHRH, albeit in reduced numbers (Young et al,
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1983) and the mutant is capable of releasing LH in response to
exogenous LHRH. Both the releasing action and self-priming effect
of LHRH were not significantly different in hpg compared with normal
mice. Raised plasma concentrations of oestradiol-17e reduced the
pituitary responsiveness to LHRH in normal, but not in hpg mice.
Taken together, these data showed that LHRH is not essential for the
biosynthesis of some biologically active and immunoreactive LH and
that in the mouse neither long-term exposure to normal levels of
LHRH nor a normal pituitary content of LH are necessary for either
the releasing or the priming action of LHRH.
The secretion of LHRH into hypophysial portal blood was studied
in female rats anaesthetized with a steroidal anaesthetic
(alphaxolone; 'Saffan') which when given i.p., in contrast to other
anaesthetics, does not block the pro-oestrous surge of LHRH. The
administration of A^-tetrahydrocannabinol (THC) during the
critical period (c.a. 14.00-16.00 h) of pro-oestrus blocks the
pre-ovulatory surge of gonadotrophins and ovulation (Ayalon et al,
1977). The present results confirmed that injection of THC at 13.30
h on the afternoon of pro-oestrus blocked the expected surge of LH
and showed that this was a consequence of a central action of THC in
reducing the output of LHRH into portal blood. The endogenous
opioid peptides also inhibit the secretion of LH and may play a
functional role in the regulation of LHRH secretion (Kalra and
Kalra, 1983, 1984). Pulsatile release of LH is infrequent on the
day of oestrus, but Fox and Smith (1985) showed that regular pulses
of LH secretion could be induced by continuous infusion of the
opioid antagonist, naloxone. However, in the present experiments no
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difference between the secretion of LHRH or LH was apparent in
oestrous rats infused with naloxone and saline and similarly
naloxone did not alter LHRH output or the magnitude of the
pro-oestrous surge of LH.
The plasma and pituitary concentrations of LH and FSH are
suppressed during lactation therefore the release of LHRH was
examined in suckled and non-suckled lactating rats. Plasma
concentrations of LH were low in both groups of rats and no
difference in the secretion of LHRH into portal vessel blood was
apparent. Oxytocin was shown to be present in hypophysial portal
blood in greater concentrations than in peripheral blood confirming
previous reports of its secretion from nerve terminals in the
external layer of the median eminence (Gibbs, 1984; Sarkar and
Gibbs, 1984; Horn, Robinson and Fink, 1985c). As with LHRH, there
was no difference in the concentration of oxytocin in portal blood
between suckled and non-suckled rats.
In contrast to the large increase in the release of LHRH
(Chiappa et al, 1977) and SS in response to electrical stimulation
of the ME, stimulation of either the terminals of the TRH-containing
neurons in the ME, or the cell bodies of these neurons in the PVN,
did not increase the release of either authentic TRH or the
associated TRH-IR material. The amount of TRH released into portal
blood during a 1 h collection period was high relative to the
hypothalamic TRH content. In this respect the secretion of TRH
differs from both SS and LHRH; although authentic TRH constituted
about 37% of the total TRH-IR in portal blood, the amount released
during a 1 h collection period (1.7 ng) in relation to hypothalamic
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content (~ 5 ng) was high (~ 34%) compared with that of LHRH (~
0.6%) and SS (~ 0.3%). The high secretion rate of TRH did not
result in a depletion of its hypothalamic content, which suggests
that the turnover rate for this tripeptide is correspondingly
higher. The capacity for more rapid synthesis, processing and
release of TRH than LHRH or SS may be related to the presence of
multiple copies of TRH in the precursor molecule compared with the
single copies of the LHRH and SS peptides contained in their
respective precursors. As shown here for TRH, previous studies
showed that stimulation of the ME or PVN did not result in the
increased release into portal blood of VIP (Brar et al, 1985a) or
oxytocin and vasopressin (Horn et al, 1985c). It is likely that the
apparent lack of any effect of hypothalamic stimulation on the
release of these three peptides is due to their maximal secretion
into portal blood following sectioning of the pituitary stalk which
thus renders it impossible to drive the system further by electrical
stimulation.
In order to examine the thyrotrophin and prolactin responses to
electrical stimulation of the ME or PVN, the ME and pituitary gland
was exposed but the pituitary stalk not cut. Samples of peripheral
blood were withdrawn from the external jugular vein at regular
intervals before and after the period of stimulation. Stimulation
of either the PVN or the ME resulted in a massive increase in the
plasma concentration of prolactin, however possibly due to the
trauma of surgery, increased secretion of thyrotrophin in response
tostimulation was not seen unless a 4 h delay period was interposed
between the completion of surgery and the onset of stimulation.
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This delay of 4 h between surgery and blood collection was used to
permit plasma concentrations of thyrotrophin and prolactin to return
to steady baseline after the stress of surgery and also to allow
comparison of the electrical stimulation studies with the suckling
model referred to below. As an alternative to direct measurements
of TRH secretion, passive immunization with anti-TRH serum was used
to investigate the role of TRH in mediating the thyrotrophin and
prolactin response to electrical stimulation of the hypothalamus and
the prolactin response to suckling in lactating rats. Injection of
sheep anti-TRH serum, but not control non-immune or anti-bovine
serum albumin, blocked the rise in plasma thyrotrophin concentration
in response to stimulation of either the ME or PVN, but did not
block the rise in plasma prolactin concentration. In anaesthetized
lactating female rats, the suckling stimulus produced a significant
increase in the plasma prolactin concentration, but did not alter
the plasma thyrotrophin concentration. Injection of anti-TRH serum,
but not control serum, significantly decreased the basal release of
thyrotrophin, but did not abolish the prolactin response to
suckling. These results showed that TRH is the principal mediator
of the neural control of thyrotrophin release in the rat, but is not
crucial for the release of prolactin in response to either
hypothalamic stimulation or suckling.
The secretion of several anterior pituitary hormones was
examined in male rats in which the CA-containing neurons of the ME
and NIL had been lesioned by the intravenous injection of a high
dose of 6-OHDA. The changes in the CA contents of both the
hypothalamus and ME-NIL were monitored by CA-fluorescence
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histochemistry and also by HPLC with electrochemical detection.
Fluorescence histochemistry revealed a complete depletion of NA and
DA from nerve terminals in the ME and NIL (whilst the remainder of
the hypothalamus remained relatively unaffected) 24-48 h after the
injection of 150 mg/kg 6-0HDA. When measured directly by HPLC, the
magnitude of the depletion (~ 50%) appeared less than was suggested
by histochemistry, probably as a result of the accumulation of
amines behind the lesioned terminals. There was a progressive
return to a normal fluorescent appearance of the ME over a period of
several weeks. Regenerating nerve terminals were visible in the ME
after 7 days, and by 36 days after injection the fluorescent
appearance of the ME could not be distinguished from untreated or
ascorbic acid injected control animals. Studies of plasma and
pituitary hormone concentrations measured at various time intervals
after injection of either 6-0HDA or ascorbic acid (vehicle) showed
that:
1. Plasma concentrations of prolactin were similar in 6-OHDA and
untreated control animals, but were increased in ascorbic acid
injected animals. This increased secretion of prolactin in ascorbic
acid treated rats was possibly due to a long term stress effect
following the injection which might be mediated by way of
facilitatory NA terminals in the ME-NIL which were lesioned in the
6-OHDA treated animals.
2. Plasma corticosterone concentrations were increased in rats
killed 24 h after 6-OHDA injection supporting previously reported
findings (Cuello et al, 1974) that the secretion of ACTH is
inhibited by hypothalamic CA neurons which were depleted by 6-OHDA.
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3. The CA neurons of the ME—NIL may also inhibit the secretion
of thyrotropin'n.
4. Plasma and pituitary concentrations of LH and FSH were
relatively unaltered in lesioned rats showing that the CA neurons
terminating in the ME—NIL are not important in the control of basal
secretion of these hormones in the male rat, although Tn the female
rats these neurons may be important in the control of LH secretion.
Measurements of CA content in the ME and NIL of animals which
had been pretreated with desipramine (to block the uptake of 6-OHDA
into NA terminals) provided direct confirmation of the fact that a
selective lesion of DA neurons could be produced by this treatment.
As shown by studies of gonadotrophs secretion in female rats
(Sarkar et al, 1981) this model may be of further use for studying
aminergic-peptidergic interactions in the hypothalamic control of
hormone release from the anterior pituitary gland.
In conclusion, this thesis has described and illustrated some of
the interactions which occur between peptidergic and aminergic
neurons in the regulation of anterior pituitary hormone secretion.
In comparison with techniques such as passive immunization, the
technique for collection of hypophysial portal blood has several
advantages for studies of these complex interactions between a
number of inhibitory and stimulatory factors in that, with the aid
of appropriate, sensitive assay systems, variations in the secretion
of a number of amine, amino acid and peptide neurotransmitters may
be studied simultaneously. However, collection of portal blood
requires anaesthesia and entails surgical trauma and therefore may
be more suited to studies of the release of some peptides (e.g. LHRH
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and SS) than other peptides (e.g. TRH and VIP). The studies of the
immunoreactive forms of LHRH, SS and TRH present in portal blood
show that, in addition to facilitating studies of their
physiological function, the measurement of peptides in hypophysial
portal blood provides a useful approach for determining which of the
hypothalamic peptides derived from a precursor are secreted and
which are not, and also for examining the possibilities of minor
modifications of these peptides during or after their release from
the nerve terminals in the median eminence.
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0.01 M Phosphate buffered
saline (PBS)
0.05 M Phosphate buffer
pH = 7.6
8.17 g sodium chloride
1.193 g disodium hydrogen phosphate
(anhydrous)
0.25 g sodium dihydrogen orthophosphate
(2H20)
0.1 g sodium merthiolate
990 ml distilied water
pH adjusted to 7.6
1.235 g disodium hydrogen phosphate
0.203 g sodium dihydrogen orthophosphate
200 ml distilled water
0.5 M Phosphate buffer
pH = 7.6
12.35 g disodium hydrogen phosphate
2.03 g sodium dihydrogen orthophosphate





500 ml 0.01 M PBS
9.306 g EDTA
2 ml normal rabbit serum
pH adjusted to 7.0
0.01 M boric acid
0.01% sodium merthiolate
pH adjusted to 8.6 with 0.1 M sodium
hydroxide
100 ml 0.2 M TRIS (Tris [hydroxymethyl]
aminomethane)
80 ml 0.1 M hydrochloric acid
170 g sucrose
0.58 g EDTA
Volume made up to 2 1 with distilled
water and pH adjusted to 8.0
5 mg dextran T-70 (Sigma UK)
500 mg Norit-A activated charcoal
200 ml TRIS buffer
1FAGLU1 buffer 30.5 ml 0.2 M disodium hydrogen phosphate
19.5 ml 0.2 M sodium dihydrogen
orthophosphate
10.5 ml formaldehyde (38% solution)
2.0 ml gluteraldehyde (25% solution)
37.5 ml distilled water
Appendix B
The Iodination and Chromatographic Purification of Tracers for
Radioimmunoassays
The iodination reactions and subsequent chromatographic steps were
all performed at room temperature. Iodinated products were either
used immediately in the assay or were stored at -70°C until
required. In some cases (TRH and LH) after storage for 2-3 weeks
the iodinated product was re-chromatographed before use.
B.l Thyrotrophin Releasing Hormone
Synthetic TRH (2.5 yg/25 pi of 0.05 M phosphate buffer)
iodine (1 mCi/10 yl)
Reaction started by the addition of
Chloramine T (25 yl of a 2 mg/ml solution in 0.05 M phosphate
buffer)
Reaction terminated 30 s later by the addition of
Sodium metabisulphite (10 yl of a 15 mg/ml solution in 0.05 M
phosphate buffer)
Contents of reaction vial were applied to a 1 x 12 cm column of
sephadex(^) G-10 (pre-coated with 0.05 M phosphate buffer/0.25 %
BSA) and 125j_trh eluted with 0.05 M phosphate buffer/0.25% BSA.
1 ml fractions of the eluent collected; elution volume of 125j_jrh
was approximately 12 mis.
B.2 Luteinizing Hormone Releasing Hormone
Synthetic LHRH (2 yg/10 yl PBS)
0.5 M phosphate buffer, pH 7.5 (10 yl)
125iocj-jne (i mCi/10 ylj
Reaction started by the addition of
Chloramine T (20 yl of a 1 mg/1 ml solution in PBS)
Reaction stopped after 15 s by the addition of
Sodium metabisulphite (50 yl of a 1 mg/1 ml solution in PBS)
Contents of the reaction vial were applied to a 0.75 x 20 cm column
of sephadex G-25, pre-coated and eluted with PBS/0.1% gelatine. The
elution volume of ^25i_LHRH was approximately 16-19 ml.
B.3 Thyrotroph in
Purified TSH (5 pg/20 pi 0.25 M phosphate buffer, pH 7.5)
0.5 M phosphate buffer, pH 7.5 (25 pi)
125iocj-jne (i mCi/10 pi)
Reaction started by the addition of
Chloramine T (20 pi of a 1.5 mg/ml solution in 0.05 M phosphate
buffer)
Reaction stopped 40 s later by the addition of
Sodium metabisulphite (50 pi of a 2.4 mg/ml solution in 0.05 M
phosphate buffer)
and with the addition 40 s later of
Normal rabbit serum (100 pi)
The contents of the reaction vial were applied to the top of a 1 x
30 cm column of sephadex G-75 which had been pre-coated with 4 ml of
PBS/2% BSA. The labelled TSH was eluted from the column with PBS.
0.5 ml fractions were collected into tubes which contained 0.5 ml of
PBS/1% BSA.
B.4 Prolactin
Purified protein (5 pg/20 pi 0.01 M sodium bicarbonate)
0.5 M phosphate buffer, pH 7.5 (40 pi)
125j0(jine (i mCi/10 pi)
Reaction started by the addition of
Chloramine T (15 pi of a 1 mg/ml solution in 0.05 M phosphate
buffer)
Reaction stopped after 20 s by the addition of
Sodium metabisulphite (50 pi of a 2.4 mg/ml solution in 0.05 M
phosphate buffer)
followed by the addition of
Potassium iodide-sucrose solution (100 pi of a solution
containing 0.1 g potassium
iodide and 0.8 g sucrose/10 ml
distilled water)
The contents of the reaction vial (together with a further 100 pi of
the potassium iodide-sucrose solution used to rinse the vial) were
applied to a 1 x 25 cm column of sephadex G-50 which had previously
been coated with 200 pi of a 4.5% solution of human serum albumin in
PBS buffer. 125j_pro-|actin was eluted from the column using
borate buffer. 0.5 ml fractions were collected into tubes which
contained 0.5 ml of PBS/1% BSA. The iodinated material was freshly
prepared for each radioimmunoassay as freezing resulted in
subsequent loss of immunoreactivity.
B.5 Luteinizing Hormone
Purified ovine LH (5 pg/10 pi distilled water)
0.5 M phosphate buffer, pH 7.5 (25 pi)
ocjine (1 mCi/10 pi)
Reaction started by the addition of
Chloramine T (10 pi of a 5 mg/ml solution in PBS)
Reaction stopped after 2 m by the addition of
Sodium metabisulphite (25 pi of a 5 mg/ml solution in PBS)
Contents of the reaction vial were applied to a 1 x 12 cm column of
Biogel(R) P-60 which had been coated with 1.5 ml of PBS/5% egg
white. 1251_-| abel 1 ed LH was eluted from the column with PBS and
0.5 ml fractions collected into tubes which contained 0.5 ml PBS/5%
egg white.
B.6 Follicle Stimulating Hormone
Purified FSH (2 pg/20 pi distilled water)
0.5 M phosphate buffer, pH 7.5 (25 pi)
125Iodine (2 mCi/20 pi)
Reaction started by the addition of
Chloramine T (10 pi of a 2.5 mg/ml solution in PBS)
Reaction terminated after 45 s by the addition of
Sodium metabisulphite (25 pi of a 2.5 mg/ml solution in PBS)
The contents of the reaction vial were applied to a 1 x 12 column of
Biogel P-60 which had previously been coated with 1.5 ml of PBS/5%
egg white and the iodinated hormone eluted from the column with
PBS. 0.5 ml fractions of the eluate were collected into tubes which





ARGG Anti-rabbit gamma globulin
Bound (total)
BSA Bovine serum albumin
CA Catecholamine
CNS Central nervous system






FSH Follicle stimulating hormone
GABA y-aminobutyric acid
GAP Gonadotrophin releasing hormone associated peptide
GH Growth hormone
GHRH Growth hormone releasing hormone
5-HIAA 5-hydroxyindole acetic acid
HMW High molecular weight
hpg Hypogonadal









LHRH Luteinizing hormone releasing hormone
LPZ Lateral palisade zone
MBH Medial basal hypothalamus
ME Median eminence
(m)RNA (messenger) ribonucleic acid
NA Noradrenaline
nAcDA n-acetyl dopamine





OVLT Vascular organ of the lamina terminal is
PBS Phosphate buffered saline
PHI Peptide histidine isoleucine amide
PIF Prolactin inhibitory factor
PMSG Pregnant mare serum gonadotrophin
POI Pars oralis infundibuli




RER Rough endoplasmic reticulum
RIA Radioimmunoassay
SAPU Scottish Antibody Production Unit









TRH Thyrotrophin releasing hormone
TSH Thyrotrophin (thyroid stimulating hormone)
V Ventricle
VIP Vasoactive intestinal peptide
